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1. Introduction 
Chapter Summary:
Chapter 1 provides a description of the history of prescription drug shortages 
from the late 1990s to the present day landscape. This chapter also introduces the 
clinical and public health implications of drug shortages, as well as mitigation 
shortages that have been implemented to date. Finally, this chapter outlines the 
methods and goals of the research conducted within the context of this thesis. 
2. Emergency Medicine/Acute Care
Mazer-Amirshahi M, Pourmand A, Singer S, Pines JM, van den Anker J. 
Critical drug shortages: implications for emergency medicine. Academic 
Emergency Medicine 2014;21: 704-11. PMID: 25951876. 
Chapter Summary:
Chapter 2 discusses the clinical and public health implications of shortages as 
they apply to the practice of emergency medicine. Situations that may occur as a 
result of shortages, such as delayed or suboptimal therapy and medication errors 
are reviewed. Specific considerations to the specialty of emergency medicine are 
discussed and examples of how patient care is impacted are provided. For 
instance, we reviewed a case where a patient was given a fatal dose of 
methohexital when propofol was in short supply. We also explore how the 
healthcare system is impacted on a larger scale, such as increased cost and 
resource utilization, and increased pharmacy staff required to manage inventory 
during times of shortage. We discuss mitigation strategies to date at the 
governmental and non-governmental levels. We address challenges facing 
emergency medicine providers and offer strategies for bedside clinicians. Finally, 
future directions for mitigation and prevention are discussed. It should be noted 
that many of the situations and strategies presented are applicable to other 
specialties as well.
Hawley K, Mazer-Amirshahi M, Zocchi M, Fox E, Pines J. Longitudinal trends 
in U.S. drug shortages for medications used in emergency departments. Academic 
Emergency Medicine, 2016;23:63-9. PMID: 26715487.
Chapter Summary:
Chapter 3 is a retrospective study of the impact of shortages on drugs within the 
scope of adult emergency medicine from 2001-14. During the course of the study 
period, over a third of drugs impacted by shortages were within the scope of 
emergency medicine practice and there was an overall increase in shortages over 
time. Over 50% of the drugs on shortage were used for high-acuity or life-saving 
conditions and 10% of these high-acuity drugs had no substitute available. 
Generic injectable drugs were most commonly affected by shortages and 
infectious disease drugs were the most common type of drug impacted, followed 
by analgesics and toxicology drugs. The median duration of resolved shortages 
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Mazer-Amirshahi M, Fox ER, Zocchi M, Pines JM, van den Anker J. Trends in 
U.S. sterile solutions shortages, 2001-2017. American Journal of Health Systems
Pharmacy, 2018;75:1903-8. PMID: 30463866.
Chapter Summary:
Chapter 6 examines shortages of sterile medical solutions, including normal 
saline, dextrose, lactated ringers, and sterile water for injection over time. We 
found a substantial number of sterile solution shortages. The median shortage 
duration was 13.9 months but the longest shortage lasted over 10 years. The most 
common product type involved was saline solutions. The most commonly cited 
reason for shortage was manufacturing problems. While there here was an overall 
increase in the number of sterile solutions over time, there was a significant 
increase at the end of 2017, which correlated with Hurricane Maria, which 
precipitated a critical saline shortage. We discuss the potential clinical impact of 
these shortages and coping strategies for providers and health systems. 
Mazer-Amirshahi M, Fox E. Saline shortages: many causes, no simple solution. 
New England Journal of Medicine, 2018.  DOI:10.1056/NEJMp1800347. PMID: 
29561694. 
Chapter Summary:
Chapter 7 is a perspective piece from the New England Journal of Medicine that 
further examines the critical saline shortages precipitated by Hurricane Maria. We 
review the history of saline shortages and explore factors that contributed to the 
previously existing shortages, such as lack of manufacturing redundancy and 
transparency. These shortages were acutely worsened by the natural disaster. We 
review implications for patient care and discuss coping strategies for health 
systems and providers as well. Finally, we offer policy strategies to prevent future 
shortages. 
3. Pediatrics
Donnelly K, Zocchi M, Katy T, Fox E, van den Anker J, Mazer-Amirshahi M. 
Prescription drug shortages: implications for pediatric ambulatory care. Journal of 
Pediatrics, 2018. DOI: 10.1016/j.jpeds.2018.4.0008. PMID: 29752177.
Chapter Summary:
Chapter 8 is a study of drug shortages that impact the practice of general 
ambulatory pediatrics from 2001 to 2015. There were over 300 ambulatory 
pediatric shortages over the study period, with a median duration of 7.6 months. 
Similar to prior studies, infectious disease drugs were the most commonly 
impacted class of medications. Nearly 20% of shortages were for pediatric 
friendly formulations. An alternative agent was available for the majority of 
medications impacted; however, nearly 30% of alternatives were affected by 
shortages. In the discussion, we explore issues unique to pediatric shortages, such 
as a lack of safety and efficacy data for drugs in this population as well as a need 
was 9 months and the most common reason for shortage reported was 
manufacturing problems and delays. We discuss potential reasons for these 
findings and offer coping strategies for front line providers. 
Mazer-Amirshahi M, Goyal M, Umar S, Fox E, Zocchi M, Hawley K, Pines JM. 
U.S. drug shortages for medications used in adult critical care, 2001-16. Journal 
of Critical Care 2017;41:283-8. PMID: 28622641. 
Chapter Summary:
Chapter 4 is a study of drug shortages affecting medications used in adult 
intensive care units (ICUs) from 2001-2016. During the study period, there were 
nearly 2000 drug shortages and over 50% impacted medications used in the ICU. 
Nearly a quarter of medications on shortage were used for high-acuity or life-
threatening conditions. Over 70% of shortages were for parenteral medications 
and nearly 40% were for single-source drugs. Generic drugs were also more 
commonly affected compared to their brand name counterparts. Therapeutic 
alternatives were available for the majority of the medications affected but nearly 
25% of alternatives were also impacted during the study period. The median 
duration of resolved shortages was even longer than described for adult 
emergency medicine being13.6 months! The most commonly impacted 
medications, similar to prior studies were infectious disease drugs, which 
accounted for nearly 20% of ICU shortages. We discuss specific implications for 
the ICU, which is a particularly high-acuity environment and close by offering 
mitigation strategies for intensivists.
Mazer-Amirshahi M, Hawley K, Zocchi M, Fox E, Pines J, Nelson L. Drug 
shortages in the United States: implications for medical toxicology. Clinical 
Toxicology 2015;56:519-24. PMID: 25951876.
Chapter Summary:
Chapter 5 is a study of shortages for drugs used to treat poisoned patients from 
2001-2013. We reviewed shortages of antidotes as well as medications used 
commonly in the management of poisoned patients. Toxicology shortages 
accounted for 8.1% of all shortages and shortages generally increased overtime, 
peaking in 2011. The median shortage duration was 5.5 months. Generic and 
injectable products were most commonly impacted and 41% of shortages 
involved single-source drugs. An alternative was available for 86% of drugs; 
however, 73% of alternatives were impacted at some point during the study 
period. The agent with the greatest number of shortages was naloxone. The most 
common class of toxicology drugs on shortage was sedative/hypnotics. 
Manufacturing problems was the most common reason for shortages. In the 
discussion, we draw attention to challenges faced by toxicologists and providers 
caring for poisoned patients, particularly with multiple naloxone shortages during 
the current opioid epidemic. 
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in Clinical Practice. Clinical Infectious Disease 2015;60;1737-42. PMID: 
25908680.
Chapter Summary:
Chapter 11 focuses on shortages of the most commonly impacted drug class-
antimicrobials. From 2001-2013, we found 148 antimicrobial shortages, with a 
median duration of 6 months. Over 20% of antimicrobials were impacted by 
multiple shortages.  Shortages for broad-spectrum antibiotics were more common 
and nearly half of shortages involved medications used to treat high-risk 
pathogens such as methicillin-resistant Staphylococcus aureus. Cephalosporins 
and aminoglycosides were the most commonly impacted antimicrobial classes. 
We discuss mitigation strategies in the setting of increasing microbial resistance 
and a limited number of therapeutic options in the drug development pipeline. 
Ziesenitz V, Mazer-Amirshahi M, Zocchi M, Fox E, May L. Trends in US 
vaccine and immunoglobulin shortages 2001-15. American Journal of Health-
System Pharmacy, 2017; DOI: 10.2146/ajhp170066. PMID 28970246.
Chapter Summary:
Chapter 12 examines shortages for vaccines and immune globulins (agents used 
for passive immunity). There were 58 shortages noted, with a median duration of 
16.8 months. Shortages for products that were for viral illnesses, such as hepatitis 
A, were more common. Thirty products on the pediatric schedule were on 
shortage and vaccine deferral was required for 21 shortages. Over half of the 
shortages were for single-source products. The most common reason for shortage 
was manufacturing problems. In the discussion, we focus on the public health 
implications in the setting vaccine deferrals for primary immunizations, as this 
may impact herd immunity, as well as coping strategies for clinicians. 
5. Discussion and Summary
for palatable formulations. We close by offering mitigation strategies for general 
pediatricians and suggesting policy solutions, in order to protect this particularly 
vulnerable population. 
Donnelly K, Zocchi M, Katy T, Fox E, Pines J, van den Anker J, Mazer-
Amirshahi M. Prescription drug shortages: implications for pediatric emergency 
and critical care. Pediatric Emergency Care 2019; 
DOI:10.1097/PEC.0000000000001773. PMID: 30829846. 
Chapter Summary:
Chapter 9 examines shortages involving pediatric emergency medicine and 
critical care (ICU) drugs. During the study period from 2001 to 2015, there were 
nearly 800 shortages impacting pediatric emergency and critical care. There was 
an overall increase in shortages over time, peaking in 2011. The median shortage 
duration was 7.6 months and similar to prior trends, infectious disease drugs and 
sterile injectable products were the most commonly impacted. Over a quarter of 
shortages impacted drugs used for high-acuity or life-threatening conditions. 
While most drugs affected by shortages had an alternative, 43% of alternatives 
were impacted. Pediatric friendly formulations were impacted in 11% of 
shortages. In the discussion, we explore the safety issues unique to pediatric 
emergency and critical care, which is a particularly high-acuity environment and 
ways to mitigate the impact. 
Ziesenitz V, Fox E, Zocchi, Samiee-Zafarghandy S, van den Anker J, Mazer-
Amirshahi M. Prescription drug shortages: impact on neonatal intensive care. 
Neonatology, 2018;115:108-15. PMID: 30384374.
Chapter Summary:
Chapter 10 examines shortages that affected the top 100 drugs used in the 
neonatal intensive care unit (NICU). Nearly 75% of the 100 most commonly used 
NICU drugs were impacted by multiple shortages. The median shortage duration 
was 8.8 months. Generic injectable medications were the most commonly 
impacted. A significant number of medications used in extremely low birth 
weight infants also experienced shortages. We discuss the potential consequences 
of these shortages in this particularly fragile population in the setting of critical 
illness. This is further confounded by the fact that medications have the least 
safety and efficacy data in neonates and some excipients are contraindicated in 
this age group, leaving few alternatives. In addition, dosing must be very precise, 
and as such, adult formulations may not be a suitable alternative and dilution and 
compounding may lead to medication errors. 
4. Infectious Diseases
Quadri F, Mazer-Amirshahi M, Fox E, Hawley K, Zocchi M, Pines J, May L. 
Antibacterial Drug Shortages from 2001 to 2013: Implications for Patient Safety 
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Medical Inc.) at full capacity. In addition, the shortage was further exacerbated by a 
severe influenza season during which intravenous saline was in high demand.8  
Drug shortages can have a profound impact on patient care and the healthcare system as a 
whole. This can take the form of delayed or suboptimal care when first line therapies are 
not available. One study revealed that 80% of hospitals reported a delay in treatment due 
to drug shortages.9 In addition, medication errors can occur when providers must use 
alternative therapies they are less familiar with. In fact, one survey found that 89% of 
hospitals attributed a patient safety issue or medication error directly to drug shortages.9 
An associated press report attributed 15 deaths to medication shortages.10 In addition to 
the human costs, there is also a significant financial burden placed on the healthcare 
system by shortages. It is estimated that hospitals spend an additional $230 million 
annually due to the higher costs of therapeutic substitutions.9, 11 There is also the 
increased time and staff resources required to mitigate shortages. There are currently 
limited data regarding both the human and economic consequences of shortages.  
There have been efforts to mitigate the impact of drug shortages; however, shortages 
remain a major public health problem. As mentioned previously, the FDA’s DSP was 
established in 1999, however; it was not that active until there was an increase in the 
number of shortages reported, around 2005.2 The FDA has worked in a variety of ways to 
prevent and mitigate shortages. The FDA has worked with manufacturers to bring 
facilities into compliance and assists by coordinating with other manufacturers of 
products impacted by shortages. The FDA maintains an active drug shortage website to 
disseminate information. Other actions the FDA may take is to allow for temporary 
importation of products, extension of expiration dates, and allowing for filtering of 
products with particulate matter. Despite these strategies, the number of shortages 
continued to increase. One criticism is that the FDA has limited regulatory and 
enforcement authority. FDA does not have the authority to require a manufacturer to 
produce a specific product or volume of product. There were limited reporting 
requirements on the part of manufacturers who anticipated shortages as well as limited 
enforcement authority on the part of the FDA for those who failed to comply with current 
regulations.12  
In response to the rising number of drug shortages, the Food and Drug Administration 
Safety and Innovation Act (FDASIA) was passed in 2012.13 FDASIA expanded the 
requirement that manufacturers report anticipated shortages or product discontinuation to 
the FDA. The FDA was also provided authority to expedite the review of drug 
applications and manufacturing facilities in cases where these actions would mitigate a 
shortage situation. FDASIA also provided for the establishment of a drug shortages task 
force, with the goals of both mitigating existing shortages and enacting long-term 
solutions to prevent new shortages.13 At the same time, FDASIA had some significant 
shortcomings. The FDA still lacks enforcement authority to punish manufacturers who do 
not comply with notification requirements. In addition, FDA also does not have the 
authority to require a company to manufacturer to make a particular drug, no matter how 
great the need. There has been much debate over future directions, which could include 
additional legislation and incentives to manufacturers, to name a few.  
Prescription Drug Shortages: Implications for Public Health and Potential Solutions 
Introduction 
Prescription drug shortages have reached critical levels in the United States and represent 
a significant threat to healthcare quality and patient safety. A prescription drug shortage 
is defined by the U.S. Food and Drug Administration (FDA) as a scenario in which “the 
total supply of all clinically interchangeable versions of an FDA-regulated drug product 
is inadequate to meet the projected demand at the user level.” Alternatively, the 
American Society of Health-System Pharmacists (ASHP) defines a shortage as “a supply 
issue that affects how the pharmacy prepares or dispenses a drug product or influences 
patient care when prescribers must use an alternative agent.”1
Although drug shortages have been in existence for decades, they have become much 
more severe in recent years.2,3 In the late 1990s, there were a limited number of drug 
shortages. They were often not long-standing and rarely impacted patient care. However, 
in response to these shortages and concerns over the potential for disruption caused by 
the turn of the millennium (Y2K), the FDA developed the Drug Shortage Program (DSP) 
in 1999.2 The DSP remained relatively inactive until the early 2000s when there was a 
significant increase in drug shortages.2  
The increase in drug shortages that occurred was attributed to a variety of factors, 
although some underlying themes prevail. The most commonly occurring reason for 
shortage has been reported as quality problems at manufacturing facilities. Quality 
problems generally refer to particulate matter, microbial contamination, or formulation 
instability.2 In addition, the FDA has issued citations to several manufacturers for 
violations of good manufacturing practices, which has delayed production and even 
closed facilities. It is costly and time consuming to bring facilities up to current standards, 
which can have a serious impact on the supply chain.5
In addition to quality problems, market factors have also contributed to the rise in drug 
shortages. Manufacturing sterile injectable products is costly and only a handful of 
companies make these products, due to limited profit margins, particularly for generic 
drugs.6 In addition to a limited number of manufacturers, several companies have 
consolidated their resources into a small numbers of facilities because this is a more cost 
effective approach. This has produced a fragile manufacturing system with a lack of 
redundancy.7 When there is a problem at one facility, there is often not enough capacity 
or redundancy in the system to avoid a shortage. This is also why generic injectable drugs 
are disproportionately impacted by shortages.2, 7
Additional reasons for shortages exist, such as increased demand or natural disasters. For 
example, in late 2017, a critical shortage of saline solution was precipitated when 
Hurricane Maria impacted Baxter International’s Puerto Rico manufacturing facility. This 
facility made nearly 50% of small volume saline bags supplied to the United States. At 
the same time, a second saline manufacturer, B. Braun Medical Inc., was cited for quality 
problems at one of its facilities, leaving only one major saline manufacturer (ICU 
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Medical Inc.) at full capacity. In addition, the shortage was further exacerbated by a 
severe influenza season during which intravenous saline was in high demand.8  
Drug shortages can have a profound impact on patient care and the healthcare system as a 
whole. This can take the form of delayed or suboptimal care when first line therapies are 
not available. One study revealed that 80% of hospitals reported a delay in treatment due 
to drug shortages.9 In addition, medication errors can occur when providers must use 
alternative therapies they are less familiar with. In fact, one survey found that 89% of 
hospitals attributed a patient safety issue or medication error directly to drug shortages.9 
An associated press report attributed 15 deaths to medication shortages.10 In addition to 
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increased time and staff resources required to mitigate shortages. There are currently 
limited data regarding both the human and economic consequences of shortages.  
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prevent and mitigate shortages. The FDA has worked with manufacturers to bring 
facilities into compliance and assists by coordinating with other manufacturers of 
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disseminate information. Other actions the FDA may take is to allow for temporary 
importation of products, extension of expiration dates, and allowing for filtering of 
products with particulate matter. Despite these strategies, the number of shortages 
continued to increase. One criticism is that the FDA has limited regulatory and 
enforcement authority. FDA does not have the authority to require a manufacturer to 
produce a specific product or volume of product. There were limited reporting 
requirements on the part of manufacturers who anticipated shortages as well as limited 
enforcement authority on the part of the FDA for those who failed to comply with current 
regulations.12  
In response to the rising number of drug shortages, the Food and Drug Administration 
Safety and Innovation Act (FDASIA) was passed in 2012.13 FDASIA expanded the 
requirement that manufacturers report anticipated shortages or product discontinuation to 
the FDA. The FDA was also provided authority to expedite the review of drug 
applications and manufacturing facilities in cases where these actions would mitigate a 
shortage situation. FDASIA also provided for the establishment of a drug shortages task 
force, with the goals of both mitigating existing shortages and enacting long-term 
solutions to prevent new shortages.13 At the same time, FDASIA had some significant 
shortcomings. The FDA still lacks enforcement authority to punish manufacturers who do 
not comply with notification requirements. In addition, FDA also does not have the 
authority to require a company to manufacturer to make a particular drug, no matter how 
great the need. There has been much debate over future directions, which could include 
additional legislation and incentives to manufacturers, to name a few.  
Prescription Drug Shortages: Implications for Public Health and Potential Solutions 
Introduction 
Prescription drug shortages have reached critical levels in the United States and represent 
a significant threat to healthcare quality and patient safety. A prescription drug shortage 
is defined by the U.S. Food and Drug Administration (FDA) as a scenario in which “the 
total supply of all clinically interchangeable versions of an FDA-regulated drug product 
is inadequate to meet the projected demand at the user level.” Alternatively, the 
American Society of Health-System Pharmacists (ASHP) defines a shortage as “a supply 
issue that affects how the pharmacy prepares or dispenses a drug product or influences 
patient care when prescribers must use an alternative agent.”1
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The increase in drug shortages that occurred was attributed to a variety of factors, 
although some underlying themes prevail. The most commonly occurring reason for 
shortage has been reported as quality problems at manufacturing facilities. Quality 
problems generally refer to particulate matter, microbial contamination, or formulation 
instability.2 In addition, the FDA has issued citations to several manufacturers for 
violations of good manufacturing practices, which has delayed production and even 
closed facilities. It is costly and time consuming to bring facilities up to current standards, 
which can have a serious impact on the supply chain.5
In addition to quality problems, market factors have also contributed to the rise in drug 
shortages. Manufacturing sterile injectable products is costly and only a handful of 
companies make these products, due to limited profit margins, particularly for generic 
drugs.6 In addition to a limited number of manufacturers, several companies have 
consolidated their resources into a small numbers of facilities because this is a more cost 
effective approach. This has produced a fragile manufacturing system with a lack of 
redundancy.7 When there is a problem at one facility, there is often not enough capacity 
or redundancy in the system to avoid a shortage. This is also why generic injectable drugs 
are disproportionately impacted by shortages.2, 7
Additional reasons for shortages exist, such as increased demand or natural disasters. For 
example, in late 2017, a critical shortage of saline solution was precipitated when 
Hurricane Maria impacted Baxter International’s Puerto Rico manufacturing facility. This 
facility made nearly 50% of small volume saline bags supplied to the United States. At 
the same time, a second saline manufacturer, B. Braun Medical Inc., was cited for quality 
problems at one of its facilities, leaving only one major saline manufacturer (ICU 
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substitution 
Staff education and engagement 
Report adverse events related to shortages 
Monitoring of inventory by pharmacy staff 
Ethical framework for rationing 
This thesis is intended to explore the impacts of drug shortages across a wide range of 
specialties, care settings, and populations. This work will explore trends in drug shortages 
over time and the potential implications for patient care and public health. The goals of 
this thesis are to: 
1. To review the history and current state of prescription drug shortages, using the
specialty of emergency medicine as an example (Chapter 2).
2. To describe trends over time in drug shortages as well as clinical implications and
potential solutions for acute care medicine. Chapter 3 will examine shortages
related to adult emergency medicine and Chapter 4 will explore shortages
affecting medications used in the adult intensive care unit. Chapter 5 will cover
shortages impacting antidotes and drugs used in the treatment of poisoned
patients. In Chapter 6, we evaluate shortages in sterile solutions and in Chapter 7
we further explore the critical saline shortages that occurred following Hurricane
Maria.
3. To describe trends over time in drug shortages and clinical implications for the
special population of pediatrics. This is of particular importance because of the
limited therapeutic options with safety and efficacy data in the pediatric
population. Chapter 8 describes and discusses the considerations unique to the
practice of ambulatory pediatrics. Chapter 9 evaluates trends over time and
implications in the setting of pediatric emergency and critical care. Chapter 10
examines one of the most fragile of populations and that with the fewest
therapeutic options, the neonate. In this chapter we evaluate the impact of
shortages impacting the most commonly used neonatal intensive care unit drugs,
including those used in extremely low birth weight infants.
4. To describe trends over time and clinical implications for infectious disease drugs.
We choose to explore this subspecialty in further detail because when examining
shortages in the aforementioned specialties, infectious disease drugs were the
most heavily impacted. In addition, there are increasing concerns regarding
increasing resistance with few novel drugs in the development pipeline. Chapter
11 focuses specifically on antimicrobial shortages. Chapter 12 examines trends in
vaccine shortages.
5. To discuss potential interventions and future areas of study. Chapter 13 will
summarize key findings and offer additional mitigation and prevention strategies
and explore areas of future study.
Local government and non-governmental initiatives have also helped to mitigate current 
shortages. The ASHP provides valuable shortage information and guidance for providers 
and health systems on their drug shortages website.14 On a local level, state and regional 
emergency medical services and some state boards of medicine have implemented 
protocols to mitigate shortages. 
At the institutional and health systems level, providers have been managing shortages in 
an attempt to optimize patient care and prevent medication errors. This may be in the 
form of minimizing waste, designing substitution protocols, developing a framework for 
ethical distribution of limited resources, or staff education, to name a few examples. 
Despite widespread knowledge of drug shortages and mitigation initiatives, drug 
shortages remain at critical levels. At the same time, it is less clear what the optimal 
strategies are to combat shortages. Until recently, it was unclear to what extent shortages 
impacted particular specialties and patient care settings. In addition, there are limited data 
as to how shortages directly impact patient safety, particularly because adverse drug 
events related to shortages are likely under reported. Finally, there are limited data as to 
how delays in therapy or suboptimal therapy due to shortages have impact patient 
outcomes. 
Examples of Mitigations Strategies for Drug Shortages to Date 
Governmental/Regulatory Increased notification requirements 
Facilitation of inspections 
Coordination between manufacturers 
FDA drug shortages website 
Expedite new product approvals  
Temporary importation 
Extension of expiration dates 
Allowing for particulate matter 
Proposal of FDA Task Force 
Industry Development of business continuity plans 
Compliance with good manufacturing 
practice 
Providing advanced notification 
Non-Governmental ASHP drug shortages website  
Patient advocacy groups 
Specialty organization involvement (e.g. 
American College of Emergency 
Physicians) 
State and Local Efforts Texas Board of Medicine shortage website 
Texas EMS protocols during times of 
shortage 
Health Systems and Providers Promote awareness of current shortages 
Minimize waste of products in shortage 
Proactively develop protocols for 
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Abstract
Prescription drug shortages have become increasingly common and more severe over the past decade. In
addition, reported shortages are longer in duration and have had a greater effect on patient care. Some of
the causes of current drug shortages are multifactorial, including the consolidation of drug
manufacturers, quality problems at production plants that restrict the supply of drugs, and a lack of
ﬁnancial incentives for manufacturers to produce certain products, particularly generic medications.
Generic injectable medications are most commonly affected by shortages because the production process
is complex and costly for these drugs, and proﬁt margins are often smaller than for branded medications.
Many commonly used emergency department (ED) generic injectables have been affected by shortages,
including multiple resuscitation and critical care drugs. Several reports have shown that shortages can
potentially have major effects on the quality of medical care, including medication errors, treatment
delays, adverse outcomes, and increased health care costs. Currently, no published data exist outside of
case reports that directly link ED-based drug shortages to overall patient safety events; however, there are
several examples in the ED where ﬁrst-line therapies for life-saving medications have been in short
supply, and alternatives have higher rates of adverse events, narrower therapeutic indexes, or both. Aside
from increasing notiﬁcation about shortages, the U.S. Food and Drug Administration has little power to
coerce manufacturers to produce medications during a shortage. Therefore, ED providers must learn to
mitigate the effects of shortages locally, through active communication with pharmacy staff to identify
safe and effective alternatives for commonly used medications when possible. Particularly given the effect
on critical care medications, therapeutic alternatives should be clearly communicated to all staff so that
providers have easy access to this information during resuscitations. This review focuses on the etiology
of drug shortages, their effect on the ED, and potential solutions and mitigation strategies.
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Prescription drug shortages have become increas-ingly common and more severe over the pastdecade, a trend that is projected to continue into
the foreseeable future.1–4 Although typically associated
with oncology drugs, drug shortages can affect a wide
variety of medications and can lead to delays in treat-
ment, suboptimal treatment, or no treatment being
available when indicated.5,6 Drug shortages can also
contribute to medication errors and increased health
care costs.7,8 Shortages have had a dramatic effect on
the practice of emergency medicine, as many commonly
used medications in the emergency department (ED)
have been affected.3,9 This review will focus on the etiol-
ogy of drug shortages, their effect on the ED, the role
of the U.S. Food and Drug Administration (FDA), and
potential solutions and mitigation strategies.
THE DEFINITION AND SCOPE OF THE PROBLEM
According to the FDA, a drug shortage occurs when
“the total supply of all clinically interchangeable ver-
sions of an FDA-regulated drug product is inadequate
to meet the projected demand at the user level.”10 Drug
shortages have existed for decades; however, histori-
cally they were more infrequent and relatively short-
lived and were not broadly disruptive to patient
care.11,12 The primary reasons for the recent increase in
drug shortages are a consolidation of manufacturing for
From the Department of Emergency Medicine, The George Washington University (MM, AP, SS, JMP), Washington, DC; and the
Department of Clinical Pharmacology, Children’s National Medical Center (MM, JvdA), Washington, DC.
Received November 10, 2013; revision received January 21, 2014; accepted January 23, 2014.
The authors have no relevant ﬁnancial information or potential conﬂicts of interest to disclose.
Dr. Pines, an associate editor for this journal, had no role in the peer review or publication decision for this paper.
A related article appears on page 701.
Supervising Editor: Sandra Schneider, MD.
Address for correspondence and reprints: Maryann Mazer-Amirshahi, PharmD, MD; e-mail: maryannmazer@gmail.com.
704 ISSN 1069-6563 704 © 2014 by the Society for Academic Emergency Medicine
704 PII ISSN 1069-6563583 doi: 10.1111/acem.12389
15
generic injectables and greater scrutiny on the manu-
facturing process, which has identiﬁed quality problems
that can be expensive to address. This has been super-
imposed on ephemeral economic issues with generic
drugs, such as low proﬁt margins and lack of penalties
for running out of drug. As a result, over the past dec-
ade, drug shortages have increased considerably. In
2005, the FDA’s Drug Shortage Program (DSP) reported
limited supplies of 61 medications. By 2011, this number
increased more than fourfold, to 251 medications, the
vast majority being sterile injectable medications, many
of which are used in EDs.3,10 Existing shortages are
severe and have reported effects on patient care. One
recent survey found that 89% of hospitals implicated a
drug shortage as a potential cause for a medical error
or patient safety issue.13 In 2012, an Associated Press
article reported 15 deaths over the course of 15 months
directly attributed to drug shortages.14 While chemo-
therapeutic drugs have been most commonly involved
in shortage-related deaths, several therapeutic classes
used in the ED have also been implicated, including opi-
oid analgesics, electrolyte solutions, antibiotics, and
phytonadione.13–15 In one survey, 80% of institutions
reported that drug shortages were responsible for
delays in or cancellations of treatment.13 The vast
majority of institutions also reported signiﬁcant
increases in operating costs as a result of drug short-
ages. Increased costs can result from buying more
costly brand name and alternative medications, price
increases due to limited supplies, compounding ser-
vices, and administrative time to locate alternative sup-
plies and effectively manage and distribute existing
inventories.7,13 It has been estimated that it costs $216
million annually for hospitals to manage drug short-
ages.7 Finally, there is the ultimate cost to the patient,
who may experience adverse effects as a result of a
drug shortage.2,5,16
WHY DRUG SHORTAGES OCCUR
The etiology of drug shortages is multifactorial and var-
ies depending upon the speciﬁc product involved. Yet,
there are common themes that underlie the vast major-
ity of shortages. The most frequent cause of drug short-
ages is identiﬁed broadly as “quality problems.” This
includes issues such as microbial contamination, partic-
ulate matter found in vials, or tablet disintegration.1
There may be a shortage of raw materials to make the
medication or problems with shipping.4 Another major
reason for drug shortages is increased demand; for
example, oseltamivir demand has exceeded supplies
during inﬂuenza season. Some older medications that
were on the market prior to the implementation of cur-
rent FDA safety and efﬁcacy standards are in the pro-
cesses of being reviewed to bring them into compliance.
During this process, these medications may also experi-
ence interruptions in supply.1
One of the major factors that has contributed to the
recent surge in drug shortages has been the changing
landscape of pharmaceutical manufacturing, particularly
as it pertains to generic injectable drugs. The manufac-
turing of sterile injectable products is often complex,
costly, and specialized, and only small numbers of man-
ufacturers make these products. Over the past decade,
manufacturers have been consolidating production into
fewer facilities in an effort to control costs.4 This has
important implications because problems at one manu-
facturing facility can have a profound effect on the sup-
ply chain. Because of the lack of redundancy in the
supply chain, it is more difﬁcult for a small number of
facilities to make up for production problems at one
speciﬁc manufacturing plant.1,4
Another related factor is that production facilities
must meet manufacturing quality standards. Recently,
the FDA has issued warnings to six of the top 10 manu-
facturers of sterile injectable products for severe viola-
tions of current good manufacturing practices.17 This is
particularly an issue for generic drugs, because manu-
facturers may be unwilling or unable to make capital
investments to sufﬁciently upgrade infrastructure to
address manufacturing problems. Generic manufactur-
ers will not get the return on their investment because
generic medications yield much smaller proﬁt margins
compared to their brand name counterparts. This is in
part due to Medicare legislation that sets ﬁxed prices for
generic drugs.18 In some cases, problems at production
facilities have led to permanent shutdown of manufactur-
ing plants. Manufacturers may also choose to discon-
tinue the production of products that do not have large
market shares or have limited target populations (such
as orphan drugs), as they do not generate sufﬁcient reve-
nue to justify costs.19,20 For those manufacturers who
choose to upgrade their facilities to FDA standards, the
process can be time-consuming and also slows produc-
tion of medications in short supply. In addition, the pro-
cess for new manufacturers to enter the marketplace is
costly and also takes a signiﬁcant amount of time.18
Finally, in the current climate, pharmaceutical manufac-
turers are not held directly accountable for failing to
meet market demand or product quality standards.
These factors alone and in combination further contrib-
ute to the lack of redundancy in pharmaceutical manu-
facturing, which can potentiate drug shortages.17
THE EFFECT OF SHORTAGES IN THE ED
Common ED Medications Affected
There are several medications currently on the FDA
drug shortage list that potentially affect ED care.3 Many
medications in short supply are routinely used for criti-
cal care patients, including drugs for rapid sequence
intubation (RSI), seizures, antidotes, and resuscitation.
Other commonly used medications also affected include
analgesics, antiemetics, and anticoagulants3 (Table 1). It
is important to note that these shortages also have the
potential to affect supplies to emergency medical ser-
vices (EMS) in the prehospital setting.
Substitution Errors
Shortages of commonly used ED medications can have
an effect on patient care and outcomes for many rea-
sons. First, providers in the ED often memorize speciﬁc
medications and dosages for high-acuity conditions,
such as those requiring RSI or for status epilepticus.
When alternative medications must be prescribed
because of a shortage, the prescriber may be less
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familiar with available alternatives, speciﬁcally, proper
dosing, administration procedures, and contraindica-
tions. When patients are in extremis, as commonly
occurs in the ED, there is limited time to consult a drug
reference, nor are medications commonly reviewed
prior to administration unless there is a dedicated ED
pharmacist available around the clock. These factors
can contribute to medication errors.8,21 Nursing admin-
istration errors also can be facilitated by drug short-
ages.22 In one case, methohexital was being used as a
substitute during a shortage of propofol. The methohex-
ital, which is not commonly used, was improperly
diluted and a patient received a fatal overdose.14
Use of Therapeutic Alternatives
Another potential consequence of ED drug shortages is
that alternative agents may be less effective or have
more adverse effects. For example, the FDA has listed
succinylcholine in short supply for over a year.3 This
has resulted in the use of alternative paralytics for RSI,
such as rocuronium. Alternative paralytics may be less
effective than succinylcholine or have the unwanted
effect of prolonged paralysis, leading to suboptimal in-
tubating conditions and increasing the risk of complica-
tions.23 As another example, several benzodiazepines
that are considered ﬁrst-line treatment for ethanol with-
drawal (midazolam, lorazepam, and diazepam) have had
reported shortages within the past year.3,24 Barbiturates
may be used as a substitute for benzodiazepines in a
shortage situation. While barbiturates are effective to
treat withdrawal, they have more adverse effects and a
narrower margin of safety.24,25
Delayed or Inadequate Treatment
In some shortage scenarios, there may not be an alterna-
tive treatment, which can lead to delayed treatment or
nontreatment. Some hospitals have the practice of relo-
cating medications that are in short supply from the
ﬂoors to the pharmacy to better manage use. This prac-
tice can be dangerous when the medication is needed
during an emergency and can have potentially fatal con-
sequences in the ED and critical care settings.26 Short-
ages that have affected several opioid analgesics can
also result in other consequences, such as inadequate
pain control.27 When a medication is completely unavail-
able, there may also be adverse outcomes. This has been
described in the oncology literature; however, this may
also affect the ED.28–30 For example, during previous
inﬂuenza seasons, there have been shortages of both
oseltamivir and inﬂuenza vaccines. This can have a
Table 1
Recently Reported Shortages for Common ED Therapeutic Categories
Therapeutic
Category Agents Involved Reasons for Shortage Potential Substitute
Analgesics Fentanyl IV
Hydromorphone IV
Ketorolac IV
Morphine IV
Good manufacturing practice
Increased demand
Manufacturing delay
Other
Fentanyl transmucosal
Hydromorphone oral
Ketorolac oral
Morphine oral
Oxycodone oral
Antiemetics Metoclopramide IV
Ondansetron IV
Prochlorperazine IV
Promethazine IV
Good manufacturing practice
Increased demand
Manufacturing delay
Product discontinuation
Shipping delay
Other
Metoclopramide oral
Ondansetron oral
Prochlorperazine oral,
suppository
Promethazine oral,
suppository
Antimicrobials Amikacin IV
Doxycycline IV
Oseltamivir liquid
Sulfamethoxazole/
trimethoprim IV
Tobramycin IV
Good manufacturing practice
Increased demand
Manufacturing delay
Shipping delay
Other
Gentamicin IV
Doxycyline oral
Oseltamivir capsules
Sulfamethoxazole/TMP oral
Gentamicin IV
Benzodiazepines Diazepam IV
Lorazepam IV
Midazolam IV
Increased demand
Manufacturing delay
Product discontinuation
Diazepam oral, rectal
Lorazepam oral
Oxazepam, chlordiazepoxide,
barbiturates for alcohol
withdrawal
Electrolyte
solutions
Calcium chloride IV
Calcium gluconate IV
Magnesium sulfate IV
Potassium chloride IV
Sodium bicarbonate IV
Increased demand
Manufacturing delay
Other
For electrolyte deficiency
could use oral preparations,
but in fatal electrolyte
abnormality of cardiac
dysrhythmia no substitute
Potassium acetate IV
Sodium acetate IV
Local anesthetics Bupivacaine injection
Lidocaine injection
Increased demand
Manufacturer delay
Product discontinuation
Benzocaine topical
Lidocaine topical
Procaine injection
Tetracaine injection
Rapid sequence
induction
Etomidate IV
Propofol IV
Succinylcholine IV
Increased demand
Manufacturing delay
Shipping delay
Other
Ketamine IV
Methohexital IV
Rocuronium IV
Vecuronium IV
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major effect on the ED and may pose a public health
hazard during an epidemic, when patients at high risk of
complications go untreated and more patients present to
the ED because of the lack of vaccination.31
Different Concentrations
Medication errors can also occur when there is a
change in concentration or packaging due to a short-
age. Under routine circumstances, drugs of the same
concentration are often stocked in the ED. However,
during a shortage, pharmacy purchasers may need to
procure medications in nonroutine concentrations. In
one reported case that happened in a gastroenterology
suite, there was a shortage of the usual ketamine con-
centration (10 mg/mL). Instead the pharmacy was using
the 50 mg/mL concentration because that was what was
available. The provider did not properly dilute the medi-
cation and a patient was overdosed, experiencing con-
fusion and delirium.32 Such errors have also been
reported with different concentrations of opioids and
benzodiazepines.14
Compounding Errors
In an effort to ensure access to medications during
shortages, some pharmacies are compounding these
products themselves. Also, many products traditionally
available in premixed packages now have to be admixed
in pharmacies prior to dispensing. The process of com-
pounding medication introduces another step that can
potentially lead to errors. One case that was reported
involved a pharmacy that compounded a small batch of
bupivacaine and epinephrine; however, too much epi-
nephrine was put into the admixture. The drug was
administered to two patients who developed signiﬁcant
adverse effects.14 In addition to calculation errors, there
is also concern regarding microbial contamination of
compounded products, particularly in light of the recent
fungal meningitis outbreak.33–35 Small-scale pharmacy
compounding does not have to comply with the same
quality control standards as large-scale manufacturing
operations, increasing the potential for microbial
contamination, improper labeling, and substandard
product.34,35
Compromised Sterility and Infectious Complications
During shortages, efforts to preserve scarce resources
can have unwanted consequences. It is not uncommon
practice for sterile single-use vials of injectable products
to be penetrated multiple times to conserve medication
despite violating labeling recommendations. This prac-
tice can lead to compromised sterility and infectious
complications. In addition, improper use can lead to dis-
ease transmission between patients, including hepatitis
B and C and the human immunodeﬁciency virus. This
was reported in Nevada when 50-mL vials of propofol
were reused for multiple patients to conserve the medi-
cation. This practice resulted in the transmission of hep-
atitis C virus between patients.36
Increased Costs and Resource Utilization
Drug shortages can also increase health care costs. For
drugs that have been affected by shortages, the price of
the product often increases due to market forces.
Although proﬁt margins may increase, it is often not
enough to overcome the underlying reasons shortages
occur, particularly for generic drugs, as their prices are
often ﬁxed by Medicare legislation.18 Because generic
drugs are disproportionately affected by shortages,
health care facilities may need to purchase higher cost
brand name products or more expensive alternative
medications. Patients in the ambulatory setting may also
have to bear the burden of more costly alternative ther-
apies when purchasing medications at the pharmacy.
Drug shortages have also sparked the formation of a
“gray market,” where distributors buy up available sup-
plies of medications on the shortage list. These distribu-
tors then can sell the medications at signiﬁcantly higher
prices. One study reported up to a 335% increase in
drug prices on the gray market during a shortage.13,37
In addition, the labor costs can also be higher to man-
age inventory and locate medications during times of
shortage.7,8
MITIGATION STRATEGIES
The Role of the FDA and Governmental
Interventions
In response to shortages in the late 1990s and concerns
about potential disruptions from turn of the millennium
(Y2K), the FDA established the DSP in 1999. The pro-
gram was relatively small and less active until 2005,
when drug shortages started to become more pro-
nounced. At that time, the DSP had begun tracking
drug shortage reports and became more active in
resolving and mitigating the effects of shortages.1 The
DSP can serve various roles, depending on the charac-
teristics of the particular shortage. In addition, the FDA
has specialists with diverse knowledge to deal with dif-
ferent aspects of drug shortages. Once the DSP has
been notiﬁed that the potential for a shortage exists, the
program works with manufacturers to address the rea-
sons for compromised supply to prevent or mitigate the
shortage. The DSP will determine the necessity of the
medication involved and focus efforts on medications
deemed to have a greater necessity and those with lim-
ited therapeutic alternatives.38 The reasons for the
potential shortage are identiﬁed and addressed when
possible. This might involve the DSP helping to identify
different suppliers of raw materials or alternative manu-
facturers. In addition, the DSP can expedite FDA review
of supplemental applications and facility inspections.
The DSP can also provide guidance in bringing manu-
facturing facilities up to required standards.1,38
One of the most important ways in which drug short-
ages are mitigated is through the dissemination of
information on the FDA’s website. This is maintained
and updated daily by the DSP.3 Included is information
on which drugs are experiencing shortages, speciﬁc
products affected, the duration of the shortage, reasons
for the shortage, availability, and anticipated release
date if known. Timely knowledge of anticipated or
actual shortages can allow health care providers and
institutions to implement strategies to minimize the
effects of the shortage.1
There are additional roles that the FDA can perform
to mitigate drug shortages. The FDA has allowed for
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temporary importation of medications affected by short-
ages that meet U.S. quality standards. The FDA has per-
mitted the distribution of medications that have
particulate matter found on inspection if a ﬁlter is used
prior to administration to eliminate risk to the patient.39
Another way the FDA has increased supplies of medica-
tions affected by shortage is to extend expiration dates
on medication that is on the market and about to expire.
An example of this practice involved coral snake anti-
venin, which was discontinued by the manufacturer and
would otherwise be completely unavailable to treat
potentially life-threatening envenomations.40
Although the FDA plays a critical role in the manage-
ment of drug shortages, it has limited regulatory
authority. Currently, the FDA cannot require a manu-
facturer to produce a speciﬁc product or regulate the
volume of product produced. In addition, the FDA can-
not determine how the product is distributed or to
whom it is distributed. Pharmaceutical manufacturers
are not required to specify production goals to the
FDA, and the FDA does not have the ability to repri-
mand manufacturers who do not meet these goals or
current quality standards.20
Prior to the Food and Drug Administration Safety
and Innovation Act (FDASIA) of 2012, manufacturers
had to provide advanced notiﬁcation of anticipated
shortages only in selected circumstances. The passage
of FDASIA helped to expand the authority of the FDA
in managing drug shortages.39 Speciﬁcally, it requires
all manufacturers of medically important drugs to notify
the FDA in advance if they anticipate production prob-
lems or plan to discontinue a product. These early noti-
ﬁcation clauses also include biologic products.39 In late
2011, President Obama also issued an executive order
to promote the voluntary reporting of potential short-
ages. This advanced notiﬁcation may allow the FDA,
other manufacturers, distributors, and health care facili-
ties to mobilize resources to minimize the effects of
anticipated shortages. The FDA was also provided
authority to expedite the review of drug applications
and manufacturing facilities in cases where these
actions would mitigate a shortage situation. The FDA-
SIA also allows health care facilities and third parties to
report shortages and has loosened restrictions on
hospitals that repackage medications that are in short
supply. Finally, FDASIA provides for the establishment
of an FDA task force to develop a strategic plan for the
future management of drug shortages that was submit-
ted to Congress in October 2013. The initial strategic
plan focused on two main priorities: strengthening miti-
gation response and developing long-term prevention
strategies (Table 2).41 The FDA must provide Congress
with an annual report regarding the state of drug short-
ages in the United States.39
One major shortcoming of FDASIA is that there are
no provisions for penalties for manufacturers who do
not comply with notiﬁcation requirements. The FDA
can issue publically available letters of noncompliance
to manufacturers but cannot levy civil or monetary pen-
alties. In addition, the FDA cannot force manufacturers
to produce a particular medication, nor can they penal-
ize manufacturers for the quality of products pro-
duced.39 Although the initial response by manufacturers
has been positive, it is unclear if this is adequate incen-
tive to ensure compliance with FDASIA. One report
found that there was a signiﬁcant increase in the num-
ber of shortages that were both reported and pre-
vented; however, there has not been a decline in the
total number of drug shortages since the passage of
FDASIA.42
Because drug shortages continue to be a major prob-
lem after the passage of FDASIA, there has been much
debate over what additional steps can be taken to fur-
ther mitigate the situation. Many have proposed holding
manufacturers responsible for failure to comply with
FDASIA notiﬁcation requirements by allowing civil and
monetary penalties.42 In 2011, there were bills intro-
duced and supported primarily by Democrats into the
Senate and House of Representatives, both called the
Preserving Access to Life-Saving Medications Act.
These bills would allow for such penalties and further
expand the authority of the FDA. At this time, neither
bill has been enacted into law.43,44 There has been some
opposition to these bills primarily by the Republican
party, which has traditionally been a strong supporter
of the pharmaceutical industry, a major opponent of
such legislation.45 Another option would be to provide
incentives to manufacturers for keeping their facilities
in good working order and for expanding their capacity
to produce medications that may be affected by short-
ages. These incentives could take the form of tax credits,
rebates, or temporary market exclusivity.43 Such incen-
tives would in part address some of the major underly-
ing causes of drug shortages, in particular the
proﬁtability of generic injectable drugs. Another inter-
vention that has been proposed by Republicans would
be to remove price limitations on injectable generic
drugs that are imposed by Medicare legislation, which
would allow prices to increase based on market forces,
increasing proﬁtability for manufacturers.46 At the same
time, this would also increase drug costs for Medicare
programs, health care facilities, and patients, which
could have unintended consequences.18
Nongovernmental Efforts
There are a variety of strategies that can be employed
to prevent or mitigate the consequences of drug short-
ages both in the ED and on a larger scale. In addition to
the FDA’s DSP, the American Society of Health Systems
Pharmacists (ASHP) has become a valuable resource.47
Table 2
Key Elements of the FDA’s Strategic Plan to Address Drug
Shortages
Goal 1: Strengthen Mitigation Response
Develop and/or streamline internal FDA processes
Improve data and response tracking
Clarify manufacturer’s roles and responsibilities
Enhance public communication about drug shortages
Goal 2: Develop Long-term Prevention Strategies
Develop methods to prioritize and incentivize manufacturing
quality
Use regulatory science to identify early-warning signals of
shortages
Increase knowledge to develop new strategies to address
shortages
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The ASHP regularly maintains a website with detailed
shortage information, focusing on clinical management
and ensuring optimal drug therapy. The organization
has drafted guidelines for the management of shortages
and purchasing guidelines for pharmacies.48,49 The
ASHP website also provides therapeutic alternatives to
drugs in current shortages when available.47 In
response to widespread drug shortages, many institu-
tions have attempted to develop speciﬁc evidence-based
protocols for substitutions when possible. One recent
example included the use of sodium acetate as a
replacement for sodium bicarbonate as an antidote for
speciﬁc poisonings.49 Information from these various
sources can be used by hospital-based pharmacy staff,
ED administration, and providers, to mitigate the effects
of shortages.
At the state level, the Texas Medical Board has set an
example by working to promote awareness and mitigate
the effects of drug shortages. The board has taken the
step of acknowledging that shortages can affect patient
care, provides resources on its website, and has made it
a point to take shortages into consideration when
addressing complaints to the board.50 In addition, the
Texas Department of State Health Services has also
issued guidance for EMS providers in managing short-
ages.51 Hopefully these state and local initiatives will
continue to develop and augment national-level efforts.
The Role of EDs and Hospitals
Although oncology drugs have been most commonly
affected by shortages, there have been valuable lessons
learned that can be translated into the ED. Oncology
practitioners have become vigilant in identifying poten-
tial shortages and being proactive in inventory manage-
ment. In efforts to expand existing supplies, different
formulations (preservative containing vs. preservative
free) have been substituted when possible. In addition,
to minimize waste from partially used vials, multiple
patients are scheduled for their chemotherapy on the
same day to avoid wasting leftover medication. Finally,
when medication supplies cannot provide treatment for
all patients, an ethical framework has been designed for
prioritizing patients who should receive existing drugs.
Examples of patients who receive priority during times
of shortage include those undergoing curative therapy,
those on regimens with proven survival beneﬁts, those
with cancers without acceptable alternative regimens,
pediatric patients, and those patients involved in clinical
trials.52 Such strategies have helped to mitigate the
effects of shortages in the oncology population and
some principles may be applied to managing shortages
in the ED; however, drug shortages are becoming a
mounting problem for a broader range of patients.
When it comes to managing ED drug shortages, we
recommend a proactive approach. ED providers, phar-
macists, and administrators should become familiar
with current medication shortages that may affect their
departments. Frequent communication with the phar-
macy department and the hospital pharmacy and thera-
peutics (“P and T”) committee can mitigate the effects of
shortages. P and T committees can assist in prioritizing
use of medications in short supply and designing proto-
cols for substitution. Emergency physicians play an
active role in P and T committees in many institutions.
When an ED shortage occurs, it is important to identify
available therapeutic alternatives. It is equally important
to ensure that there are protocols in place for use of
alternative medications and that staff is properly edu-
cated regarding use.9 One strategy might be to spell out
alternative drug names and doses in a large sign in crit-
ical care rooms to ensure that providers have a back-up
when common RSI medications are in short supply.
Alternatively, clinical decision support at the point of
electronic order entry might even suggest appropriate
alternatives for a medication in shortage. When no ther-
apeutic alternative exists, there should be an organized
and ethical approach for allocating existing supplies.10
In these situations, patients with the greatest need for
the medication should receive priority.10 For example,
when tetanus vaccine was in short supply, only patients
with high-risk wounds were vaccinated.9 When
resources permit, ED-based pharmacists can play a crit-
ical role in managing drug shortages. In addition to
managing shortages in the ED, EMS medical directors
must also be aware of current shortage trends, identify
therapeutic alternatives, and revise protocols as neces-
sary to ensure that patients in the prehospital setting
receive the best possible drug therapy.53
Because drug shortages might result in adverse medi-
cal outcomes, ED providers could potentially be held lia-
ble. At the same time, there is little legal precedent with
regard to liability in such situations and the details of
each individual case will often determine liability. Cur-
rently, pharmaceutical manufacturers are not liable for
adverse outcomes that result from drug shortages.1 Pro-
viders and health care facilities are not likely to be held
liable simply because a medication was not available,
but more likely because there were not proper policies
in place to mitigate the effects of the shortage or
because a medical error occurred in using an alternative
medication.45 Liability for adverse outcomes can be min-
imized in health care facilities by taking a proactive
approach, primarily by being aware of and anticipating
shortages, having appropriate protocols in place when
a shortage occurs, educating providers, and performing
continuous quality review.45 Similarly, in the prehospital
setting, knowledge of current shortages with proactive
incorporation into protocols and education of providers
is critical in avoiding liability.54 In the ED, in addition to
being aware of shortages and protocols, providers
should document that the rationale for using alternative
medications was related to a shortage of the preferred
drug. In addition, if there is a delay in therapy or
adverse drug event pursuant to a drug shortage, this
should also be carefully documented and risk manage-
ment involved.9
CONCLUSIONS
Drug shortages are caused by a variety of factors and
most commonly involve generic parenteral medications.
Many of these drugs are commonly used in the ED, par-
ticularly in the critical care setting, and may affect
patient care and increase health care costs. Current pol-
icy initiatives have had a limited effect on addressing
drug shortages. ED providers must be aware of short-
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ages and take an active role in mitigating their effects
on patient care. Ultimately, a multifaceted approach
involving regulators, manufacturers, providers, and
other stakeholders will be required to address this
growing public health problem.
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Abstract
Objectives: This was a study of longitudinal trends in U.S. drug shortages within the scope of
emergency medicine (EM) practice from 2001 to 2014.
Methods: Drug shortage data from the University of Utah Drug Information Service were analyzed from
January 2001 to March 2014. Two board-certiﬁed emergency physicians classiﬁed drug shortages based
on whether they were within the scope of EM practice, whether they are used for lifesaving
interventions or high-acuity conditions, and whether a substitute for the drug exists for its routine use in
emergency care. Trends in the length of shortages for drugs used in EM practice were described using
standard descriptive statistics and regression analyses.
Results: Of the 1,798 drug shortages over the approximately 13-year period (159 months), 610 shortages
(33.9%) were classiﬁed as within the scope of EM practice. Of those, 321 (52.6%) were for drugs used as
lifesaving interventions or for high-acuity conditions, and of those, 32 (10.0%) were for drugs with no
available substitute. The prevalence of EM drug shortages fell from 2002 to 2007; however, between
January 2008 and March 2014, the number of EM drug shortages sharply increased by 435% from 23 to
123. From January 2008 to March 2014 shortages in drugs used as a direct lifesaving intervention or for
high-acuity conditions increased 393% from 14 to 69, and shortages for drugs with no available
substitute grew 125% from four to nine. Almost half (46.6%) of all EM drug shortages were caused by
unknown reasons (the manufacturer did not cite a speciﬁc reason when contacted). Infectious disease
drugs were the most common EM drugs on shortage, with 148 drug shortages totaling 2,213 months
during the study period.
Conclusions: Drug shortages impacting emergency care have grown dramatically since 2008. The
majority of shortages are for drugs used for lifesaving interventions or high-acuity conditions. For some,
no substitute is available.
ACADEMIC EMERGENCY MEDICINE 2015;23:1–7 © 2015 by the Society for Academic Emergency
Medicine
Drug shortages are deﬁned by the U.S. Food andDrug Administration (FDA) as “a period of timewhen the demand or projected demand for the
drug within the United States exceeds the supply of the
drug.”1 A 2014 Government Accountability Ofﬁce
(GAO) report reviewed trends in drug shortages and
reported that the number of active shortages each year
almost tripled between 2007 and 2012, from 154 in 2007
to 456 in 2012.2 Quality control problems, such as bacte-
rial contamination or the presence of glass or metal
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particles in drug vials that resulted in supply disrup-
tions, were the most frequently cited causes; however,
the report also cited that half of studies reviewed by the
GAO suggested that the immediate cause of drug short-
ages are driven by underlying economics of the drug
market.2
A wide range of medications used both in the emer-
gency department (ED) and in prehospital settings, such
as antidotes, heparin, and nitroglycerin, have recently
been affected by national drug shortages. Not having
commonly used medications to treat high-acuity condi-
tions such as respiratory distress, cardiac dysrhythmias,
and overdoses can reduce the ability of ED providers to
deliver quality care because in many cases substitutes
are considerably less effective, and physicians are not
as familiar with their use.3 In addition, not having com-
monly used medications to treat everyday conditions,
such as prochlorperazine for headache and nausea, can
lead emergency physicians (EPs) to choose other less
effective medications or use more expensive alterna-
tives. In a proceedings report from the Health and
Human Services’ Emergency Care Coordination Center,
it was estimated that 40% of drug shortages affect
emergency care.4 To the best of our knowledge no stud-
ies in peer-reviewed journals have directly analyzed
data to estimate the actual proportion nor assessed
what speciﬁc types of medications have been in short-
age in emergency care for the longest periods of time.
We describe trends in U.S. drug shortages affecting
emergency care from 2001 into 2014 and categorize the
medications based on whether they are used for life-
threatening illnesses or high-acuity conditions and
whether a substitute exists. We also describe shortages
affecting speciﬁc therapies.
METHODS
Study Design
This was a secondary data analysis. This study was
determined to not be human subjects research by the
institutional review board at the George Washington
University.
Study Setting and Population
We used drug shortage data from the University of
Utah Drug Information Service (UUDIS) from January
2001, when data collection started by this service, to
March 2014. UUDIS receives reports of drug shortages
submitted via the American Society of Health-System
Pharmacists (ASHP) public website (www.ashp.org/
shortage). Anyone can report a drug shortage on this
website. Drug information specialists at UUDIS
research these shortage reports by contacting product
manufacturers to verify if a shortage exists and, if so, to
determine the reason and an estimated resupply date. If
the investigation shows a shortage exists, information is
then transferred to ASHP and is posted at the ASHP
public website. When possible, online postings on the
ASHP website contain information about alternative
medications as well as potential safety implications.
UUDIS frequently updates the information based on the
estimated resupply dates. UUDIS and ASHP deﬁne a
drug shortage as “a supply issue that affects how the
pharmacy prepares or dispenses a drug product or
inﬂuences patient care when prescribers must use an
alternative agent.”5 For example, a shortage of preﬁlled
syringes of a speciﬁc product may cause signiﬁcant
logistic and safety issues, even if the same product is
available in vials. This clinician-focused deﬁnition results
in a larger number of drug shortages tracked than by
the FDA. UUDIS considers a shortage to be resolved
when all National Drug Codes either are back in stock
or have been discontinued. Data from UUDIS were used
in this study for our analysis instead of taking data
directly from the FDA because prior to the FDA Safety
Innovation Act of 2012 (FDASIA) the FDA did not pub-
lish shortages in a publicly available database.
Study Protocol
To describe the extent of drug shortages in the ﬁeld of
emergency medicine (EM), two board-certiﬁed, practic-
ing EPs (one is JMP) (one of whom also has a Doctor of
Pharmacy degree and is a board-certiﬁed medical toxi-
cologist [MMA]) independently reviewed data from the
UUDIS on 1,798 pharmaceutical products. For each
drug entry, the two physicians assessed: 1) whether or
not the drug is used in the general scope of EM prac-
tice; 2) whether drugs within the scope of ED practice
were used as a direct intervention for a lifesaving or
high-acuity condition (i.e., medications used for resusci-
tation/intubation such as succinylcholine or vasopres-
sors or medications used in Advanced Cardiovascular
Life Support such as epinephrine or amiodarone); and
3) whether a substitute for the drug exists for the com-
mon ED practice indication (i.e., naloxone is the only
reversal agent for opioid overdose). The kappa coefﬁ-
cient for inter-rater agreement for whether the drug
was used in ED practice was 0.69 (95% conﬁdence
interval [CI] = 0.65 to 0.72), for whether it was used for
a direct intervention for a high-acuity condition was
0.59 (95% CI = 0.52 to 0.66), and whether a substitute
exists was 0.70 (95% CI = 0.58 to 0.81). Kappa coefﬁ-
cients in the range of 0.61 to 0.80 are considered to
have substantial agreement while 0.41 to 0.60 are con-
sidered to have moderate agreement.6 All discrepancies
were discussed between the two physicians for a ﬁnal
categorization for each variable.
Additional data from UUDIS included were the year
of the shortage and the length of the shortage; in addi-
tion, medications were classiﬁed by one EP (MMA) into
the following categories based on the primary indica-
tion in EM: allergy/immunology, analgesia, cardiology,
cardiovascular, critical care, endocrine, ﬂuids/elec-
trolytes, gastrointestinal, hematology, infectious disease,
local anesthetics, miscellaneous, musculoskeletal, neu-
rology, obstetrics/gynecology, ophthalmology, psychia-
try, pulmonology, sedative-hypnotic, topical, and
toxicology. The EP with the pharmacy degree deter-
mined these categories. This EP also conducted the
review of pharmaceutical data from the UUDIS.
Data Analysis
Data were described using standard descriptive
statistics. A Shapiro-Wilk test found that shortage time
was not normally distributed. Therefore, we used
the Wilcoxon rank-sum (Mann-Whitney) tests and
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Kruskal-Wallis tests to assess differences in shortage
time by reasons for shortage, acuity, substitute availabil-
ity, and year. To calculate differences in shortage time
with a 95% CI, we used Hodges-Lehmann median dis-
tances. Shortages for drugs that were discontinued
were not used in analyses of shortage time (n = 23). The
analyses used all available data in the UUDIS, and
therefore no calculations to anticipate needed sample
sizes for comparisons were performed.
Visual inspection of the drug shortages by month
showed two distinct temporal trends—a downward
(negative) trend from 2002 to the end of 2007 and an
upward (positive) trend from the beginning of 2008 to
2014. A segmented regression analysis of drug short-
ages before and after January 2008 was performed to
assess these trends. Time was coded as a continuous
variable in 1-month intervals from 1 (January 2001) to
159 (March 2014). We excluded the ﬁrst year of data col-
lection (2001) from the regression equation to adjust for
a time lag for drugs to ﬁrst appear on the shortage list.
For analytic purposes, drugs that were on shortage for
more than one time period were counted as separate
shortages. The total number of EM drugs on shortage
was regressed on a constant, a linear trend term (x), a
dummy variable equaling zero prior to January 2008
and one thereafter, and a post-January 2008 trend term
(x–84) as described by Wagner et al.7 A Durbin-Watson
test indicated presence of serial autocorrelation and was
corrected for by using the Cochrane-Orcutt transforma-
tion.8 A Shapiro-Wilk test conﬁrmed that the residuals
were normally distributed. A Breusch-Pagan/Cook-
Weisberg test indicated presence of heteroscedasticity,
and therefore robust standard errors were used. No out-
liers were detected using standard box-plot analysis (in-
terquartile method).9 A p-value of <0.05 was considered
statistically signiﬁcant for comparisons. Data were col-
lected in Microsoft Excel and analyses were conducted
using Stata 13.1.
RESULTS
Descriptive Analysis of Data
There were 1,798 drug shortages from January 2001 to
March 2014, of which 610 (33.9%) were classiﬁed within
the scope of EM (Table 1). Of the drugs used in EM,
52.6% (321 shortages) were for drugs used as a direct
intervention for life saving or high-acuity conditions.
This accounted for 17.9% of all drug shortages overall
during the study time frame (321 of 1,798). Of these 321
shortages, 10.0% (32 shortages) did not have substitutes
(Data Supplement S1, available as supporting informa-
tion in the online version of this paper).
The median shortage time for EM drugs was
9 months (interquartile range [IQR] = 4 to 20 months).
No signiﬁcant differences were found in shortage times
for drugs used as a direct intervention for high-acuity
conditions or for drugs with no available substitute.
Median shortage time for drugs used as a direct inter-
vention for high-acuity conditions was nine months
(IQR = 4 to 23) compared to nine months (IQR = 3.5 to
17) for drugs not used for this reason, with a median
difference of one month (95% CI = 0 to 2 months). Med-
ian shortage time for drugs with no available substitute
was 10.5 months (IQR = 4 to 22.5 months) compared to
Table 1
Categories of Drugs on Shortage used in Emergency Medicine and High-acuity Versus Non–High-acuity Drugs (January 2001–March
2014
Drug Category
Number of Shortages,
Total = 610
Acuity of Shortage
Drug Most Frequently on Shortage (Number
of Times on Shortage)
High-acuity,
Total = 321
Non–High-acuity,
Total = 289
Infectious disease 148 (24.3) 66 (44.6) 82 (55.4) Acyclovir injection (6)
Analgesia 57 (9.3) 3 (5.3) 54 (94.7) Hydromorphone (8)
Toxicology 52 (8.5) 51 (98.1) 1 (1.9) Antivenin polyvalent injection (5)
Critical care 50 (8.2) 49 (98.0) 1 (2.0) Epinephrine 1 mg/mL injection (7)
Gastrointestinal 48 (7.9) 9 (18.8) 39 (81.2) Pantoprazole (8)
Miscellaneous 48 (7.9) 20 (41.7) 28 (58.3) Dexamethasone (6)
Cardiology 39 (6.4) 36 (92.3) 3 (7.7) Nitroglycerin injection (8)
Fluids/electrolytes 26 (4.3) 23 (88.5) 3 (11.5) Calcium chloride (5)
Sedative-hypnotic 22 (3.6) 13 (59.1) 9 (40.9) Phenobarbital Elixir (6)
Local anesthetics 21 (3.4) 4 (19.0) 17 (81.0) Lidocaine/epinephrine (9)
Hematology 18 (3.0) 14 (77.8) 4 (22.2) Desmopressin (2)
Pulmonology 18 (3.0) 5 (27.8) 13 (72.2) Guaifenesin extended-release tablets (multiple
suppliers) (4)
Cardiovascular 12 (2.0) 9 (75.0) 3 (25.0) Bumetanide injection (3)
Neurology 11 (1.8) 6 (54.5) 5 (45.5) Phenytoin (5)
Allergy/immunology 9 (1.5) 3 (33.3) 6 (66.7) Diphenhydramine (3)
Ophthalmology 9 (1.5) 0 (0.0) 9 (100.0) Tetracaine 0.5% eye drops (2)
Endocrine 8 (1.3) 6 (75.0) 2 (25.0) Levothyroxine injection (4)
OB/GYN 5 (0.8) 4 (80.0) 1 (20.0) Methylergonovine (4)
Psychiatry 4 (0.7) 0 (0.0) 4 (100.0) Benztropine injection (2)
Musculoskeletal 4 (0.7) 0 (0.0) 4 (100.0) Methocarbamol 500 mg tablets (4)
Topical 1 (0.2) 0 (0.0) 1 (100.0) Gelfoam (1)
Data are reported as n (%).
OB/GYN = obstetrics and gynecology
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9 months (IQR = 4 to 19) for drugs with an available
substitute, with a median difference of 1 month (95%
CI = –2 to 4 months).
Most Common Drugs on Shortage
Drugs were categorized by pharmacologic class to
understand the landscape of the shortages (Table 1).
The most common categories of EM drugs found on
shortage during the study period were infectious dis-
ease, analgesia, and toxicology. For these categories,
the most common drugs on shortage were acyclovir
injection (infectious diseases), hydromorphone (analge-
sia), and antivenin polyvalent injection (toxicology).
Reasons for Shortages
Common reasons for drug shortages are presented in
Table 2. For the EM drug shortages with a known rea-
son, 25.6% were due to manufacturing delays or prob-
lems, 14.9% were due to supply and demand issues, and
4.4% were due to issues with raw materials. In 46.6% of
shortages, manufacturers did not give a reason. Other
reasons for shortages included business decisions, dis-
continued products, and regulatory reasons. Median
shortage time was longest for drugs on shortage due to
raw materials (18 months; IQR = 7 to 34 months) and
shortest for regulatory issues (3 months; IQR = 1 to 13
months).
Trends in Data by Shortage Month
The number of EM drug shortages for each month from
2001 to 2014 is shown in Figure 1. Two distinct trends
can be seen between 2002 and the end of 2007 and from
the beginning of 2008 to March 2014. These trends were
examined using segmented regression analysis. From
January 2002 to December 2007, the number of EM
drugs on shortage decreased from 52 to 20 at a rate of
b –0.60 drugs per months (95% CI = b –0.77 to b –0.43).
From January 2008 to March 2014, the number of drugs
on shortage increased from 23 to 123 at a rate of 1.49
drugs per month (95% CI = 1.33 to 1.66). A similar
trend was found in both high- and non–high-acuity con-
ditions (Table 3).
DISCUSSION
We found that drug shortages for medications impact-
ing emergency care fell from 2002 to 2008, but since
2008 have risen dramatically by more than 400%.
Nearly half of the drugs in shortage were drugs used
for high-acuity or life-threatening conditions, and in a
minority of cases (32 over 13 years), there was no sub-
stitute available (Data Supplement S1). We were not
able to directly determine the cause for the fall and sub-
sequent rise in shortages in recent years; however, sev-
eral factors likely contribute. A recent 2014 GAO report
found no clear consensus on the underlying cause of
drug shortages, citing quality problems or changes in
the way that FDA conducts inspections may be con-
tributing factors.2 The GAO report also noted other
potential causes such as the role of group purchasing
organizations, changes in Medicare Part B reimburse-
ment policy, or low-proﬁt margins that limited invest-
ments infrastructure and may have caused
manufacturers to exit the market.2
Speciﬁcally with respect to FDA inspection and com-
pliance activities, increased FDA oversight of the manu-
facturing process may have contributed to temporary
and permanent plant closures, leading to supply disrup-
tions.2,10 The House Committee Report highlighted that
between 2009 and 2010 the number of warning letters
sent by the agency increased by 42%, and between 2010
and 2011 the number of warning letters increased by an
additional 156%.10 Of the 219 drugs listed on the ASHP
shortage list as of February 21, 2012, at least 128 (58%
of the drugs on the shortage list) were produced by at
least one facility undergoing FDA remediation.10
In addition, along with these factors, the 2008–2009
economic downturn may have played a role, since 2008
is the ﬁrst year of rising drug shortages. However, even
with the recent economic recovery, drug shortages have
continued to grow. Of all EM drug shortages (n = 610),
one in four were due to manufacturing delays or prob-
lems and 15% were due to supply and demand issues
(Table 2), which suggest that shortages may be continu-
ing due to market failure.
The majority of drugs in shortage over the study per-
iod were generic sterile injectable drugs. A common
reason that is often cited behind the cause of generic
shortages is the low reimbursement rates from Medi-
care Part B, which was initiated in the Medicare Mod-
ernization Act of 2003.11 This part of the law commonly
referred to as “ASP (average sales price) plus 6%,” caps
Medicare reimbursement to hospital outpatient clinics
and individual physicians at 6% over the average sales
price of the drug. Generic sterile injectables are already
priced very low, so the proﬁt margin remains low.
Because there is a 6-month lag between manufacturers’
submission of ASP data and when changes in sales
prices are reﬂected in reimbursement, it is difﬁcult for
manufacturers to raise their prices more than 6% in any
6-month period. Even though this reimbursement policy
does not apply to inpatient settings, it still creates
risks in markets like sterile injectables, where the
Table 2
Most Common Reasons Given for Drug Shortage, January 2001
–March 2014
Reason for
Shortage*
Number of
Shortages, n (%)
Shortage
Months
Median
(IQR)
Manufacturing
delays/problems
156 (25.6) 2,901 13 (6–26)
Supply and
demand
91 (14.9) 1,364 10 (4–19)
Raw materials 27 (4.4) 596 18 (7–34)
Discontinued 23 (3.8) NA NA
Regulatory 11 (1.8) 151 3 (1–13)
Business decision 13 (2.1) 145 6 (3–14)
Other† 5 (0.8) 25 3 (2–8)
Unknown 284 (46.6) 3,532 7 (3–15)
Total 610 8,714 9 (4–20)
IQR = interquartile range; NA = not applicable.
*Reasons for shortages were given by the drug’s manufac-
turer.
†Other = short-dated product (n = 2), natural disaster (n = 2),
temporary plant closure.
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manufacturing process is not trivial and the constant
drive to lower costs can leave little room for investment
in expansion or improvement of manufacturing facili-
ties. Another frequently cited cause of the shortage in
sterile injectables is that the number of manufacturers
in the market is very small, and therefore there is a lack
of “capacity,” which means another line or facility
would not be available to manufacture the same product
if active lines or facilities were deemed inoperable.11
While data show that the overall quantity and range of
drugs produced by generic oncology manufactures has
increased substantially, the capacity of these manufac-
turing facilities have remained stable.12 Shortages are
then concentrated in drugs where the volume of sales
and drug prices were declining in years preceding the
shortage, suggesting that manufacturers may be divert-
ing resources to more proﬁtable product lines.12
Drug shortages are of particular concern in emer-
gency care settings where providers must rapidly treat
ill and injured patients. In our study, some of the
drugs that were most commonly on shortage included
medications such as epinephrine and amiodarone,
which are used in relatively rare emergency situations
and also more commonly used medications that have a
variety of indications, such as promethazine, loraze-
pam, and diphenhydramine. For most medications,
substitutes exist but may not be as effective and may
have more side effects or providers may not have as
much experience using them. This could lead to
increases in medication errors, such as issues with
dosing or interactions.
In 32 drugs over the 14-year period, there was no
substitute for a drug on shortage. These include anti-
dotes that reverse the effects of drug overdose (thera-
peutic or recreational drugs) or are treatments for
exposure to toxic substances. The longest affected medi-
cation in the infectious disease category was the rabies
immune globulin. While relatively rare, this can put
patients at serious risk if unavailable. Shortages of other
injectables like naloxone are also problematic because
there is no other substitute for opioid intoxication.13
Figure 1. Shortages of emergency medicine drugs, January 2001 through March 2014. EM = emergency medicine.
Table 3
Segmented Regression Analysis of Monthly Drug Shortages:
January 2002–March 2014
Shortages
b
Coefficients 95% CI
All EM drugs
Trend January
2002–December 2007
–0.60 –0.77 to –0.43
Trend January 2008–March
2014
1.49 1.33 to 1.66
Trend change 2.09 1.80 to 2.38
R2 0.76
Non–high-acuity drugs
Trend January
2002–December 2007
–0.23 –0.31 to –0.16
Trend January 2008–March
2014
0.60 0.52 to 0.69
Trend change 0.83 0.70 to 0.97
R2 0.66
High-acuity drugs
Trend January
2002–December 2007
–0.33 –0.56 to –0.10
Trend January 2008–March
2014
0.87 0.71 to 1.02
Trend change 2008–2014 1.20 0.87 to 1.52
R2 0.54
No substitute available
Trend January
2002–December 2007
0.03 –0.00 to 0.06
Trend January 2008–March
2014
0.08 0.05 to 0.10
Trend change 2008–2014 0.05 0.00 to 0.09
R2 0.49
EM = emergency medicine.
*The estimates have been corrected for first-order autocorre-
lation by means of the Cochrane-Orcutt procedure.8
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With increasing drug shortages in the United States,
hospital systems and pharmacies need to inform
front-line EM providers of these shortages and have
hospital-wide protocols available for delivery of care
when critical drugs are on shortage. While local and
regional systems can collaborate to prepare for short-
ages and put protocols in place to protect patients to
the best of their ability, the root cause of drug shortages
should be aggressively explored at the national level by
policymakers, manufacturers, physician-led organiza-
tions, and patient advocacy groups. Attempts should
continue to be made by the FDA and other relevant
organizations to provide high-quality, timely informa-
tion about the availability of medically necessary drugs
to hospital pharmacies.
LIMITATIONS
Data collected by UUDIS are limited because they
depend on voluntary reports of shortages by clinicians;
therefore, drug shortages may have existed that are not
included in the UUDIS data set. We did not conduct an
anticipated needed sample size analysis because we
used all available data in the UUDIS. However, this is
the most comprehensive available source of drug short-
age information.
This study is also limited because we relied on two
physician reviewers to categorize the UUDIS drug list.
For example, the decision on whether or not a drug had
a substitute was a subjective distinction made by two
physician reviewers. The inter-rater agreement in these
classiﬁcations was reasonably high and was resolved
after discussion; however, had these classiﬁcations been
performed by other physicians, results may have been
different. We also only examined drug shortages in the
hospital setting and did not describe shortages impact-
ing prehospital care. We removed discontinued drugs
because many did not have any shortage time calcu-
lated. This action may have caused an underestimate of
total shortages and shortage time in cases where a drug
was on shortage for a period of time and then later dis-
continued.
Another limitation is that the data includes active
shortages. By deﬁnition, these shortages have not been
resolved, and therefore we do not know their actual
duration. For example, an active shortage that began in
January 2014 will only appear to have a shortage time
of 3 months (January 2014–March 2014). However, the
actual time of this shortage may be longer. As a result,
the shortage times reported may be underestimated.
CONCLUSIONS
Drug shortages affecting emergency care have grown
dramatically since 2008. The majority of shortages are
for drugs used for lifesaving interventions or high-
acuity conditions. For a minority of drugs, no therapeu-
tic alternative is available. Further work is needed to
understand the impact of drug shortages on ED quality
of care and outcomes. Drug shortages continue to be a
national concern to public health and should be pre-
vented by the continued efforts made by industry and
government. Until the problem is resolved, attempts
should continue to be made by the FDA and other rele-
vant organizations to provide high-quality, timely infor-
mation about the availability of medically necessary
drugs to hospital pharmacies.
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Purpose:We describe trends in U.S. shortages impacting critical care drugs from 2001 to 2016.
Materials and methods: Shortages within the scope of critical care were identiﬁed using data from the University
of Utah Drug Information Services. Shortage characteristics were described using standard descriptive statistics
and regression analysis.
Results:Of 1969 shortages reported, 1004 (51%)were for drugs used in critical care. New shortages fell from 2001
to 2004, then increased, peaking in 2011 (116). For critical care shortages, 247 (24.6%) involved drugs used for
high acuity conditions. The majority of drugs on shortage were parenteral, (720; 71.7%) and 393 (39.1%) were
single source drugs. Alternatives were available for 887 (88.3%) drugs, although 250 (24.9%) alternatives were
impacted by shortages. Infectious disease drugs were the most common drugs on shortage, with 200 (19.9%)
shortages,with amedian duration of 7.7months (IQR=2.8–17.3). By the end of the study, 896 (89.2%) shortages
were resolved and 108 (10.8%) remained active. Themedian duration for active shortages was 13.6months (IQR
= 5.8–58.4) while the duration for resolved shortages was 7.2 months (IQR = 2.8–17.3).
Conclusions: Although the number of new shortages peaked in 2011 and is now declining, there remain a
substantial number of active shortages impacting critical care drugs.
© 2017 Elsevier Inc. All rights reserved.
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1. Introduction
Prescription drug shortages are a major public health threat in the
U.S [1]. The Food and Drug Administration (FDA) deﬁnes a drug short-
age as “a period of time when the demand or projected demand for
the drug within the U.S. exceeds the supply of the drug” [2]. Despite ef-
forts to curb shortages, such as the 2012 Food and Drug Administration
Safety and Innovation Act (FDASIA), there was an increase in new drug
shortages between 2013 and 2014. The American Society of Health-Sys-
tem Pharmacists (ASHP) reported there were more than triple the
number of total new drug shortages in 2014 as there were in 2004 [3].
Many reported shortages have been attributed to business decisions
and supply disruptions arising from quality control problems [4]. The
most recent data from the Government Accountability Ofﬁce (GAO)
note many shortages are the result of a small number of manufacturers
combined with quality problems at the facilities and low proﬁt margins
[5]. Survey data suggest that drug shortages can result in increased
medication errors and adverse events translating into suboptimal care,
higher institutional costs, and poorer patient experience [6,7]. Drug
shortages have also been associated with delays in care [8].
The impact of shortages may be ampliﬁed in the critical care setting
where providers deliver time-sensitive, life-saving, high intensity care.
Shortages disproportionately impact sterile injectable medications,
which are commonly used in critical care settings. Use of alternative
medications, when available, may increase the likelihood of medication
errors because of provider unfamiliarity, or increased toxicity, due to
use of second-line medications that may have more adverse effects
than ﬁrst-line agents [9,10].
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While studies have examined overall and class-speciﬁc drug short-
ages, shortage trends pertaining speciﬁcally to critical care medicine
are less well described [1,11-14]. The objective of this study was to de-
scribe trends in U.S. shortages impacting drugs used in critical care prac-
tice from 2001 to 16.
2. Materials and methods
2.1. Study design and setting
Thiswas a retrospective study using shortage data from theUniversity
of Utah Drug Information Service (UUDIS) from January 2001 to June
2016. UUDIS receives reports of drug shortages submitted via the
American Society of Health-System Pharmacists (ASHP) public website
(www.ashp.org/shortage). Reported shortages are researched by Drug
Information Specialists at UUDIS who contact product manufacturers to
verify if a shortage exists. Once conﬁrmed, they obtain the reason and
an estimated resupply date. They transfer this information to the ASHP
who posts it on the ASHP public website. UUDIS frequently updates the
information based on the estimated resupply dates. UUDIS and ASHP de-
ﬁne a drug shortage as “a supply issue that affects how the pharmacy pre-
pares or dispenses a drug product or inﬂuences patient care when
prescribers must use an alternative agent.” [12] For example, a shortage
of a medication supplied in preﬁlled syringes may cause signiﬁcant logis-
tic and safety issues, even if the samemedication is available in vials. This
clinically focused deﬁnition results inmore drug shortages tracked by the
UUDIS than by the FDA,who deﬁnes a shortage as “a period of timewhen
the demand or projected demand for the drugwithin the U.S. exceeds the
supply of the drug” [2]. UUDIS considers a shortage to be resolved when
all National Drug Code (NDC) line items are either back in stock or have
been discontinued. Data pertaining to clinical outcomes regarding short-
ages are not collected by UUDIS. This study was determined to not be
human subjects researchby the Institutional ReviewBoard at theMedStar
Health Research Institute.
2.2. Data acquisition
To identify drug shortages in the ﬁeld of critical care, a medical tox-
icologist/clinical pharmacologist/emergency physician, board certiﬁed
critical care/emergency medicine physician, and a pulmonary medi-
cine/critical care attending independently reviewed data from the
UUDIS on 2161 pharmaceutical products. For each drug entry, we
assessed: 1)whether or not the drug is used in the scope of adult critical
care practice, 2) whether drugs within the scope of critical care practice
were used as a direct intervention for a life-threatening or high acuity
condition, and 3) whether a substitute for the drug existed for the crit-
ical care-related indication. Discrepancies were discussed between the
three physicians for a ﬁnal categorization of each variable.
We also investigated shortage trends based on length of shortage,
whether the drug was a parenteral product, brand versus generic, or if
the drug was a single source product (made by one manufacturer). In
addition, medications were classiﬁed into the following categories
based on themost common critical care-related indication for subgroup
analysis: anesthesia/analgesia, allergy and immunology, cardiovascular,
endocrine, gastroenterology, hematology, infectious diseases, ﬂuids,
electrolytes, and nutrition, neurology, pulmonology, psychiatry, renal,
Fig. 1. Number of new critical care drug shortages.
Fig. 2. Number of active critical care shortages.
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topical, and toxicology. When available, we examined the reason the
shortage occurred; however, manufacturers were not required to re-
lease this information.
2.3. Data analysis
Data were described using standard descriptive statistics. A Shapiro-
Wilk test demonstrated shortage duration was not normally distributed.
Therefore, we describe average shortage durations using median and in-
terquartile range (IQR). To calculate differences in shortage durations
with a 95% conﬁdence interval (CI), we used Hodges-Lehmann median
distances. Drugs that were on shortage multiple times were counted as
separate shortages. Discontinued drugs and drugs with a reported short-
age length of less than one day were removed prior to analysis.
Visual inspection of critical care drug shortages reported bymonth in-
dicated a non-linear (sigmoidal) trend with inﬂection points occurring in
2002, 2008, and 2013. A segmented linear regression approach was used
to examine three linear trends from January 2002 to December 2007, Jan-
uary 2008 to December 2012, and January 2013 to June 2016. Time was
coded in 1-month intervals from 1 (January 2001) to 186 (June 2016).
A Durbin-Watson d-statistic found no presence of serial autocorrelation
[15]. A Shapiro-Wilk test of the residuals found some evidence of non-
normality and a Breusch-Pagan/Cook-Weisberg test indicated presence
of heteroscedasticity; therefore, robust standard errors were used. No se-
vere outliers were detected using standard box-plot analysis (interquar-
tile method). A p-value of b0.05 was considered signiﬁcant. Data were
collected in Microsoft Excel (Microsoft, Seattle, WA) and analyses were
conducted using Stata 14.2 (College Station, TX).
3. Results
3.1. Descriptive analysis of data
After removing discontinued drugs and drugs with a shortage length
of less than one day (n=192), a total of 1969 drug shortageswere exam-
ined over the 15.5-year period. Of these, 1004 (51.0%) were classiﬁed as
within the scope of critical care practice. A complete list of shortages
and excluded drugs are included in Supplemental Appendixes 1 and 2.
Fig. 1 shows the number of newly reported critical care shortages from
2001 to 2016. Although the number of new critical care drug shortages
initially fell from 2001 to 2004, shortages increased signiﬁcantly, peaking
in 2011 with 116 new shortages. Fig. 2 shows the total number of critical
care drugs on shortage, from 2001 to 2016. The data in this ﬁgure include
any new shortages plus any shortages in previous months that had yet to
be resolved. The total number of critical care drugs on shortage decreased
at a rate of β−0.7 per month (95% CI = β−0.7 to β−0.6; r2 = 0.84)
from January 2002 to December 2007. From January 2008 to December
2012, the total number of critical care drugs on shortage increased at a
rate ofβ+2.5permonth (95%CI=β2.4 toβ−2.6; r2=0.98). From Jan-
uary 2013 to June 2016, the total number of critical care drugs on shortage
decreased at a rate of β−1.7 per month (95% CI = β−2.1 to β−1.4; r2
= 0.70). Similar trends can be seen in shortages of drugs used for high-
acuity conditions.
Drugs were categorized by therapeutic category in order to under-
stand the landscape of the shortages (Table 1). Infectious disease
drugs were the most common critical care drugs on shortage, with
200 (19.9%) shortages with a median shortage duration of 7.7 months
(IQR= 2.8–18.3), followed by cardiovascular drugs with 154 shortages
(15.3%) with a median duration of 8.1 months (IQR = 3.4–22.6), and
anesthesia/analgesia drugs with 147 (14.6%) shortages with a median
duration of 10.2 months (IQR = 3.4–23.7).
Across all therapeutic categories, 247 (24.6%) shortages were for
critical care drugs used for high acuity or life-threatening conditions
(Table 2). The majority of critical care drug shortages (720; 71.7%) were
parenteral. Three hundred and ninety-three (39.1%) were single source
drugs. No alternative was available for 117 critical care drugs (11.7%).
Alternativeswere available for 887 (88.3%) critical care drugs on shortage,
although 250 (24.9%) of those alternatives were also impacted by a
shortage during the study period (Table 2).
By the end of the study period, 896 (89.2%) critical care shortages had
been resolved and 108 (10.8%) drugs remained on active shortage. The
median duration for active shortages was 13.6 months (IQR = 5.8–58.4)
Table 1
Drug shortages by therapeutic category.
Therapeutic category Number of shortages Median shortage months (IQR) Most common drug on shortage (times on shortage, median shortage length)
n (%), total n = 1004
Anesthesia, analgesia 147 (14.6) 10.2 (3.4–23.7) Lidocaine (13×, 7.6 months)
Allergy and immunology 26 (2.6) 5.1 (3.0–18.6) Diphenhydramine (4×, 10.8 months)
Hydroxyzine (4×, 20.7 months)
Cardiovascular 154 (15.3) 8.1 (3.4–22.6) Phentolamine (7×, 2.7 months)
Endocrine 26 (2.6) 9 (4.2–22.5) Levothyroxine (6×, 9.6 months)
Gastroenterology 76 (7.6) 8.3 (2.9–18.9) Pantoprazole (6×, 11.8 months)
Prochlorperazine (6×, 10.1 months)
Hematology 45 (4.5) 6.6 (3.0–15) Phytonadione (5×, 10.2 months)
Infectious diseases 200 (19.9) 7.7 (2.8–18.3) Meropenem (9×, 7.9 months)
Fluids, electrolytes, nutrition 7 (0.7) 8.1 (6.0–13.9) None with multiple shortages
Neurology 66 (6.6) 6.1 (2.8–16.2) Edrophonium (7×, 7.4 months)
Pulmonology 52 (5.2) 5.2 (2.0–9.5) Albuterol (6×, 1.1 months)
Dexamethasone (6×, 7.7 months)
Psychiatry 12 (1.2) 8.2 (6.1–10.5) Haloperidol (2×, 40.2 months)
Zaleplon (2×, 5.5 months)
Renal 7 (0.7) 10.8 (1.8–41.9) Acetazolamide (3×, 1.8 months)
Topical 34 (3.4) 5.9 (1.8–10.9) Mupirocin (8 × 7.6 months)
Toxicology 48 (4.8) 6.7 (3.2–21.9) Naloxone (5×, 4.6 months)
Table 2
Characteristics of critical care shortages.
Number of
shortages
n (%)
Median length of
shortage in months
(IQR)
Total ICU shortages 1004 (100) 7.4 (2.9–18.8)
Total active shortages 108 (10.8) 13.6 (5.8–58.4)
Total resolved shortages 896 (89.2) 7.2 (2.8–17.3)
Total generic drug shortages 725 (72.2) 8.6 (3.5–22.5)
Total single source shortages 393 (39.1) 5.2 (2.1–13.2)
Total parenteral shortages 720 (71.7) 8.6 (3.2–24.9)
Total high acuity shortages 247 (24.6) 9.9 (3.7–26.6)
Total shortages with no alternatives available 117 (11.7) 5.8 (2.5–20.1)
Total shortages with alternatives available 887 (88.3) 7.7 (3.1–18.8)
Total shortages with alternatives impacted
(of drugs with substitute available)
250 (24.9) 12.5 (5.3–31.4)
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while the median duration for resolved shortages was 7.2 months (IQR
= 2.8–17.3), with a median difference of 6.2 (95% CI = 3.1–12.4). Me-
dian shortage duration for drugs used for high acuity conditions
was greater than that of drugs used for non-high-acuity conditions
(9.9 months vs. 7.3 months), with a median difference of 1.9 months
(95% CI = 0.7–3.4). Median shortage duration for drugs with no avail-
able alternative was not statistically different from drugs with an avail-
able alternative. A list of high-impact shortages is presented in Table 3.
Table 3
Examples of drug shortages for medications used in adult intensive care units (2001–2016).
Medication Therapeutic
category
Number of times short during
study period
Potential impact
Amino acid solutions Fluids, electrolytes,
nutrition
Total = 8
1/30/09 to 02/13/09
03/19/09 to 11/11/09
8/05/10 to 07/20/11
03/31/10 to 06/08/10
02/01/12 to 06/13/13
08/06/13 to 04/14/14
03/04/15 to 04/29/16
06/29/16 to ongoing
Customized parenteral nutrition not possible during the shortage.
Amiodarone Cardiovascular Total = 3
03/27/02 to 11/28/06
01/10/08 to 11/05/13
03/12/14 to 10/02/14
May have limited stock for use during post-operative period and for use during Advanced
Cardiac Life Saving (ACLS)
Calcium chloride Fluids, electrolytes,
nutrition
Total = 5
10/17/10 to 04/23/02
02/06/06 to 70/10/06
02/15/07 to 11/03/08
06/11/10 to 03/14/11
04/13/11 to ongoing
May have limited stock available for use during Advanced Cardiac Life Saving (ACLS) as well as
unfamiliar presentations (vials vs. syringes)
Cisatracurium Anesthesia,
analgesia
Total = 4
11/19/01 to 12/03/03
08/14/09 to 07/01/10
08/12/11 to 10/05/11
01/15/14 to 05/19/15
Shortage occurred at the same time as alternative neuromuscular blocking agents
Dobutamine Cardiovascular Total = 2
04/30/01 to 07/07/04
12/02/11 to 10/09/14
Shortage occurred at the same time as other pressors
Dopamine Cardiovascular Total = 4
04/24/06 to 07/11/06
03/26/10 to 05/17/10
09/20/10 to 03/27/15
05/20/16 to ongoing
Shortages occurred at the same time as other pressors
Epinephrine injection Cardiovascular Total = 5
02/11/09 to 02/27/09
07/22/10 to 01/13/11
05/25/10 to 12/06/10
05/02/11 to 11/16/11
01/12/12 to ongoing
May have limited stock available for use during Advanced Cardiac Life Saving (ACLS) as well as
unfamiliar presentations (vials vs. syringes)
Lorazepam Anesthesia,
analgesia
Total = 3
01/4/07 to 07/09/07
05/23/08 to 09/29/15
02/11/16 to current
Nitroglycerin Cardiovascular Total = 4
03/16/17 to 07/30/07
08/28/09 to 05/28/10
08/09/10 to 10/28/11
06/27/12 to 06/30/15
First-line treatment for patients with acute MI. Required the use of nitroglycerin ointment as an
alternative in some cases.
Norepinephrine Cardiovascular Total = 3
05/21/01 to 07/11/01
04/26/10 to 07/07/10
11/18/10 to 01/26/15
Use of alternatives may lead to greater mortality
Propofol Anesthesia,
analgesia
Total = 3
12/12/07 to 08/11/08
10/16/09 to 10/06/11
03/30/12 to 06/19/14
Other sedatives may have been required during this shortage.
Piperacillin/tazobactam Infectious diseases Total = 5
05/03/01 to 12/03/03
10/03/05 to 11/29/06
01/24/05 to 08/02/05
07/13/10 to 05/11/11
05/08/13 to current
Commonly used antibiotic – shortage occurred at the same time as many potential alternatives.
Vecuronium Anesthesia,
analgesia
Total = 3
09/04/02 to 12/03/03
11/30/07 to 03/25/08
09/16/08 to ongoing
Shortage occurred at the same time as alternative neuromuscular blocking agents
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3.2. Reasons for shortages
Of the 1004 critical care drug shortages, 27.6% were due to
manufacturing delays or problems, 15.0% were due to supply and
demand issues, and 50.5% of drugs were on shortage for reasons not pro-
vided by the manufacturers (Fig. 3). The rest of the delays were due to
rawmaterial shortages, business decisions, regulatory issues, and natural
disasters. Median shortage timewas longest for drugs on shortage due to
problems obtaining raw materials (14.7 months, IQR = 7.6–34.2) and
shortest for delays due to regulatory issues (4.2months, IQR=1.4–12.5).
4. Discussion
We found a substantial number of critical care drug shortages during
the study period. Trends in shortages ﬂuctuated over time and the rea-
sons for theseﬂuctuations are likely to bemulti-factorial [16]. The initial
increase in shortages in 2005 has been in part attributed to increased
FDA oversight and scrutiny at manufacturing sites [8,15,16]. There was
a signiﬁcant increase in the number of shortages that occurred starting
in 2008, which coincidedwith the economic downturn in the U.S. Inter-
estingly, shortages have declined but persisted despite economic recov-
ery. Many of the critical care drugs impacted by shortages were generic
injectable products. Thismay be due in part to low reimbursement rates
and lower proﬁt margins for these products from Medicare Part B,
which was initiated as part of the Medicare Modernization Act of 2003
[17]. Low proﬁt margins or declining sales may force manufacturers to
concentrate their production efforts on more proﬁtable products [18].
Another reason cited for the increase in shortages has been
manufacturing problems, which we also found in our study. One area
of concern has been increased FDA inspection and compliance activities,
as well as FDA scrutiny of the manufacturing process. This has resulted
in temporary cessation of manufacturing activities at many production
sites, which can contribute to supply disruptions. One investigation
showed that 58% of the drugs on the ASHP's shortage listwere produced
by at least one facility undergoing FDA remediation [19].With lowproﬁt
margins and high production and remediation costs, some manufac-
turers have chosen to close a number of plants, resulting in a lack of re-
dundancy in the manufacturing system and further supply disruptions.
New critical care shortages began to level off in 2012 and declined
from 2013 to 2016. Like the increases in shortages, the decline\ in short-
ages is also multi-factorial. There has been an economic recovery from
the 2008 recession. In addition, there have been multiple initiatives to
combat drug shortages, particularly the passage of the FDASIA in 2012,
which expanded the FDA's authority to manage shortages [20]. The
FDAalso implemented a task forcewith a strategic plan to further devel-
op mitigation and prevention strategies [21]. Associating the decline in
shortageswith the FDASIAwould take amuchmore robust analysis, ad-
ditional data, and could be an area for future research. Also, the FDA
does notmake the number of shortages reported to thempublicly avail-
able. There is a GAO analysis from 2014 that showed that since the im-
plementation of the 2012 FDASIA, the FDA has prevented more
shortages [4].
The most commonly affected medication class was antimicrobials,
representing nearly 20% of all shortages. Shortages of antimicrobials
may lead to use of substitute drugs with more limited activity against
pathogens. Piperacillin/tazobactam, which is recommended by the In-
fectious Disease Society of America to be administered within 3 h of di-
agnosis of certain infections causing septic shock, was on shortage for
over ﬁve years during the study period [22]. Delays may have devastat-
ing effects in septic shock patients who are usually cared for in the ICU.
Kumar and colleagues demonstrated a N7% increase in mortality per
hour effective antimicrobials were not administered [23]. Cardiovascu-
lar drugs were the second most common class of medications impacted
by shortages. Amiodarone, considered favorable in ICU patients because
it is a multichannel blocker with less negative inotropic effects than
other agents with the same indication, was the most common
cardiovascular drug on shortage [24]. In addition, there were shortages
of norepinephrine, considered by many the ﬁrst-line vasopressor for
septic shock. A recent study demonstrated that during times of
Fig. 3. Reasons for critical care shortages.
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norepinephrine shortage, phenylephrine use increased, which was as-
sociated with an increase in mortality [25]. Almost 15% of all shortages
were analgesics including fentanyl, an agent recommended by the Soci-
ety of Critical Care Medicine to control pain in the ICU [26].
There are several ways to address drug shortages at the institutional
and departmental levels. Intensivists must work proactively as part of
an interdisciplinary team including pharmacy and nursing. Protocols
should be established for the use of alternative therapies during times
of shortage to preventmedication errors in combination with staff edu-
cation. In addition, allocation schemes should be in place in the event of
an ethically challenging case in which a drug needs to be rationed with
preference given to one patient over another [27].
There were some limitations to this study that should be addressed.
Data collected by UUDIS rely on clinicians to voluntarily report short-
ages; therefore, drug shortages never reported are not included in the
UUDIS data set. However, this is one of the most comprehensive avail-
able sources of drug shortage information [5]. The major limitation of
this study was that we could not assess the actual impact shortages
had on individual institutions or on patient care, either in the form of
delayed/suboptimal therapy, resultant medication errors, or adverse
outcomes, as these data are not collected by UUDIS. We could not de-
scribe the severity of shortages affecting a particular product (e.g.,
whether the product was in limited supply or completely unavailable).
Ourmethodswould have underestimated the duration of shortages that
were active at the end of the study period. Data were not collected
pertaining to time and costs of mitigating shortages.
This study is also limited because we relied on three physician re-
viewers to categorize the UUDIS drug list. The inter-rater agreement
for classiﬁcation of ICU drugs was substantial with a kappa statistic of
0.63. Had these classiﬁcations been done by other physicians, included
medications may have been somewhat different. We also only exam-
ined drug shortages in the adult critical care setting and did not describe
shortages impacting pediatric critical care. We removed discontinued
drugs because many did not have any shortage time calculated. This
may have resulted in an underestimate of both shortage time and
total number of shortages in cases where a drug was on shortage for a
period of time and subsequently discontinued.
5. Conclusion
Drug shortages impacting critical care rose from 2001 to 2012 and
declined from 2013 to 2016. However, even in 2016, shortages still im-
pact a substantial number of medications used in critical care practice.
Although mitigation strategies have reduced the number of new short-
ages reported, a large number of long standing shortages remain. Criti-
cal care providers must be cognizant of drug shortages and take a
proactive role in mitigation in order to prevent adverse patient out-
comes. The clinical impact of these shortages as well as optimal mitiga-
tion strategies remain areas of prospective study.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jcrc.2017.06.005.
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Context. Drug shortages have significantly increased over the past decade. There are limited data describing how shortages impact medical 
toxicology of drugs. Objective. To characterize drug shortages affecting the management of poisoned patients. Materials and Methods. 
Drug shortage data from January 2001 to December 2013 were obtained from the University of Utah Drug Information Service. Shortage 
data for agents used to treat poisonings were analyzed. Information on drug type, formulation, reason for shortage, shortage duration, 
marketing, and whether the drug was available from a single source was collected. The availability of a substitute therapy and whether 
substitutes were in shortage during the study period were also investigated. Results. Of 1,751 shortages, 141 (8.1%) impacted drugs used 
to treat poisoned patients, and as of December 2013, 21 (14.9%) remained unresolved. New toxicology shortages increased steadily from 
the mid-2000s, reaching a high of 26 in 2011. Median shortage duration was 164 days (interquartile range: 76–434). Generic drugs were 
involved in 85.1% of shortages and 41.1% were single-source products. Parenteral formulations were often involved in shortages (89.4%). 
The most common medications in shortage were sedative/hypnotics (15.6%). An alternative agent was available for 121 (85.8%) drugs; 
however, 88 (72.7%) alternatives were also affected by shortages at some point during the study period. When present, the most common 
reasons reported were manufacturing delays (22.0%) and supply/demand issues (17.0%). Shortage reason was not reported for 48.2% of 
drugs. Discussion. Toxicology drug shortages are becoming increasingly prevalent, which can result in both suboptimal treatment and 
medication errors from using less familiar alternatives. Conclusion. Drug shortages affected a substantial number of critical agents used 
in the management of poisoned patients. Shortages were often of long duration and for drugs without alternatives. Providers caring for 
poisoned patients should be aware of current shortages and implement mitigation strategies to safeguard patient care.
Keywords Drug shortages; Antidotes; Medical toxicology
Introduction
Over the past decade, prescription drug shortages have 
become increasingly common and more severe.1–4 In 2005, 
the FDA’s Drug Shortage Program (DSP) reported limited 
supplies of 61 medications. By 2011, this number increased 
more than fourfold, to 251 medications.3 In addition to 
being more frequent, recent shortages have been of longer 
durations and are more likely to impact patient care.5,6 Drug 
shortages can result in treatment delays or require subopti-
mal treatment with a less effective or more toxic alternative 
medication. If an alternative therapy is not available, patients 
may go without indicated treatment.2,7,8 Drug shortages can 
also compromise patient safety because they may lead to 
medication errors or non-treatment due to the lack of avail-
ability of an effective treatment. One survey demonstrated 
89% of hospitals reported that a patient safety issue was 
potentially caused by a drug shortage.9 A recent Associated 
Press article drew attention to 15 deaths reported over 15 
months attributed to drug shortages.10
Drug shortages most commonly occur with generic 
injectable products, and a great deal of attention has been 
focused on shortages affecting chemotherapeutic agents.11–14 
Shortages have also been reported of important critical care 
drugs and antidotes, such as sodium bicarbonate.15,16 Drug 
shortages can have significant implications for the manage-
ment of poisoned patients; however, there are limited data 
describing the extent to which shortages affect such medi-
cations. The objective of this study is to describe trends in 
drug shortages that can impact the management of poisoned 
patients.
Methods
The University of Utah Drug Information Service (UUDIS) 
began collecting national drug shortage data in January 
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2001, and publishes critical drug shortage information 
on a public website (www.ashp.org/shortage) hosted by 
the American Society of Health-System Pharmacists 
(ASHP).17,18 There is a legal agreement between UUDIS 
and ASHP for the provision of services and maintenance of 
the database. UUDIS defines a shortage as a supply issue 
that affects how the pharmacy prepares or dispenses a drug 
product or influences patient care when prescribers must 
use an alternative agent.17 This definition differs slightly 
from, but is more inclusive than, the FDA definition of 
a shortage. For example, a shortage of prefilled syringes 
of a specific product may cause significant logistic and 
safety issues, even if the same product is available in vials. 
UUDIS receives voluntary reports of drug shortages via 
the reporting feature on the ASHP website. Clinical phar-
macists at UUDIS then research each shortage reported, to 
verify if a shortage actually exists. This research includes 
determining all potential manufacturers of a reported drug 
shortage and all relevant National Drug Codes (NDCs). 
Next, each manufacturer is contacted to determine which 
of their drugs, based on NDC codes, are in shortage at the 
national level. UUDIS collects the following drug short-
age data: generic and product name, therapeutic category, 
date shortage began, resolved date, duration, reason for 
the shortage, controlled substance schedule (if applicable), 
and whether or not the drug is an injectable product. The 
manufacturers are also asked for a reason for the shortage 
as well as an estimated release date; however, they are not 
required to provide a reason. If most manufacturers are 
having a national shortage of the same drug, then UUDIS 
will post information at the ASHP drug shortage website 
noting which products are affected, which products are 
available, specific methods for accessing the product, rea-
sons for the drug shortage, and estimated resupply dates. 
UUDIS considers a shortage to be resolved when all suppli-
ers have all formulations of a product available or have dis-
continued their products. UUDIS also follows FDA’s drug 
shortage website and will generally resolve shortages when 
FDA considers the shortages resolved. The Government 
Accountability Office (GAO) considers the UUDIS data 
to be the most comprehensive and reliable source of drug 
shortage information for several reasons. Although both 
FDA and UDDIS collect data on drug shortages, UDDIS 
data are more detailed, with a broader definition of short-
ages. Additionally, the ASHP website provides clinicians 
with recommendations for alternatives or management 
strategies, which the FDA does not do.19,20
The data set was restricted to shortages that occurred 
between January 1, 2001 and December 31, 2013. An a 
priori list of medications used to treat poisoned patients 
was developed prior to reviewing the list of pharmaceutical 
shortages. Two board-certified medical toxicologists inde-
pendently and systematically reviewed all pharmaceutical 
products affected by shortages and identified agents that are 
used to treat poisonings (both antidotes and medications 
commonly used to treat toxicological conditions). All dis-
crepancies were discussed between the two physicians until 
a consensus was reached. General supportive medications 
such as vasopressors and drugs used for rapid sequence 
intubation were not included. The list generated by system-
atic review was more comprehensive than the a priori list 
and was therefore used for the rest of the analysis. Short-
age data were then further analyzed focusing on the type 
of drug involved, formulation, reason for shortage, shortage 
duration, marketing status (brand vs. generic), and if the 
drug was a single-source product (produced by one manu-
facturer). For some portions of the analysis, products were 
grouped together based on therapeutic category. The avail-
ability of a substitute therapy and whether the alternative 
was also affected by a shortage at any time during the study 
period as well as multiple shortages (those that were resolved 
but then had another shortage) of the same drug were also 
noted. Descriptive statistics were used to characterize trends 
in drug shortages over time. Univariate analysis found that 
drug shortage time (in months) was not normally distrib-
uted (right skewed). Therefore, we used the non-parametric 
two-sample Wilcoxon rank-sum (Mann–Whitney) test to 
compare shortage times and describe average shortage time 
using median and interquartile ranges (IQRs). Discontinued 
products were not included in analyses of shortage time. 
A p value of ? 0.05 was considered significant. Data were 
collected in Microsoft Excel (Microsoft, Seattle, WA) and 
analyzed using Stata 13.1 (College Station, TX). The data 
do not meet the definition of human subjects’ research, and 
therefore were exempt from Institutional Review Board or 
IRB review. A comprehensive list of products affected by 
Fig. 1. Number of shortages of medical toxicology drugs reported 
annually.
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shortages is listed in a Supplementary Appendix (To be 
found online at http://informahealthcare.com/doi/abs/10.31
09/15563650.2015.1043441).
Results
Number and duration of shortages
There were a total of 1,751 drug shortages reported to 
UUDIS from January 2001 to December 2013. Of these 
shortages, 141 (8.1%) affected products used to treat poi-
soned patients. The median number of shortages reported 
annually was 10 (range: 3–26). The total number of new 
shortages reported annually increased steadily from the 
mid-2000s, reaching a high of 26 in 2011, with a decline 
in recent years (Fig. 1). The year 2011 also experienced 
the longest median shortage duration (23 months). Of the 
141 shortages, 21 (14.9%) remained active (had not been 
resolved) as of December 31, 2013. The median duration 
of resolved shortages was 164 days (range: 0–2193, IQR: 
76–434). A total of 37 drugs experienced multiple short-
ages. The drugs with the greatest number of shortages were 
sodium bicarbonate and naloxone, each with 6 shortages 
each during the study period.
Table 1. Medical toxicology agents without alternatives in short supply.
Agent
Number of 
shortages Days in shortage
Percent of study 
period on shortage
Antivenin Latrodectus mactans 
(Black widow spider)
3 362 with ongoing shortages since 12/2010 31
Deferoxamine 1 1140 24
Digoxin antibody fragments 2 262 6
Lipid emulsion 1 Ongoing shortages since 11/2008 39
Mannitol 1 Ongoing shortages since 11/2011 16
Methylene blue 3 898 with ongoing shortages since 3/2013 25
Naloxone 6 1601 35
PEG 3350 1 121 3
Pralidoxime 3 1089 23
Protamine 4 1228 26
Table 2. Types of medical toxicology drugs affected by shortages.
Type of medication
Number of  
shortages (n = 141)*
Percent 
of drugs
Total shortage 
months**
Percent of study 
period on shortage***
Median shortage 
months (IQR)**
Anticholinergic antidotes 8 5.7 97 53 7 (4.5–13.5)
Antihypoglycemic antidotes 8 5.7 151 54 17.5 (7.5–28)
Antivenom/immune Fab 7 5.0 118 71 8 (4–37)
Chelators 6 4.3 86 44 15 (6–22)
Cholinergic antidotes 9 6.4 181 70 10 (4–31)
Cyanide antidotes 6 4.3 51 24 4.5 (2–5)
Decontamination products 2 1.4 27 17 27
Electrolytes 15 10.6 262 65 12 (5–31)
Hematologic 13 9.2 153 61 7 (3–23)
Other 24 17.0 396 81 12 (5–26)
Naloxone 6 4.3 37 24 5.5 (3–15.5)
Sedative/hypnotics 22 15.6 336 85 9 (4–22)
Vitamin/elements 15 10.6 78 44 3 (2–6)
 
*Includes both active and resolved shortages.
**Does not include products that were discontinued/withdrawn (n ? 9).
***Refers to the percentage of time during the study period when at least 1 drug of that type was on shortage.
Types of drugs impacted
Generic drugs were involved in the vast majority of short-
ages (85.1%, n ? 120), and 41.1% (n ? 58) of shortages were 
single-source products. In addition, single-source products 
had a significantly longer median shortage duration (10 vs. 
5 months, p ? 0.0011). There was no difference in median 
shortage months when comparing brand to generic medi-
cations (p ? 0.34). Parenteral drugs were more commonly 
affected by shortages (126, 89.4%) than were orally admin-
istered medications; however, the median shortage duration 
was not different between the two groups (p ? 0.89). The 
most common type of medications involved was sedative/
hypnotics (benzodiazepines/barbiturates). Antihypoglyce-
mic agents had the longest median shortage duration (17.5 
months, IQR: 7.5–28) (Table 1). An alternative agent was 
available for 121 (85.9%) drugs; however, 88 (72.7%) of 
these alternatives were affected by a shortage at some time 
during the study period. There was no difference in median 
shortage duration between drugs with therapeutic alterna-
tives compared with those without therapeutic alternatives 
(p ? 0.62). In addition, there were several agents without 
therapeutic alternatives that were impacted by multiple 
shortages (Table 2).
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Reasons for shortage
The reason for shortage was not reported for 48.2% of the 
drugs. When present, the most common reasons reported 
were manufacturing delays (22.0%), followed by supply/
demand issues (17.0%). The median number of shortage 
months was the highest for drugs where a reason for short-
age was raw materials (25 months, IQR: 9–27), followed by 
those with manufacturing delays (16 months, IQR: 4–27). A 
complete list of reasons for shortage is presented in Table 3.
Discussion
Our findings demonstrate an increase in the number of 
shortages for drugs used to treat poisoned patients over 
time. In addition, many drugs had multiple shortages with 
long cumulative durations. Several drugs in the same class 
experienced shortages, as did certain drugs without any 
alternative. These shortages have the potential to impact the 
care of poisoned patients, primarily due to the lack of treat-
ment when indicated, or through the need for an alternative 
or suboptimal treatment. In addition, there is an increased 
risk for medication errors while using unfamiliar therapeutic 
alternatives.15,18–20
Lack of treatment when indicated, particularly for com-
monly used drugs and for those used to treat high acuity con-
ditions, is a major concern. The most striking example in our 
study was the opioid receptor antagonist, naloxone. Naloxone 
is commonly used to treat opioid overdose, a potentially fatal 
condition, and there is currently no therapeutic equivalent 
available for use in the U.S. There were multiple naloxone 
shortages during the study period of considerable duration. 
Lack of access to naloxone can have public health implica-
tions in the setting of the current prescription drug abuse epi-
demic along with rising rates of heroin abuse.21–24 Demand 
for naloxone has also increased secondary to public access 
programs designed to mitigate the morbidity and mortality 
associated with opioid overdose.25 This mismatch in supply 
and demand for naloxone can have potentially fatal conse-
quences for patients with opioid poisoning. This situation may 
be further complicated by recent rises in naloxone prices.26
Drug shortages may also force providers to use less effective 
or more toxic therapeutic alternatives, or less evidence-based 
therapies to treat poisoned patients. For example, there were 
multiple shortages of sodium bicarbonate, an antidote used to 
treat common poisonings including tricyclic antidepressant or 
salicylate overdose, during the study period. Sodium acetate 
has been proposed as a therapeutic alternative; however, there 
is less evidence regarding the efficacy of this drug for overdose 
compared with sodium bicarbonate. There are also potential 
toxicities, including hypotension, which require that lower 
infusion rates be utilized.16 Another example encountered in 
our study pertains to benzodiazepines, which are the first-line 
agents for ethanol withdrawal, drug-induced seizures, and 
agitation.27,28 Several benzodiazepines (midazolam, loraze-
pam, and diazepam) had shortages during the study period.3 
Barbiturates may be used as a substitute for benzodiazepines, 
but while effective for these indications, they have more 
adverse effects and a narrower margin of safety.27,28 This situ-
ation was further complicated by the fact that certain barbitu-
rates and propofol, another benzodiazepine alternative, were 
also impacted by shortages during the study period.
Therapeutic alternatives can also be more logistically dif-
ficult to use than standard therapies. For example, when there 
is a shortage of fomepizole, intravenous or oral ethanol can be 
used as an equally effective alternative. At the same time, there 
are several disadvantages to the use of ethanol. Intravenous 
ethanol may necessitate the placement of a central venous 
catheter for higher concentrations due to venous irritation. 
Additionally, intensive care unit admission may be required 
for close observation as patients may be clinically intoxicated 
and for frequent dose titration and laboratory monitoring; 
however, this practice may vary based on individual institu-
tional policies. Furthermore, some hospitals may not stock or 
permit the use of intravenous, or even oral, ethanol.
Medication errors can occur as a result of drug shortages, 
particularly when providers are forced to use a therapeutic 
alternative with which they are less familiar. For example, 
shortages of calcium chloride and calcium gluconate were 
quite frequent and the dosing between the two products is 
not interchangeable. Errors can also occur when different 
concentrations, than are usually stocked, are used during a 
shortage situation or when products are extemporaneously 
compounded.15,29,30
Several attempts have been made to mitigate the impact 
of drug shortages on the national level with a focus on policy 
reform.31–33 On a local level, medical toxicologists and other 
Table 3. Reported reasons for medical toxicology shortages.
Reason for shortage
Number of 
drugs (n = 141)*
Percent of 
drugs
Total short-
age months
Percent of study  
period on shortage**
Median shortage 
months (IQR)
Business decision 3 2.1 73 37 15 (1–57)
Discontinued/withdrawn 
product
9 6.4 NA NA
Low inventory 1 0.7 4 3
Manufacturing delays 31 22.0 569 76 16 (4–27)
Raw materials 5 3.6 127 44 25 (9–27)
Supply/demand 24 17.0 301 72 9 (4.5–17)
Not reported 68 48.2 899 98 5.5 (4–22.5)
 
*Includes both active and resolved shortages.
**Percent of study period refers to the percentage of time during the study period when at least 1 drug was on shortage for that
reason.
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providers who care for poisoned patients can take a proactive 
approach by designing protocols for the allocation of existing 
supplies, substitution protocols, and staff education.15,34,35 
Participation in institutional Pharmacy and Therapeutics 
or Drug Shortage committees and frequent communication 
with the pharmacy department are also potential roles served 
by medical toxicologists. It is also important for individual 
providers to be cognizant of shortages as to avoid poor 
patient outcomes and potential liability.15,16
The practice of stock-piling antidotes or other medications 
in anticipation of a shortage is currently not recommended.18,36 
Antidote par levels (the minimum quantity of a stocked item 
which is automatically reordered when stock falls below a 
preset level) are important tools for institutions to ensure 
an adequate treatment course is available. Expert consensus 
guidelines are available outlining suggested par levels and 
most poison centers offer suggested par levels for their local 
area.37 Routine checks of par levels are also important as 
antidotes may be infrequently used. While par levels are an 
important tool to ensure antidote availability, par levels are 
a poor tool to prevent drug shortages. Shortages of antidotes 
are frequently long in duration. A par level of one month 
would be insufficient to last through a shortage. It is also 
difficult to predict which antidotes may be in short supply 
and impractical to store large quantities of all potential anti-
dotes. Additionally, many antidotes are manufactured by just 
a single source. If all products are compromised due to a 
recall for poor quality, having a large par level will make 
no difference to the organization.18 Many antidotes are also 
used for other therapeutic uses (methylene blue and sodium 
bicarbonate) and if only small amounts of product remain, 
Pharmacy and Therapeutics Committees or Ethics Commit-
tees may elect to reserve some products for antidote use.9,18
Because of the way we identified agents used to treat 
poisoned patients, some medications may not have been 
included. Additionally, because we did not include medica-
tions that were used for more general supportive measures 
and less specifically for poisoned patients, (such as vaso-
pressors and rapid-sequence intubation drugs), the true 
impact of drug shortages in this patient population may have 
been underestimated. The major limitation of this study was 
that we could not assess the actual impact shortages had on 
individual institutions or on patient care, either in the form 
of suboptimal therapy or in terms of resultant medication 
errors. We could also not describe the severity of shortages 
affecting a particular product (e.g., whether the product was 
in limited supply or completely unavailable). There were 
limited data pertaining to the comparative efficacy of some 
therapeutic alternatives. Finally, we could not account for 
the time and resources used by institutions to mitigate short-
ages. These are areas for additional prospective study.
Conclusions
There was a significant increase in shortages affecting drugs 
used in the treatment of poisoned patients. The impact of 
these shortages at the patient level is unclear. Future research 
should evaluate patient harm derived from shortages. Medical 
toxicologists and other providers who care for these patients 
should be cognizant of current shortages that may impact 
their practice and implement mitigation strategies proac-
tively to prevent adverse outcomes for poisoned patients. 
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Purpose. Trends in the shortages of sterile solutions in the United States 
were evaluated.
Methods. A retrospective review of shortage data from the University of 
Utah Drug Information Service (UUDIS) was performed. Shortages of ster-
ile solutions, including saline, dextrose, lactated Ringer’s, and sterile water 
for injection, were identified. We extracted the product name, reason for 
the shortage, shortage duration, and primary use of the solution, examin-
ing trends in shortages over time. 
Results. There were 37 sterile solution shortages in the UUDIS data set, 
22 of which had been resolved. The mean ± S.D. duration of a resolved 
shortage was 13.9 ± 9.6 months. The most common category of solution 
shortage was for saline products (n = 11). Manufacturing delay was the 
most common reason given for shortages (n = 19). In 2017, 12 new short-
ages were reported, and 15 solutions remained in shortage by year’s end. 
This was the highest number of shortages at any time during the study 
period. The longest active shortage was for 5% dextrose/0.45% sodium 
chloride, which began in October 2007 and has yet to be resolved. 
Conclusion. There were 37 shortages of sterile solutions from 2001 
through 2017. Shortages became more severe after Hurricane Maria dam-
aged manufacturing facilities in Puerto Rico, with 12 new shortages re-
ported in 2017. 
Keywords: drug shortages, sterile solutions 
Am J Health-Syst Pharm. 2018; 75:1903-8
Prescription drug shortages have become commonplace in recent 
years.1,2 Long-standing shortages 
of medications used across a broad 
range of specialties, such as cancer 
chemotherapy and antimicrobials, are 
increasing and pose a threat to patient 
safety.1-4 The main reasons for these 
shortages include quality-related 
manufacturing problems and insuf-
ficient capacity and redundancy to 
maintain production continuity dur-
ing manufacturing problems.2 Drug 
shortages have not only affected ther-
apeutics, but also basic medical sup-
plies such as saline solutions.5-7 For ex-
ample, Hurricane Maria, which made 
landfall on Puerto Rico on September 
20, 2017, affected Baxter Internation-
al’s manufacturing facility there and 
caused a preexisting shortage of saline 
solutions to reach critical levels.5-8 The 
lack of redundancy and manufactur-
ing capacity prolonged the recovery of 
recent fluid shortages. 
Sterile solutions (e.g., 0.9% so-
dium chloride injection, 5% dextrose 
injection, lactated Ringer’s injection, 
sterile water for injection) are used for 
a wide variety of indications. Larger-
volume products can be used for fluid 
resuscitation or as maintenance or ir-
rigation fluids. Smaller-volume prod-
ucts are used to reconstitute products 
for injection or dilute medications for 
administration via infusion.9 Short-
ages of such products may impact pa-
tient care, as has been demonstrated 
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in the current shortage of saline solu-
tions.4 However, limited data exist to 
describe the extent of shortages of ster-
ile solutions. The purpose of this article 
is to describe trends in sterile solution 
shortages from 2001 through 2017. 
Methods
Data on solution shortages were 
collected from the University of Utah 
Drug Information Service (UUDIS), 
which has been collecting national 
drug shortage data since January 
2001 and provides all drug shortage 
content for the ASHP Drug Short-
age Resource Center. The Govern-
ment Accountability Office considers 
the data from UUDIS to be the most 
comprehensive and reliable source of 
drug shortage information available.10 
Detailed methods on how UUDIS 
collects and verifies drug shortage 
data are described elsewhere.1 Briefly, 
UUDIS receives voluntary reports 
from clinicians and works to verify if 
a national shortage exists by directly 
contacting manufacturers to deter-
mine which products at the specific 
National Drug Code (NDC) level are 
affected. Each product is assigned a 
specific NDC. For example, 0.9% so-
dium chloride injection would have 
a different NDC code for each manu-
facturer and volume. UUDIS follows 
shortages until manufacturers verify 
that all drug presentation NDCs are 
either discontinued or available. This 
study was not human subjects’ re-
search and did not require review by 
the institutional review board.
We used the UUDIS’s (and ASHP’s) 
definition of a shortage: “a supply is-
sue that affects how the pharmacy 
prepares or dispenses a drug prod-
uct or influences patient care when 
prescribers must use an alternative 
agent.” This is a broader definition 
than that used by the Food and Drug 
Administration (FDA), which defines 
a shortage as “a period of time when 
the demand or projected demand 
for a medically necessary drug in the 
United States exceeds its supply.”2
We examined all drug shortag-
es reported in the UUDIS between 
KEY POINTS
• The frequency of shortages of
sterile solutions has increased
in recent years, particularly after
Hurricane Maria damaged man-
ufacturing facilities in Puerto
Rico in 2017.
• Shortages of solutions may
compromise patient safety and
require increased pharmacy
resources.
• A multifaceted approach will
be required to mitigate current
shortages and prevent new
shortages from occurring.
the dates of January 1, 2001, and 
December 31, 2017, to identify short-
ages of sterile solutions. We included 
shortages involving sodium chloride, 
dextrose, lactated Ringer’s, and ster-
ile water as well as combinations of 
these products, such as dextrose plus 
sodium chloride. We included prod-
ucts used parenterally, such as fluids 
used for resuscitation, for mainte-
nance hydration, and for reconstitu-
tion or dilution of other medications. 
We also included solutions used for 
irrigation. We excluded discontinued 
products and solutions used for oth-
er indications, such as 50% dextrose 
injection. 
We extracted the product name, 
reason given for the shortage, date the 
shortage began, and date the short-
age was resolved. UUDIS defines the 
start of a shortage as the date the drug 
was verified to be in short supply by 
the manufacturer. UUDIS considers a 
shortage to be resolved when all sup-
pliers have all formulations available 
or have discontinued their products. 
UUDIS also follows FDA’s drug short-
age website and will generally list 
shortages as resolved when FDA con-
siders the shortages resolved.
We calculated shortage duration 
as the length of time, in months, be-
tween the shortage start and shortage 
resolved dates to examine trends over 
time. We grouped shortages together 
for the 4 common types of fluids in-
volved: dextrose solution, lactated 
Ringer’s solution, sodium chloride, 
and sterile water. Solutions were also 
classified by their primary use in pa-
tient care (e.g., diluent vial, small 
volume, large-volume maintenance, 
large-volume resuscitation). Solu-
tions were considered small volume 
if they were 250 mL or less and large 
volume if they were 500 mL or greater. 
We calculated the mean short-
age duration, in months, for short-
ages that had resolved by the end of 
the study period. We also counted the 
number of new shortages reported 
in each year as well as the number of 
products that remained on shortage 
at year’s end. Data were managed in 
Microsoft Excel (Redmond, WA), and 
analyses were done with Stata version 
14 (College Station, TX).
Results
There were 37 sterile solution 
shortages in the UUDIS data set, 22 
of which had been resolved and 15 of 
which were active at the end of 2017 
(Table 1). The mean ± S.D. duration 
of resolved shortages was 13.9 ± 9.6 
months. The most common category 
of solution shortage was for those 
containing sodium chloride (n = 11). 
The most common solution types in 
shortages were large-volume main-
tenance solutions and small-volume 
products (n = 10 each). Manufacturing 
delays were the most common reason 
given for shortages (n = 19).
Table 2 displays the number of new 
shortages reported each year and the 
number of solutions that remained on 
shortage at year’s end. In 2017, 12 new 
shortages were reported, and 15 solu-
tions remained in shortage by year’s 
end. This was the highest number of 
shortages at any time during the study 
period. Before 2017, the most solution 
shortages reported in any calendar 
year was 7, occurring in both 2013 and 
2014. No shortages of solutions were 
reported from 2001 through 2006. 
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The product name and length of 
each resolved and active shortage are 
listed in the appendix. The longest re-
solved shortages were for sterile water 
injections (250 and >250 mL), which 
began in March 2013 and resolved in 
September 2015 (30 months). The lon-
gest active shortage was for 5% dex-
trose/0.45% sodium chloride, which 
began in October 2007 and had yet to 
be resolved.
Discussion
While the total number of ster-
ile solution shortages was relatively 
small, even a single fluid shortage can 
have a tremendous impact on health 
systems, clinicians, and patients. 
This has been demonstrated by the 
recent shortage of saline, which has 
been worse since Hurricane Maria. 
In particular, small-volume saline 
bags were in severe shortage be-
cause Baxter International supplied 
nearly 50% of U.S. hospitals with 
this product.5-8 
The work involved to minimize 
the impact of these shortages on pa-
tients cannot be underestimated. For 
example, making a switch to dilute a 
product in 5% dextrose injection or 
changing an i.v. infusion to i.v. push 
can result in hundreds of hours of 
work to make changes to electronic 
health record (EHR) systems, auto-
mated dispensing cabinets, smart 
pumps, and other technology. Im-
ported products may not have bar 
codes, or those bar codes may not 
be compatible with scanners. How-
ever, for most fluid shortages, pa-
tients are not affected and are able 
to receive necessary treatments. In-
stead, the burden of these shortages 
is shouldered by the healthcare team 
(e.g., surgical technicians who must 
use smaller bags of i.v. fluids during 
large-volume irrigation shortages, 
informatics pharmacists who must 
make changes to order sets in EHR 
systems, pharmacy technicians who 
must make changes to automated 
dispensing cabinets). Even small 
changes might require pharmacists 
to reenter orders for every patient 
receiving the product during a short-
age. This not only takes time but may 
cause medication errors during order 
entry.
Many pharmaceutical products 
require di-2-ethylhexyl phthalate 
(DEHP)-free bags to prevent patient 
exposure to potentially toxic concen-
trations of DEHP. However, manufac-
turers may minimize the production 
of these bags during shortages, requir-
ing workarounds such as draining 1-L 
bags to make 200-mL doses during 
severe shortages. When small-volume 
products are affected, medications 
administered via short infusions may 
have to be administered by i.v. push, 
which can increase nursing time and 
the risk of adverse drug events or 
medication errors. Medications may 
also need to be switched to oral for-
mulations when possible, which also 
consumes pharmacy staff resources. 
These additional activities can affect 
patient care. Longer preparation times 
may delay patient doses. Frequent 
switching of concentrations and infu-
sion times can lead to administration 
errors. 
Shortages of the most basic ne-
cessities for hospitals represent a 
market failure. A small number of 
Table 1. Characteristics of Shortages of Sterile Solutions, 2001–17
Characteristic
No. Shortages
Mean ± S.D. 
Shortage 
Duration, 
monthsTotal Active Resolved
All solution shortages 37 15 22 13.9 ± 9.6
Solution content
5% Dextrose 7 4 3 21.3 ± 7.6
Lactated Ringer’s 5 1 4 13.7 ± 12.0
Sodium chloridea 11 4 7 9.7 ± 7.6
Sterile water 8 3 5 19.6 ± 10.2
Otherb 6 3 3 7.2 ± 3.9
Solution use
Diluent vial 6 2 4 8.1 ± 6.2
Irrigation 5 1 4 13.0 ± 2.0
Large-volume diluentc 2 1 1 30.0d
Large-volume maintenancee 10 5 5 14.8 ± 11.0
Large-volume resuscitationf 4 2 2 15.0 ± 20.4
Small volume 10 4 6 14.5 ± 9.9
Shortage reason
Manufacturing delays 19 7 12 14.5 ± 9.3
Natural disaster 1 1 0 Not applicable
Supply–demand mismatch 8 5 3 13.3 ± 1.4
Unknown 9 2 7 13.0 ± 12.7
aIncludes solutions containing sodium chloride, including 0.9% and 0.45% sodium chlo-
ride, without other constituents.
bIncludes electrolyte solutions, 10% dextrose solutions, and combined dextrose–sodium 
chloride solutions.
cSterile water labeled for reconstitution of medications.
dStandard deviation not calculated.
eSolutions typically used to provide continuous hydration, such as solutions containing 
both dextrose and sodium chloride, or electrolyte solutions.
fSolutions typically used in large quantities during resuscitation efforts such as lactated 
Ringer’s injection and 0.9% sodium chloride injection.
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Table 2. Numbers of New 
Solution Shortages, 2001–17
Year
New 
Shortages 
Reported
Active 
Shortages 
at Year’s 
End
2001 0 0
2002 0 0
2003 0 0
2004 0 0
2005 0 0
2006 0 0
2007 4 4
2008 0 1
2009 0 1
2010 0 1
2011 1 2
2012 4 4
2013 7 6
2014 7 12
2015 0 5
2016 2 4
2017 12 15
manufacturers provide these items 
to hospitals on a just-in-time basis. 
There is little resiliency or additional 
capacity in the current system. Some 
manufacturers are unwilling to invest 
in new factories or new capacity in 
the United States, largely due to eco-
nomic factors. Instead, they look to 
FDA to approve products manufac-
tured abroad on a temporary basis to 
ameliorate shortages. FDA has taken 
action to improve the situation, such 
as approving new suppliers and al-
lowing imported products. However, 
some of these interventions are only 
temporizing measures and do not fix 
the underlying problems that cause 
shortages. For example, no govern-
ment agency can force manufactur-
ers to add capacity or improve sub-
standard facilities. 
A recent roundtable discussion 
on shortages with clinician groups 
and representatives from FDA and 
the Department of Health and 
Human Services Office of the As-
sistant Secretary for Preparedness 
and Response provided 11 recom-
mendations for improvement.11 One 
recommendation was for FDA to im-
plement manufacturing quality rat-
ings, similar to star ratings for hos-
pitals. This would require suppliers 
to disclose the true manufacturer of 
products. Hospital purchasers could 
make quality-based purchasing de-
cisions with these changes. Another 
improvement would be for the gov-
ernment to include medication sup-
plies as part of national security eval-
uations. Experience gained from the 
aftermath of Hurricane Maria dem-
onstrates that the current system is 
unable to adequately withstand a 
natural disaster, as manufacturers 
are not required to have redundancy 
or business continuity plans for life-
saving drugs. 
On a smaller scale, health systems, 
institutions, and individual practi-
tioners should be aware of current 
shortages and how they may impact 
patient care and implement mitiga-
tion strategies proactively. A variety 
of mitigation strategies and work-
arounds may be needed to minimize 
waste and conserve existing supplies, 
while ensuring patient safety and 
ethically rationing limited supplies 
when necessary.
There were several limitations to 
our study. Data collected by UUDIS 
rely on clinicians to voluntarily re-
port shortages; therefore, shortages 
may have existed that are not includ-
ed in the UUDIS data set. The major 
limitation of this study was that we 
could not assess the actual effect 
that solution shortages had on indi-
vidual institutions or on patient care. 
The duration of shortages that were 
active at the end of the study period 
would also have been underestimat-
ed. Data pertaining to the time and 
cost of mitigating shortages were not 
collected.
Conclusion
There were 37 shortages of ster-
ile solutions from 2001 through 2017. 
Shortages became more severe after 
Hurricane Maria damaged manufac-
turing facilities in Puerto Rico, with 12 
new shortages reported in 2017.
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Appendix—Active and resolved solution shortages
Shortage Type and Solution Date Notified Date Resolved Duration (months)
Resolved 
Sterile water for injection, 250 mL 3/22/13 9/22/15 30.0
Sterile water for injection, >250 mL 3/22/13 9/22/15 30.0
Lactated Ringer’s injection, 1 L 2/11/14 7/26/16 29.4
5% Dextrose injection, >250 mL 2/18/14 7/26/16 29.2
0.45% Sodium chloride injection, 1 L 2/20/14 1/27/16 23.2
5% Dextrose injection, ≤250 mL 11/6/13 7/23/15 20.5
Sterile water for injection, vials 3/22/13 8/14/14 16.8
Lactated Ringer’s irrigation 8/12/14 10/27/15 14.5
0.9% Sodium chloride injection, ≤250 mL 5/24/07 7/25/08 14.1
5% Dextrose injection, ≤250 mL 5/24/07 7/25/08 14.1
Sterile water for irrigation 8/12/14 10/13/15 14.0
0.9% Sodium chloride irrigation 8/12/14 9/24/15 13.4
10% Dextrose injection 8/1/14 7/22/15 11.7
Lactated Ringer’s irrigation 11/9/16 9/14/17 10.2
Bacteriostatic water injection 8/1/12 3/1/13 7.0
Bacteriostatic sodium chloride injection, 0.9%, vials 8/27/12 3/11/13 6.4
Sodium chloride injection, 0.9%, vials 9/28/12 4/4/13 6.2
Dextrose 10% and electrolyte no. 48 injection 12/13/07 5/20/08 5.2
Multiple electrolytes injection type 1 6/25/13 11/12/13 4.6
Bacteriostatic sodium chloride injection, 0.9%, vials 9/28/12 12/12/12 2.5
Bacteriostatic sodium chloride injection, 0.9%, vials 12/20/11 2/23/12 2.1
Lactated Ringer’s injection, 1 L 9/9/13 9/26/13 0.6
Activea
5% Dextrose/0.45% sodium chloride injection 10/4/07  . . .b 122.9
0.9% Sodium chloride injection, 1 L 1/28/13 . . . 59.1
0.9% Sodium chloride irrigation 11/9/16 . . . 13.7
5% Dextrose injection, 250 mL 2/22/17 . . . 10.3
5% Dextrose injection, 500 mL 2/22/17 . . . 10.3
5% Dextrose injection, 1 L 2/22/17 . . . 10.3
5% Dextrose/0.9% sodium chloride injection 2/22/17 . . . 10.3
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Shortage Type and Solution Date Notified Date Resolved Duration (months)
10% Dextrose injection, 250 mL 2/22/17 . . . 10.3
5% Dextrose injection in DEHP-free bagsc 5/4/17 . . . 8.0
Sodium chloride injection, 0.9%, preservative-free vials 6/12/17 . . . 6.7
Sterile water for injection, small volume (<100 mL) 8/4/17 . . . 4.9
0.9% Sodium chloride injection, small volume (<150 mL) 8/25/17 . . . 4.2
Lactated Ringer’s injection 10/4/17 . . . 2.9
Sterile water for injection, large volume (>150 mL) 12/20/17 . . . 0.4
Sterile water for injection, vials 12/28/17 . . . 0.1
aLength for active shortages calculated as of January 1, 2018.
bNot resolved.
cDEHP = di-2-ethylhexyl phthalate.
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Severe and long-standing prescription-drug shortages have become a major threat to public health and patient safety.1 Despite increased 
awareness and mitigation strategies, the United 
States has experienced shortages 
of many lifesaving drugs and 
other supplies essential to pa-
tient care. There was already a 
shortage of saline solution, for 
example, when Hurricane Maria 
devastated Puerto Rico, home to 
a key saline manufacturer, caus-
ing the problem to reach critical 
levels.2
Saline is an inexpensive prod-
uct — it’s simply salt water — 
but proper manufacturing prac-
tices are required to keep it 
sterile, pyrogen-free, and free 
from particulate matter. Produc-
tion demands are challenging, 
since very large quantities are 
needed: more than 40 million 
bags per month. Saline is re-
quired for virtually all hospital-
ized patients, whether as a com-
ponent of a medication infusion 
or as a hydration, resuscitation, or 
irrigation fluid.2 Unfortunately, 
shortages of saline have become 
commonplace in recent years (see 
table).
Most drug shortages occur with 
older, generic, injectable medica-
tions that are produced by a 
small number of suppliers — 
typically three or fewer. The 
United States gets its saline from 
just three companies: Baxter Inter-
national, B. Braun Medical, and 
ICU Medical. Most shortages are 
caused by a quality or production 
problem at the manufacturing fa-
cility — causes that apply to the 
current saline shortage as well.2,3 
In addition, when one supplier 
experiences a shortage, other sup-
pliers often have insufficient man-
ufacturing capacity to make up 
the difference. Drug manufactur-
ers are not required to have redun-
dancy in their facilities or even a 
business contingency plan in case 
of a disaster, no matter how es-
sential or lifesaving the medica-
tion they are producing.1
The shortage of small-volume 
saline bags (250 ml or less) be-
came dire almost immediately 
after Baxter’s Puerto Rico manu-
facturing plant was hit by Hurri-
cane Maria.2 Baxter supplies ap-
proximately 50% of U.S. hospitals 
with this product, which is used 
as a diluent to deliver a variety 
of parenteral medications. Despite 
this tremendous need, Baxter has 
no redundancy in manufacturing 
capacity for small-volume saline 
bags. The other two saline sup-
pliers have not been able to in-
crease their production enough 
to make up for the shortage.2,3 In 
fact, saline produced by B. Braun 
was already in short supply before 
the hurricane, as the company 
Saline Shortages — Many Causes, No Simple Solution
Maryann Mazer-Amirshahi, Pharm.D., M.D., M.P.H., and Erin R. Fox, Pharm.D. 
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import products for long periods: 
saline is heavy and bulky, making 
air transport costly and shipment 
periods lengthy. The FDA has 
also permitted extension of prod-
uct expiration dates when that 
can be done safely. And Baxter’s 
facility in Puerto Rico is expected 
to be functioning again in the 
near future, which will help to 
ameliorate the current shortage.2
In the meantime, the saline 
shortage has required clinicians 
to use a number of work-arounds 
that consume valuable resources 
and increase health care costs.3,4 
Supplies may need to be reserved 
for the sickest patients, and pro-
viders require an ethical frame-
work for rationing products,4 while 
pharmacy staff closely monitor 
inventory. Some medications now 
have to be administered as direct 
injections over several minutes, 
which increases the time nurses 
must spend with each patient. 
Some institutions have switched 
to syringe pumps or use Buretrol 
(Baxter) infusion devices (which 
hold small quantities of f luids) 
to deliver medications. Hospitals 
are also using more expensive pre-
mixed products and are chang-
ing the concentration of some 
medications so they can be mixed 
in larger volumes, when small-
volume bags are unavailable. Mak-
ing such changes requires sub-
stantial informatics resources, 
because the ordering platform in 
the electronic health record must 
be altered.4,5 To conserve large-
volume saline bags, oral hydra-
tion is recommended when pos-
sible. For patients who cannot 
take oral f luids or who require 
aggressive resuscitation, alterna-
tive crystalloid solutions may be 
considered. During shortages of 
large-volume saline irrigation solu-
tion, sterile water or even tap 
water may be substituted when 
appropriate.4
The current shortage of saline 
solutions demonstrates the pro-
found effects that drug shortages 
can have on patient care. It is an-
ticipated that the situation will 
improve in the United States in 
the coming weeks to months, 
although hospitals will continue 
to face shortages of other basic 
products. In the meantime, a mul-
tifaceted approach will be needed 
to ensure that patients safely get 
the medications they need.
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worked to correct manufacturing-
quality problems.3
The saline shortage had ac-
tually begun in 2014, affecting 
large- as well as small-volume 
products.4 Large-volume saline 
products (>500 ml) are typically 
used as maintenance or resusci-
tation f luids or for irrigation. 
Although some shortages of large-
volume saline solutions are attrib-
utable to problems at manufactur-
ing facilities, increased demand 
for intravenous fluids due to a 
severe influenza season has also 
contributed to the current short 
supply.2
Saline shortages can affect pa-
tient care in various ways. Medi-
cation errors and adverse drug 
events can result when medica-
tions that are typically adminis-
tered as short infusions are given 
by intravenous push or when pro-
viders choose less familiar but 
more readily available products 
as substitutes. Increased ad hoc 
compounding of drugs may re-
sult in dilution errors or micro-
bial contamination.3,4
Fixing the problem is difficult 
and requires a multifaceted ap-
proach entailing both focusing 
on current shortages and work-
ing to prevent future ones. Nei-
ther Congress nor the Food and 
Drug Administration (FDA) can 
force any manufacturer to pro-
duce a medication, no matter 
how lifesaving the product or how 
critical the need. Incentives such 
as accelerated approval for an-
other product or tax relief for 
funding facility repairs may help 
reduce shortages, yet these incen-
tives may have the unintended 
consequence of precipitating more 
shortages if companies value the 
incentives more than current prof-
its. Alternatively, moving forward, 
the Department of Homeland Se-
curity could mandate that saline 
be considered part of the essen-
tial infrastructure, which would 
require the relevant companies to 
develop business continuity plans, 
although implementing manufac-
turing redundancies would be 
costly and require significant time.
The FDA’s Good Manufactur-
ing Practice rules require a mini-
mum level of quality, yet short-
ages continue to occur because 
of poor conditions at manufac-
turing facilities. It is costly and 
time consuming to bring facili-
ties up to standard, and the pro-
cess of doing so can interrupt 
the supply chain. Since drug com-
panies are not required to dis-
close the identity or location of 
the manufacturer that produces a 
drug,1 a complete list of medica-
tions affected by Hurricane Maria 
is available only to the FDA and 
not to clinicians who need to plan 
for patient care. Woodcock and 
Wosinska have argued that poor 
quality is due to a lack of trans-
parency regarding which com-
pany actually makes a product, 
because without such transpar-
ency clinicians cannot purchase 
drugs and supplies on the basis 
of quality.1
Changing the transparency re-
quirements and mandating man-
ufacturing redundancies may not 
change the course of the current 
saline shortage, but they are im-
portant actions for preventing fu-
ture shortages. In response to the 
current shortage, the FDA has 
recently approved saline products 
from two additional manufactur-
ers; however, there is a lag time 
between approval and the arrival 
of these products on the market. 
The newly approved products may 
also cost more than the currently 
available ones, since most orga-
nizations purchase their saline in 
a bundle that also includes tubing, 
pumps, and other accessories.
Importation of products can 
help in some cases. In response 
to the current saline shortage, the 
FDA has permitted manufactur-
ers to import saline from their 
facilities in other countries, such 
as Brazil.2 Importation is usually 
a temporary measure, because the 
FDA generally cannot find a 
company with sufficient foreign 
supplies to share with the U.S. 
market without creating a short-
age in the country providing the 
import. When it comes to saline, 
logistics make it impractical to 
Product
Date Shortage 
Began
Date Shortage 
Resolved Reason for Shortage
0.9% Sodium chloride, 
small-volume bags
5/24/2007 7/25/2008 Supply unable to meet 
 demand
0.9% Sodium chloride, 
large-volume bags
1/28/2013 Not yet resolved Manufacturing delays
0.9% Sodium chloride  
for irrigation
8/12/2014 9/25/2015 Manufacturing problems
0.9% Sodium chloride  
for irrigation
11/9/2016 Not yet resolved Manufacturing delays
0.9% Sodium chloride, 
small-volume bags
8/25/2017 Not yet resolved Manufacturing delays due 
to Hurricane Maria
*  The reasons for shortages are as determined by the University of Utah Drug Information Service.
Drug-shortage information is available at www.ashp.org/shortages.
History of Saline Shortages in the United States.*
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Prescription Drug Shortages: Implications for Ambulatory Pediatrics
Katie A. Donnelly, MD1, Mark S. Zocchi, MPH2, Tamara A. Katy, MD3, Erin R. Fox, PharmD4, John N. van den Anker, MD, PhD5,
and Maryann E. Mazer-Amirshahi, PharmD, MD, MPH6
Objective To describe contemporary drug shortages affecting general ambulatory pediatrics.
Study design Data from January 2001 to December 2015 were obtained from the University of Utah Drug In-
formation Service. Two pediatricians reviewed drug shortages and identified agents used in ambulatory pediatrics.
Shortage data were analyzed by the type of drug, formulation, reason for shortage, duration, marketing status, if a
pediatric friendly-formulation was available, or if it was a single-source product. The availability of an alternative,
and whether that alternative was affected by a shortage, also was noted.
Results Of 1883 products in shortage during the study period, 314 were determined to be used in ambulatory
pediatrics. The annual number of new pediatric shortages decreased initially but then increased to a high of 38 in
2011. Of the 314 pediatric shortages, 3.8% were unresolved at the end of the study. The median duration of re-
solved shortages was 7.6 months. The longest shortage was for ciprofloxacin 500-mg tablets. The most common
class involved was infectious disease drugs. Pediatric-friendly dosage forms were affected in 19.1% of shortages.
An alternative agent was available for 86% drugs; however, 29% of these also were affected. The most common
reason for shortage was manufacturing problems.
Conclusions Drug shortages affected a substantial number of agents used in general ambulatory pediatrics.
Shortages for single-source products are a concern if a suitable alternative is unavailable. Providers working in
the ambulatory setting must be aware of current shortages and implement mitigation strategies to optimize patient
care. (J Pediatr 2018;■■:■■-■■).
D rug shortages are a significant issue facing pediatric health professionals. A drug shortage is defined as a time whenthe projected demand for a drug is expected to overwhelm the supply of the drug.1 These shortages remain a consis-tent threat to optimal patient care and safety.2 The driving forces behind these shortages include supply issues, quality
concerns, and economic forces.3 Despite recent interventions from the federal government and the Food and Drug Adminis-
tration (FDA), drug shortages remain a critical issue that can negatively affect patient care.4
Drug shortages disproportionately affect pediatric patients.5 The recent shortages of clindamycin suspension and intramus-
cular penicillin are just a few examples of medications used in the pediatric ambulatory setting that are affected by shortages.
These shortages force healthcare providers to use medications that may be less familiar, less efficacious, less evidenced-based,
or with more adverse effects. Even seemingly unrelated shortages can have devastating consequences for pediatric patients, such
as when a shortage of sodium bicarbonate lead to an incorrect compounding of baclofen suspension.6 This led to an invasive
workup and intensive care unit admission for the patient. Fifty-six percent of children in the US use at least 1 prescription or
over-the-counter medication at home per week, yet there are limited data describing shortages of medications used in the pe-
diatric ambulatory setting.7 Therefore, we describe trends in drug shortages for
medications commonly used in ambulatory pediatrics.
Methods
Drug shortage data from January 2001 to December 2015 were obtained from the
University of Utah Drug Information Services (UUDIS). UUDIS has clinical phar-
macists who receive voluntary reports on drug shortages from clinicians and hos-
pitals, confirm the shortage with the manufacturer, and compile data on the specific
formulations of drug on shortage. They rely on the manufacturer to determine
the reason for the shortage. They also confirm the end of a shortage with the manu-
facturer and the FDA. This drug-shortage information is published online on the
ASHP American Society of Health-Systems Pharmacists
FDA Food and Drug Administration
UUDIS University of Utah Drug Information Service
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Web site of the American Society of Health-Systems Pharma-
cists (ASHP). UUDIS started this data compilation in January
2001.
A pediatrician practicing in emergency medicine and a spe-
cialist in pediatric emergency medicine reviewed pharmaceu-
tical products affected by shortages in the UUDIS database and
identified agents that are used in ambulatory pediatrics
(n = 314). Identification was based on the practitioners’ clini-
cal experience in their respective fields. Pharmaceuticals pri-
marily prescribed by subspecialties were excluded.An additional
member of the study team, an emergency medicine physi-
cian who is also a registered pharmacist and board-certified
clinical pharmacologist and practices at a pediatric hospital,
reviewed discrepancies until a consensus was reached.
Shortage data were analyzed with a focus on the type of drug
involved (eg, infectious disease, pulmonary), formulation, reason
for shortage, shortage duration, marketing status (brand vs
generic), and whether the drug was a pediatric-friendly for-
mulation (liquid/chewable dosing form or having a pediatric
concentration) or a single-source product (produced by one
manufacturer). Drugs may have multiple uses, but they were
included with the most common ambulatory care use, as de-
termined by the authors. The availability of a substitute therapy
and whether the alternative also was affected by a shortage at
any time during the study period also was noted. Discontin-
ued products were excluded. This study was not evaluated by
an institutional review board because it does not involve human
subjects.
The final dataset was analyzed for annual trends, shortage
duration, and the reasons given for the shortages. To examine
annual trends, counts of new shortages were aggregated by
month and by year and were examined graphically. We then
compared the number of shortages reported per month in the
first half of the study period (2001-2008) with the last half of
the study period (2009-2015) using the Wilcoxon rank-sum
(Mann–Whitney) test. Shortage duration was defined as the
number of days between the date of notification to the date
of shortage resolution as reported by the UUDIS. Product
discontinuations (shortages that lasted zero days) were ex-
cluded.A standard conversion factor of 30.4375 days = 1month
was used to convert shortage days to shortage months for ease
of interpretation. Shortage duration was not normally dis-
tributed (long right tail) as evidenced by a histogram and con-
firmed by a Shapiro–Wilk W test for normal data. Therefore,
shortage duration is presented as medians and IQRs. The non-
parametric 2-sampleWilcoxon rank-sum (Mann–Whitney) test
and the Kruskal–Wallis equality-of-populations rank tests were
used to compare shortage durations.
To determine whether shortage length was changing over
time, we used ordinary least-squares linear with month fixed-
effects to estimate the annual (yearly) trend in shortage du-
ration.We used the log of shortage duration as our outcome,
so the coefficient of year can be approximately interpreted as
the percent change in the dependent variable (shortage du-
ration) per year. For all hypothesis tests, a P value of <.05 was
considered statistically significant. For shortages still active as
of December 31, 2015, data from the first quarter of 2016 were
examined to determine whether the shortage had been re-
solved. If the shortage was still active as of March 31, 2016,
shortage duration was calculated as the number of months
between the shortage notification and March 31, 2016. Data
were collected in Microsoft Excel (Microsoft, Seattle, Wash-
ington) and analyzed with Stata 14.1 (StataCorp LLC, College
Station, Texas).
Results
After we excluded discontinued products (n = 221), a final
dataset of 1883 drug shortages reported between January 2001
to December 2015 was examined. Of these, 314 (17%) were
identified as being used in ambulatory pediatrics, 60 of which
were identified as having a pediatric-friendly form (19.1%).
Annual shortage totals by year are displayed graphically in
Figure 1. There was a median of 22 ambulatory pediatric short-
ages reported each year from 2001 through 2015 (IQR = 11-
28). Shortages becamemore frequent in the last half of the study
period, where the median number of annual shortages in-
creased to 28 between 2009 and 2015 (P = .003). For short-
ages of pediatric-specific drug forms, there was a median of
4.5 shortages per year (IQR = 1-7). Shortages of pediatric-
specific forms becamemore frequent in the last half of the study
period, averaging 7 new shortages per year (IQR = 4-8,
P = .026).
Table I presents median duration of ambulatory pediatric
drug shortages. Of the 314 shortages, 302 were resolved by the
end of the study period (96.2%). The median duration of a
resolved shortage was 7.6 months (IQR = 3.0-15.2). The 12 un-
resolved drug shortages had a median duration of 11.1 months
(IQR = 5.1-41.9). Shortage duration experienced a continu-
ous linear decline over the study period (2001-2015, P = .004),
at a rate of approximately −4.8% per year (95% CI −7.9% to
−1.5%). One in four drug shortages was administered paren-
terally, and the majority of these were vaccines. Parenterally
administered drugs were on shortage longer than orally ad-
ministered drugs (16.2 vs 6.2 months, P < .001). Drugs with
no alternative available were on shortage longer compared with
drugs with an alternative available (16.7 vs 6.8 months,
P = .002), as were drugs produced by more than one manu-
facturer compared with single-sourced drugs (9.4 vs 6.0months,
P = .035).
A reason for the shortage was not reported for 159 of the
pediatric ambulatory care drug shortages (50.6%). When a
reason was reported, the most commonly cited was manufac-
turing problems (25.8%), followed by supply/demand issues
(13.7%), raw material shortages (4.8%), regulatory issues
(2.9%), and business decisions (1.6%). Shortage duration did
not differ significantly based on the reason given for the short-
age (P = .082).
Therapeutic classifications of the drug shortages are pre-
sented in Table II. The most common type of shortage for am-
bulatory pediatric drugs were used to treat infectious diseases
(n = 60), with a median shortage of 8.9 months (IQR = 4.0-
17.9). Vaccine shortages (n = 36) had a median length of 18.5
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months (IQR = 5.4-30.9) and were on shortage significantly
longer than all other drug classifications (P < .001).
Figure 2 presents the 20 longest shortages during the study
period. The longest shortage was for ciprofloxacin 500-mg
tablets, which was on shortage fromOctober 14, 2009 to August
25, 2015 (70 months). The longest active shortage (as of March
31, 2016) was for methylphenidate chewable tablets, which
started February 8, 2011 (62 months).
Discussion
We found a substantial number of drug shortages that affect
the practice of ambulatory pediatrics during our study period.
Many drugs had prolonged shortages, some of which were not
resolved at the end of this study period. Shortages overall in-
creased over the course of the study, although the numbers of
shortages appear to have reached a peak in 2011. This may be
an effect of the FDA Safety and Innovation Act, passed in 2012.
One section of this Act requires manufacturers to notify FDA
of a shortage. Advanced notification allows FDA to ask other
suppliers to increase production, expedite reviews, or take other
actions to prevent shortages.8
Our study found that overall length of shortage was pro-
longed, at a median of 7.6 months but that median length of
shortage had a slight decrease (4.8% per year). It may be that
the FDA’s efforts regarding early notification about short-
ages may be improving time to resolution. In the past years,
Pediatric-friendly form
Nonpediatric-friendly form
Figure 1. Annual number of pediatric ambulatory care drug shortages, 2001-2015.
Table I. Ambulatory pediatric drug shortages, 2001-2015
Categories of drugs Total shortages % Median duration, mo IQR P value
Active shortages* 12 3.8 11.1 5.1-41.9 .082†
Resolved shortages 302 96.2 7.6 3.0-15.2
Generic 194.0 61.8 9.4 3.7-15.6 .133
Nongeneric 120.0 38.2 5.9 2.3-16.7
Pediatric-specific form 60 19.1 9.7 4.2-17.6 .223
Not pediatric-specific form 254 80.9 7.1 3.1-14.5
Single source 111 35.4 6.0 2.3-12.6 .035
Multiple sources 203 64.6 9.4 3.7-16.3
Alternative available 270 86.0 6.8 3.1-13.8 .002
No alternative available 44 14.0 16.7 5.4-30.9
Alternatives also impacted 91 29.0 10.1 3.4-15.6 .572
Parenteral 76 24.2 16.2 5.4-27.4 <.001
Not parenteral 238 75.8 6.2 2.8-12.8
Reason for shortage
Business decision 5 1.6 7.6 3.7-10.2 .082
Manufacturing problems 81 25.8 9.3 4.1-23.0
Natural disaster/weather 2 0.6 2.3 2.3-2.3
Raw materials 15 4.8 14.7 7.6-44.8
Regulatory issues 9 2.9 5.3 1.4-11.8
Supply/demand 43 13.7 6.5 3.0-16.1
Unknown 159 50.6 6.6 3.1-13.0
*Active shortage defined as still on shortage as of March 30, 2016.
†P values for shortage durations are from the Kruskal–Wallis equality-of-populations rank test.
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the pharmaceutical industry had been impacted severely by con-
cerns about quality control. Seven of the major sterile inject-
able drug manufacturers were cited by the FDA during our
study period, leading directly to shortages.9 The rate of these
citations to all drug manufacturers also increased from 2007
through 2013.9 To improve quality concerns, manufacturers
must slow or stop production to address the issue, leading to
shortages. Sometimes a manufacturer can spend millions of
dollars trying to fix a manufacturing concern and end up in
bankruptcy themselves, continuing a shortage crisis.10 Because
our data count a resolution of shortage as either supply im-
proving or the manufacturer discontinuing the medication, it
is possible that the decrease in duration is due to companies
discontinuing a struggling drug rather than continue to work
on quality issues.
Drugs without an alternative were on shortage for signifi-
cantly longer than those with a substitute. A critical medica-
tion on prolonged shortage could be devastating for certain
pediatric patients. For example, oseltamivir is the only ap-
proved neuraminidase inhibitor for the treatment and pre-
vention of influenza in children younger than the age of 7 years.
It may reduce the duration of symptoms and, in addition, may
decrease otitis media as a complication.11 Oseltamivir was on
shortage for multiple periods in the 15-year time span studied.
This leaves one of our most vulnerable populations without
a medication against an infection that has killed almost 1500
children since the 2004-2005 season.12 In addition, the
oseltamivir shortages of 2009, 2013, and 2014 affected the sus-
pension of the drug, requiring compounding. The need for
compounding has led to medical errors and contamination of
sterile products in the past.13
Shortages of pediatric-friendly formulations can be par-
ticularly challenging for outpatient providers, as there is often
Table II. Therapeutic classes of ambulatory pediatric
drug shortages, 2001-2015
Categories of drugs
Total
shortages Percent
Median
duration,
mo* IQR
Infectious diseases 60 19.1 8.9 4.0-17.9
Anesthesia, analgesia 37 11.8 9.6 3.1-19.5
Vaccine 36 11.5 18.5 5.4-30.9
Topical 35 11.1 5.7 3.3-13.4
Allergy and immunology 32 10.2 10.3 2.7-14.0
Gastroenterology 33 10.5 11.1 5.0-17.9
Pulmonary 25 8.0 4.2 0.9-6.1
Psychiatry 18 5.7 10.3 4.4-16.3
Gynecology 15 4.8 6.4 1.3-13.8
Fluids, electrolytes, nutrition 10 3.2 5.6 1.3-17.7
Ophthalmology 9 2.9 5.5 2.4-9.3
Ear, nose, and throat 3 1.0 2.4 1.3-5.2
Endocrine 1 0.3 24.0 24.0-24.0
*Kruskal–Wallis equality-of-populations rank test c2 = 34.9 probability = .0005.
Figure 2. Twenty longest pediatric ambulatory care drug shortages.
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not a therapeutic alternative that is palatable or available in a
strength that is appropriate for pediatric use. Although there
is some evidence suggesting that children as young as 4 years
can be taught to swallow smaller pills,14,15 children of any age
may struggle with swallowing large tablets.Also, although adults
will put aside palatability to take a prescribed medicine, a
noxious taste can cause refusal in a young child.16 If pediatric-
friendly formulations are limited or not available, providers
may need to rely on adult formulations that may not be well
tolerated by children, ultimately resulting in reduced adher-
ence. Also, compliance with a medication regimen can be chal-
lenging for any patient, but especially so for pediatric patients.
Patient compliance with medication improves as the number
of doses per day decreases.17 One clear example of a medica-
tion shortage leading to more complex dosing is the recent
shortage of intramuscular penicillin.When intramuscular peni-
cillin went on shortage, providers had to use oral penicillin or
amoxicillin for a 10-day course. This increase in dosing fre-
quency may have contributed to reduced compliance with
medication.
The drastic reduction in vaccine-preventable diseases is one
of the great achievements in public health.18 Although overall
rates of vaccination coverage remain high, pockets of vaccine
refusal and low vaccination acceptance have led to outbreaks
of several vaccine preventable diseases.19,20 Vaccine shortages
made up 11.5% of the total number of drug shortages seen
in the study period. Only endocrinology drugs had a longer
median length of shortage than vaccines, likely falsely el-
evated by the small number of endocrinology specific drugs
on shortage. Of the 20 pharmaceuticals on shortage for the
longest period of time, vaccines accounted for one quarter of
those affected. These shortages place children at an unaccept-
able risk of a developing a preventable disease.
Given these concerns about shortages, providers, pharma-
cists, and healthcare systems must be prepared for shortages.
For pediatric ambulatory providers, often without a phar-
macy department, the first challenge will be staying aware of
the current shortages. Both the FDA and the ASHP maintain
lists of the current drug shortages.21,22 The ASHP drug short-
age Web site content is supplied by UUDIS and provides
evidence-based recommendations for managing the safety and
clinical problems shortages can create. The ASHP site also will
provide recommendations for alternatives. Once a shortage is
identified, selecting an alternative medication and communi-
cating that choice to potentially involved healthcare provid-
ers in a practice is the next step. For certain medications, the
group will need to determine the patient populations that
should receive priority, like the pneumococcal vaccine for pa-
tients with sickle cell anemia.
Ambulatory pediatric healthcare providers must be advo-
cates for their patients. The American Academy of Pediatrics
recommends additional measures to protect children from drug
shortages, including creating a list of critical pediatric drugs,
creating bidirectional information systems concerning drug
shortages, and ensuring fair distribution of drugs during a time
of shortage.23 These healthcare providers can also contact their
representatives to encourage supporting laws aimed at im-
proving research on pediatric drugs and also their proper
labeling.
Our study should be interpreted in light of several limita-
tions. UUDIS data depend on voluntary reports from clini-
cians and hospitals about drug shortages. It is possible that our
data underrepresent the true number of pediatric ambula-
tory care drug shortages experienced during this time period.
The UUDIS also does not include information on medica-
tion harms or complications that result from drug shortages.
Because reporting is voluntary, the reason for shortage may
be omitted or obscured. More than one-half of the drugs on
shortage lacked a reason for the shortage, because manufac-
turers were not required to report this information. Another
limitation is that the data include active shortages. Because these
shortages have not been resolved, we do not know their actual
duration. A shortage that started 3 months before the end of
our data collection may have gone on for much longer than
currently documented. As a result, the shortage times re-
ported may be underestimated.
We relied on 3 physician reviewers to determine whether a
drug on shortage was used in general ambulatory pediatrics.
This decision was a subjective distinction. Had others per-
formed these classifications, different drugs might have been
included or excluded. We also removed discontinued drugs
because many did not have any shortage time calculated. This
may have caused an underestimate of total shortages and short-
age time in cases where a drug was on shortage for a period
of time and then later discontinued.
The UUDIS data only document if an alternative to a drug
on shortage was also on shortage at any time during our study.
Given this limitation of the data, it is difficult to say howmany
options providers had at any single time during a shortage.Also,
drugs may have many different indications, so a medication
documented as an “alternative”may not have been appropri-
ate in certain clinical scenarios. These factors may have caused
an overstatement of the impact of having an alternative medi-
cation on shortage.
Drug shortages have been and will continue to be an issue
for general ambulatory pediatrics. The impact of drug short-
ages on ambulatory pediatrics needs to be further studied.
Pediatric-specific data need to be included in reports on
drug shortages. To meet these drug shortage challenges,
multiple stakeholders, including healthcare providers and
systems, industry, and regulatory agencies, will need to
collaborate. ■
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Prescription Drug Shortages
Pediatric Emergency and Critical Care Medications
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Objectives: Drug shortages have been increasing over the past 2 decades.
There are limited data on drug shortages and their effect on pediatric emer-
gency and critical care. Our objective was to describe pediatric emergency
and critical care drug shortages.
Methods:Drug shortage data from January 2001 to December 2015 were
obtained from the University of Utah Drug Information Services. Short-
ages were reviewed, identifying agents used in pediatric emergency and
critical care. Shortage data were analyzed for the type of drug, formulation,
shortage reason, duration, marketing status (generic vs brand name), or if it
was a pediatric-friendly formulation, used for a high-acuity condition, or a
single-source product. The availability of a substitute was also described.
Results: Of 1883 products on shortage, 779 were used in pediatric emer-
gency or critical care. The annual number of shortages decreased from
2001 to 2004, but then increased, reaching a high in 2011. The median du-
ration for resolved shortages was 7.6 months (interquartile range, 3.0–17.6
months). The most common category affected was infectious disease drugs.
High-acuity agents were involved in 27% of shortages and in 11% of
pediatric-friendly formulations. An alternative agent was available for 95%
of drugs, yet 43% of alternatives were also affected at some time during
the study period. The most common reported reason for a shortage was
manufacturing problems.
Conclusions: From 2001 to 2015, drug shortages affected a substantial
number of agents used in pediatric emergency and critical care. This has
had implications to the medications available for use and may impact pa-
tient outcomes. Providers must be aware of current shortages and imple-
ment mitigation strategies to optimize patient care.
Key Words: pharmacology, drug shortages, critical care
(Pediatr Emer Care 2019;00: 00–00)
A ccording to the Food and Drug Administration (FDA), drugshortages are “a period of timewhen the demand or projected
demand for the drug within the United States exceeds the supply
of the drug.”1 Shortages are commonly caused by issues with
the quality of the drug itself or quality issues within production
facilities; however, lack of sufficient demand and other eco-
nomic concerns have also been cited as causes.2 Since the mid-
2000s, drug shortages have increased in the United States and
have been shown to negatively impact patient care.3–6 Shortages
have also lengthened in recent years, becoming increasingly
likely to affect patients.7,8
Care for children may be impacted by drug shortages. Many
drugs lack pediatric indications, which in a shortage can lead to
fewer options for treatment.9 In particular, shortages of drugs used
in pediatric emergency and critical care settings have the increased
risk of harm given the immediate life-threatening nature of the
conditions treated in those settings. Representatives of the
American Academy of Pediatrics testified before the US Congress
in 2012 to the harmful effects of drug shortages on children.10
However, there has been limited research on drug shortages in
these settings. In this study, we explore shortages of drugs used
in pediatric emergency medicine and critical care from 2001
through 2015 and discuss the potential implications of these short-
ages on patient care.
METHODS
Drug shortage data from January 2001 to December 2015
were obtained from the University of Utah Drug Information
Services (UUDIS). The UUDIS began collecting drug shortage
information in January 2001 and publishes data on critical short-
ages online on the website for the American Society of Health-
System Pharmacists. Clinical pharmacists at UUDIS confirm
the shortage with the manufacturer and gather data. They also
use information from both the manufacturers and the FDA to de-
termine the end of the shortage. The UUDIS tracks the time a
shortage begins as the date when the confirmed shortage is first
reported. Shortages may have occurred in some organizations
before this start date, whereas other organizations may not be im-
pacted until a later date. The resolved date reflects the date when
the drug is either confirmed to be available or discontinued by
the manufacturers. The UUDIS data are considered to be the most
comprehensive source of information about drug shortages by the
US Government Accountability Office.11
Two study team members, one a pediatrician practicing in
emergency medicine (T.K.) and one a specialist in pediatric emer-
gency medicine (K.D.), reviewed pharmaceutical products affected
by shortages in the UUDIS database and identified agents com-
monly or specifically used in pediatric emergency departments
and critical care units. Identification was based on the practitioners'
clinical experience in their respective fields. An additional member
of the study team, an emergency medicine physician, who is also a
registered pharmacist and board-certified clinical pharmacologist
and practices at a pediatric hospital (M.A.), reviewed discrepancies
until a consensus was obtained.
Shortage data were then analyzed focusing on the type of
drug involved, formulation, reason for shortage, shortage dura-
tion, marketing status (brand vs generic), and if the drug was
pediatric-friendly (liquid/chewable dosing form or pediatric con-
centration) or a single-source product (produced by one manufac-
turer). We also assessed the availability of a substitute therapy and
whether the alternative was also affected by a shortage at any time
during the study period. Substitutes are determined by UUDIS
and can include medications in the same class as the drug on
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shortage or drugs with the same indication. Drugs were also sub-
jectively classified as a high- or low-acuity drug. High-acuity
drugs were those commonly used to treat a life-threatening condi-
tion, such as cardiac arrest or sepsis. Discontinued products
were excluded.
The final data set was analyzed for longitudinal trends, rea-
sons for shortages, and shortage duration. Shortage duration was
determined as the number of days between the date of shortage
notification and date of resolution as reported by the UUDIS.
Shortage duration was not normally distributed (long right tail),
which was confirmed by a Shapiro-Wilk W test for normal data.
Therefore, average shortage duration was described with medians
and interquartile ranges (IQRs). The nonparametric 2-sample
Wilcoxon rank sum (Mann-Whitney) test and the Kruskal-Wallis
equality-of-populations rank tests with Bonferroni corrections were
used to compare shortage durations. For shortages still active as of
December 31, 2015, data from the first quarter of 2016 were ex-
amined to determine if the shortage had been resolved. If the
shortage was still active as of March 31, 2016, shortage duration
was calculated as the number of months between the shortage no-
tification and March 31, 2016. Data were collected in Microsoft
Excel (Microsoft, Seattle, Wash) and analyzed using Stata 14
(College Station, Tex). The study did not meet the definition of
human subjects' research and therefore were exempt from institu-
tional review board review.
RESULTS
After excluding discontinued products (n = 190), a final data
set of 1935 drug shortages was examined. Of these, 779 (40%)
were identified as being used in pediatric emergency or critical
care, 84 of which were identified as available in a pediatric-
friendly form (11%). Initial reviewers agreed on 435 drugs of a to-
tal of 842 potential identified pediatric critical care drugs. The 3
total reviewers then discussed shortages that were discordant until
consensus was reached. The total number of new shortages by
quarter is displayed graphically in Figure 1. On average, there
were 11 new pediatric emergency and critical care shortages re-
ported quarterly (IQR, 7.75–16.5). Beginning in the first quarter
of 2005, shortages steadily increased, reaching a high of 32 in
the first quarter of 2011 and then plateauing. The median number
of new shortages in each 5-year range became more frequent in
the last 5 years of the study period (Fig. 2).
The median number of new shortages showed an increase
during each period from 7 per quarter (IQR, 5–9.5) in 2001 to
2005, to 13 per quarter (IQR, 10–16) in 2006 to 2010, to 17 per
quarter (IQR, 12–21) in 2011 to 2015 (P = 0.0001). For
pediatric-friendly forms, the median number of new drug short-
ages by quarter rose from 0.5 per quarter (IQR, 0–1.5) in 2001
to 2005, to 1.0 per quarter (IQR, 0–2) in 2006 to 2010, to 2.0
per quarter (IQR, 1–2.5) in 2011 to 2015 (P = 0.048).
Table 1 presents median duration of pediatric emergency and
critical care drug shortages. Of the 779 shortages, 706 were re-
solved by the end of the study period (91%). The median duration
of a resolved shortage was 7.6 months (IQR, 3.0–17.6 months). A
reason for the shortage was not reported for 375 of the pediatric
emergency and critical care drug shortages (48%). When a reason
was reported, the most commonly cited was for manufacturing
problems (28%), followed by supply/demand issues (15%), raw
material shortages (4%), business decisions (2%), and regulatory
issues (2%). Median shortage duration was highest for drugs on
shortage due to lack of sufficient raw materials (18.6 months;
IQR, 4.3–35.2 months), followed by manufacturing problems
(12.5 months; IQR, 5.1–31.3 months).
Therapeutic classifications are presented in Table 2. The
most common types of shortage for pediatric emergency and crit-
ical care drugs were for those used to treat infectious diseases (eg,
FIGURE 1. Total number of new pediatric emergency and critical care drug shortages, by quarter, 2001 to 2015.
FIGURE 2. Box-and-whisker plot of median number of pediatric
emergency care drug shortages reported per quarter, 2001 to 2015.
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acyclovir and vancomycin; n = 170), which were on shortage for
an average of 9.1 months (IQR, 3.7–21.3 months). Drugs for pul-
monary diseases (eg, albuterol and budesonide; 3.4 months; IQR,
1.3–5.5 months) were found to have significantly shorter duration
of shortage as compared with drugs in other therapeutic classes af-
ter Bonferroni correction.
Figure 3 presents the 20 longest shortages during the study
period. The longest shortage was for rabies immune globulin
(Bay Rab), which had been on shortage for 165.3 months as of
March 31, 2016. The longest resolved shortage was for heparin
sodium injection (97.4 months, resolved March 2016). Several
other long shortages still remained active as of March 31, 2016.
DISCUSSION
We found a substantial number of shortages of pediatric
emergency and critical care medications from 2001 to 2015. In ad-
dition, many medications have had prolonged shortages, some of
which were unresolved at the end of this study period. Although
many drugs on shortage had alternatives, a large number of alter-
natives were also on shortage at some time during the study.
Drug shortages increased through 2011 and then leveled off.
This may be due to the FDA Safety and Innovation Act of 2012.
This act strengthened the ability of the FDA to manage and report
on drug shortages. It requires drug manufacturers to notify the
FDA if they anticipate a shortage or plan to discontinue a drug.12
The FDA already had the power to expedite drug approval if it
would alleviate a shortage, but this new advance notification
may have helped the FDA, hospitals, and manufacturers avoid
or mitigate shortages.
Our study found that overall length of shortage was pro-
longed, at an average of 8.6 months. We suspect that this was
due to ongoing manufacturing and quality concerns with the prod-
ucts. Seven of the major sterile injectable drugmanufacturers were
cited for quality concerns by the FDA during our study period,
leading directly to shortages.13 The rate of these citations to all
drug manufacturers also increased from 2007 through 2013.13
Typically, to improve a quality concern, manufacturers must slow
or stop production to address the issue, leading to shortages. One
of the larger producers of pharmaceutical drugs, Ben Venue of
Bedford, Ohio, spent an estimated 350 million dollars to improve
manufacturing quality but eventually closed the site because of fi-
nancial losses.14 The FDA does not currently have the power to
force a company to manufacture a drug or continue bolstering a
struggling factory. Even when the FDA focuses intently on one
area of shortage, delays can be significant. This was demonstrated
by the severe shortage of normal saline caused by Hurricane
Maria's devastating toll on Puerto Rico.15
The number of drug shortages seen in our study raises con-
cerns about potential medication errors resulting from these short-
ages. The Institute for Safe Medicine Practices has recommended
that the harms from drug shortages can be classified into 4 catego-
ries.16 One, an alternative therapy is provided but leads to inade-
quate treatment. This harm was seen with the sterile ethanol
shortage of 2011. Sterile ethanol has been shown to prevent cen-
tral line infections in parental nutrition dependent intestinal failure
patients. Providers trialed a less than once daily dosing regimen to
maintain patients on ethanol locks during the shortage, which lead
to increases in central line infections.17 Two, an error is made with
TABLE 1. Pediatric Emergency and Critical Care Drug Shortages, 2001 to 2015
Total Shortages % Median Duration, mo IQR P
Category of drug
Active shortages* 73 9.4 25.6 7.8 59.6 <0.001†
Resolved shortages 706 90.9 7.6 3.0 17.6
Generic 591 76.1 9.3 3.7 22.5 <0.001†
Nongeneric 188 24.2 5.0 2.3 14.8
Pediatric-friendly 84 10.8 7.5 3.0 12.9 0.024
Not pediatric-friendly 695 89.4 8.4 3.4 22.3
Single source 261 33.6 5.5 2.5 12.7 <0.001†
Not single source 518 66.7 9.9 4.1 23.5
High acuity 208 26.8 8.7 3.7 29.7 0.027
Low acuity 571 73.5 8.2 3.2 18.1
Alternative available 738 95.0 8.2 3.4 19.6 0.822
No alternative available 41 5.3 9.4 2.8 22.9
Parenteral 460 59.2 8.4 3.5 19.9 0.884
Not parenteral 318 40.9 8.1 3.2 20.4
Reason for shortage
Business decision 13 1.7 10.3 3.7 13.8 <0.001†
Manufacturing problems 220 28.3 12.5 5.1 31.3
Natural disaster/weather 2 0.3 3.4 0.7 6.2
Raw materials 34 4.4 18.6 4.3 35.2
Regulatory issues 12 1.5 5.2 2.7 14.5
Supply/demand 120 15.4 7.3 3.0 15.7
Other‡ 3 0.4 3.2 2.9 9.9
Unknown 375 48.3 6.2 2.7 14.7
*Active as of March 30, 2016.
†Low inventory (x1), NDC transition (x1), short-dated product (x1), temporary plant closure (x1).
‡Statistically significant after Bonferroni correction for multiple comparisons.
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the alternative drug or the dose of a different form of the drug on
shortage. There have been multiple reports of dosing errors when
substituting hydromorphone for morphine, which could result in
respiratory depression or death.18 Three, the medication is
omitted, leading to nontreatment for the patient. This has be
seen in pediatric oncology, where there is no alternative regi-
men for a chemotherapeutic drug on shortage.19 Four, an error
when the hospital pharmacy attempts to compound a product
or drug strength is no longer available.16 In one case, a short-
age of sodium bicarbonate injectable solution led to a solution
of omeprazole being compounded with baclofen powder instead.20
This error resulted in a pediatric intensive care unit (PICU) admis-
sion and extensive testing, including lumbar puncture and mechan-
ical ventilation for the patient.
Most emergency department encounters for children oc-
cur at nonpediatric hospitals.21 Only approximately one quarter
TABLE 2. Therapeutic Classes of Pediatric Emergency and Critical Care Drug Shortages, 2001 to 2015
Class of Drug Total Shortages % Median Duration, mo IQR P*
Anesthesia, analgesia 104 13.4 10.6 4.1 25.4 0.055
Allergy and immunology 48 6.2 9.8 3.4 21.8 0.397
Cardiovascular 60 7.7 6.8 2.8 35.9 0.460
Endocrine 12 1.5 9.6 3.7 20.5 0.999
Ear, nose, and throat 3 0.4 4.1 2.4 5.2 0.201
Fluids, electrolytes, nutrition 103 13.3 8.2 3.7 23.2 0.627
Gastroenterology 68 8.8 11.3 4.1 22.7 0.454
Gynecology 3 0.4 11.9 1.3 29.1 0.969
Hematology 19 2.4 8.5 3.2 15.1 0.713
Infectious diseases 170 21.9 9.1 3.7 21.3 0.471
Neurology 35 4.5 7.8 4.0 18.9 0.854
Ophthalmology 15 1.9 6.3 2.4 9.5 0.200
Pulmonology 33 4.2 3.1 1.3 5.5 <0.001†
Psychiatry 4 0.5 8.3 7.1 38.7 0.486
Renal 3 0.4 23.5 7.8 41.9 0.186
Topical 41 5.3 6.0 2.6 10.9 0.017
Toxicology 48 6.2 6.0 3.0 18.7 0.297
Vaccines 10 1.3 18.6 4.1 36.8 0.131
*Each therapeutic class is compared with median duration of drug shortage not in the same class.
†Statistically significant after Bonferroni correction for multiple comparisons.
FIGURE 3. Twenty longest drug shortages.
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of emergency department visits for children are at a children's
hospital with an affiliated PICU.22 A drug shortage could force
providers with less pediatric experience to use unfamiliar medica-
tions. This could potentially lead to medical error. For example,
the drug cefotaxime is commonly used for the empiric coverage
of a neonate with fever. When on cefotaxime is on shortage, the
American Academy of Pediatrics recommends substituting with
ceftazidime.23 Ceftriaxone, a very commonly used cephalosporin
in pediatrics, is to be used with caution in infants and contraindi-
cated in those neonates with hyperbilirubinemia or who are less
than 41 weeks' gestational age. Although no documented cases
have been reported, it is possible that during a shortage, providers
looking for an alternative to cefotaximewould choose ceftriaxone
instead given their familiarity with the drug. It is also possible,
however, that these providers would be more comfortable using
drugs not typically used in pediatrics and maybe be more
equipped to handle a shortage.
Managing drug shortages is also extremely costly. Organiza-
tions must purchase more expensive alternatives and use addi-
tional staff time to manage the shortage. One study from 2011
estimated an annual cost of more than $200 million just in person-
nel costs to manage shortages.24 Drug shortages also lead to
higher costs for purchasing for group purchasing organizations,
both through off-contract purchasing of the drug on shortage
and through purchasing more expensive alternatives.25
Since 2013, the FDA has made an annual report to Congress
on the state of drug shortages in the United States.26 These reports
are mandated by FDA Safety and Innovation Act and serve to
summarize the shortages encountered and the FDA's response to
these shortages. None of these reports directly address pediatric
drug shortages or their impact on pediatric populations. In one na-
tional survey, pediatric patients made up 20% of those injured or
affected by medication shortages.16 With the prevalence of drug
shortages seen in our study, information on pediatric specific drug
shortages should be included in the annual report.
Given these concerns, there are steps that providers and hos-
pitals can take to prepare for shortages. Providers should be famil-
iar with the current shortages and how they may affect patient
care. Collaboration with pharmacy administration and engage-
ment in the hospital's pharmacy and therapeutics committee is
key to plan how to use limited drug supplies and determine safe
alternatives. This strategy has shown to be effective in protecting
PICU patients from medication harms during a shortage of fenta-
nyl and benzodiazepines. Pharmacists and providers outlined op-
tions for sedation and analgesia once aware of the shortage to
prevent medication errors.27
Drug shortages also create an opportunity to institute
evidence-based medicine in hospital guidelines. Using the right
drug at the right time for the right patient may reduce the impact
of shortages. For example, in a survey of NICU antibiotic pre-
scribing, 28% of antibiotic courses were found to not be in
compliance with Centers for Disease Control and Prevention
recommendations for appropriate antibiotic use. An additional
24% of antibiotic days were found inappropriate, when the an-
tibiotic administered could have been switched to one targeting
an identified organism.28 More judicious use of antibiotics
could be used as a strategy to mitigate shortages. There is the
possibility that reliance on evidence-based pathways could
leave providers unprepared in the event of a shortage of a critical
drug. Hospital and division leadership must be aware of this po-
tential and plan accordingly.
The UUDIS data depend onvoluntary reports from clinicians
about drug shortages, which may have limited our study. It is pos-
sible that our data underrepresent the true number of pediatric
emergency care drug shortages experienced during this period.
We did not conduct an anticipated needed sample size analysis be-
cause we used all available data in the UUDIS. The UUDIS also
does not include information on medications harms or complica-
tions that result from drug shortages. Also, drug shortages shorts
may affect different hospital or regions at different times and with
variable severity, which was not be included in our data. Neverthe-
less, this is the most comprehensive available source of drug
shortage information.
This study is also limited because we relied on 2 physician
reviewers to categorize the UUDIS drug list. The decision on
whether or not a drug was used in pediatric emergency or critical
care was a subjective distinction made by the 2 physician re-
viewers. Had these classifications been performed by others, re-
sults may have been different. We removed discontinued drugs
because many did not have any shortage time calculated. This
may have caused an underestimate of total shortages and shortage
time in cases where a drug was on shortage for a period and then
later discontinued.
Another limitation is that the data include active shortages.
By definition, these shortages have not been resolved, and there-
fore, we do not know their actual duration. For example, an active
shortage that began in October 2015 will only appear to have a
shortage of 3 months (October 2015–December 2015). However,
the actual time of this shortage may be longer. As a result, the
shortage times reported may be underestimated.
Pediatric emergency and critical care shortages continue to
impact many medications used in these settings and have acceler-
ated in recent years. Further work is needed to understand the im-
pact of drug shortages on pediatric emergency and critical care
and patient outcomes. Pediatric-specific considerations, such as
vital pediatric emergency drugs and specific pediatric formulations
on shortage, need to be included in reports on drug shortages.
Multiple stakeholders, including providers, health care systems,
industry, and regulatory agencies, need to incorporate pediatric
concerns in their plans for managing drug shortages.
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Abstract
Background: Prescription drug shortages have increased 
significantly during the past two decades and also impact 
drugs used in critical care and pediatrics. Objectives: To ana-
lyze drug shortages affecting medications used in neonatal 
intensive care units (NICUs). Methods: Drug shortage data 
for the top 100 NICU drugs were retrieved from the Univer-
sity of Utah Drug Information Service from 2001 to 2016. 
Data were analyzed focusing on drug class, formulation, rea-
son for shortage, and shortage duration. Results: Seventy-
four of the top 100 NICU drugs were impacted by 227 short-
ages (10.3% of total shortages). Twenty-eight (12.3%) short-
ages were unresolved as of December 2016. Resolved 
shortages had a median duration of 8.8 months (interquar-
tile range 3.6–21.3), and generic drugs were involved in 175 
(87.9%). An alternative agent was available for 171 (85.8%) 
drugs but 120 (70.2%) of alternatives were also affected by 
shortages. Parenteral drugs were involved in 172 (86.4%) 
shortages, with longer durations than nonparenteral drugs 
(9.9 vs. 6.4 months, p = 0.022). The most common shortage 
reason was manufacturing problems (32.2%). Conclusions: 
Drug shortages affected many agents used in NICUs, which 
can have quality and safety implications for patient care, es-
pecially in extremely low birth weight infants. Neonatolo-
gists must be aware of current shortages and implement 
mitigation strategies to optimize patient care.
© 2018 S. Karger AG, Basel
Introduction
The number of new prescription drug shortages has 
increased significantly during the past two decades. Pre-
scription drug shortages have also impacted drugs used 
in the pediatric population [1]. With the passage of the 
US Food and Drug Administration Safety and Innovation 
Act (FDASIA) of 2012, reductions in the total number of 
new national drug shortages were observed but shortages 
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were not eliminated. On the contrary, significant short-
ages of medications used in acute care settings such as 
emergency or critical care in adults still exist and have a 
substantial impact on intensive care medicine [2–4]. The 
impact of drug shortages on pediatric care has been de-
scribed for pediatric oncology and preventive medicine 
[5–8]. 
How national drug shortages impact medications used 
in neonatal intensive care units (NICUs) is an important 
issue as it will guide the mitigation strategies in the acute 
care setting for neonates. The objective of this study was 
to evaluate the impact of drug shortages on drugs used in 
the NICU based on the most frequently used NICU med-
ications [9].
Methods
We used drug shortage data from the University of Utah Drug 
Information Service (UUDIS), which monitors prescription drug 
shortages in the USA. Methods for this work have been previously 
described [10]. In brief, UUDIS receives voluntary reports of drug 
shortages by health professionals. Each reported shortage is veri-
fied with the suppliers. UUDIS also attempts to verify the reason 
for the shortage and an estimated resupply date. If there is a critical 
national drug shortage, e.g. if a certain drug is on shortage by the 
majority of suppliers, then UUDIS will post this information on 
the website hosted by the American Society of Health-System 
Pharmacists (ASHP, www.ashp.org/shortage). A shortage is de-
clared resolved by UUDIS when all suppliers have all presentations 
available, when impacted products have been discontinued, or 
when the FDA considers the shortage resolved.
UUDIS collects the following drug shortage data: generic prod-
uct name, therapeutic category, date shortage began (date UUDIS 
was notified), resolved date, duration, reason for the shortage, con-
trolled substance schedule (if applicable), whether the drug is an 
injectable product, and whether a product was discontinued. The 
data set of this analysis was restricted to shortages that occurred 
between January 1, 2001, and December 31, 2016. 
The list of commonly used drugs for this study was derived 
from Hsieh et al. [9], who reported the most commonly used 100 
NICU drugs and the top 20 agents used in extremely low birth 
weight infants (ELBW, birth weight < 1,000 g) between 2005 and 
2010 in a study within the Pediatric Trials Network. This study 
represented a sample size of 450,386 infants (including 29,336 
ELBW infants, 3.6%) with a median gestational age of 35 (range 
33–38) weeks, a median birth weight of 2,490 g and a median 
length of hospitalization of 10 (range 5–21) days receiving a total 
of 1,655,397 medication courses for 229 medications in 305 US 
NICUs. 
Data Analysis 
We characterized drug shortages based on the type of medica-
tion involved, length of shortage, route of administration (paren-
teral vs. nonparenteral), whether the medication was used for a 
life-threatening or high acuity condition, generic availability, and 
whether the drug was a single-source product (made by one facil-
ity). We also investigated whether impacted products had an avail-
able substitute for the most common NICU indication, and for 
those with alternatives if the substitute was also affected by a short-
age at any point during the study period. We also included reasons 
for shortages when available. 
Trend Analysis
We evaluated the number of new shortages by month and de-
termined two distinct trends: an increasing trend from 2001 to the 
middle of 2010 and a declining trend from the middle of 2010 to 
2016. To determine whether the two trends were significant, we 
included a dummy variable equal to 0 for months before July 2010, 
and equal to 1 for after July 2010. We used Poisson regression 
models allowing for autocorrelation to test for significance at a p 
value of less than 0.05. We first fit a standard Poisson model, ad-
justed by the time trend and the dummy variable. We checked for 
autocorrelation using a correlogram plot of the residuals and 
found third-order autocorrelation. We then fitted a Poisson re-
gression model allowing for third-order autocorrelation using the 
Stata command “arpois.” For shortages that resolved by the end of 
the study period (n = 199), we used the Kruskal-Wallis equality of 
proportions rank test and the 2-sample Wilcoxon rank sum 
(Mann-Whitney) test to compare shortage durations because 
shortage length was not normally distributed.
Results
Number of Shortages
From 2001 to 2016, a total number of 2,229 drug short-
ages were examined. Of those, 234 shortages were identi-
fied as belonging to the top 100 NICU drugs. After re-
moving 7 discontinued drugs, 227 shortages (10.3% of 
total shortages) were included in the analysis. These 227 
shortages were related to 74 of the top 100 NICU drugs. 
Trends of Shortages over Time
Between 2001 and 2010, the number of new NICU 
drug shortages reported annually increased from 11 in 
2001 to 36 by 2010 (p = 0.023 for trend, Fig. 1). By 2016, 
the number of new shortages decreased to 16. This trend 
was also found to be significant among parenteral drugs, 
which increased from 11 to 34 between 2001 and 2010 
and declined to 14 by 2016 (p = 0.050). The majority of 
shortages (199, 87.7%) had been resolved by the end of 
the study period. The number of unresolved shortages of 
NICU drugs at the end of 2016 was 28 (12.3%). 
Characteristics of Drugs on Shortage
The analysis of resolved NICU drug shortages accord-
ing to clinical and product characteristics showed (Table 
1) that a large number of the resolved NICU shortages in-
volved generic formulations (n = 175, 87.9%), drugs which
had a substitute available (n = 171, 85.8%), and parenteral
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products (n = 172, 86.4%). Of the 171 shortages with a 
substitute available, 120 (70.2%) of the substitutes were 
also affected by a shortage during the study period. 
Duration of Shortages
The median duration of a resolved shortage was 8.8 
months (interquartile range, IQR, 3.6–21.3). The unre-
solved drug shortages were of a considerably longer dura-
tion (median) of about 28.5 months (p = 0.0021). The 
shortage duration for parenteral drugs was significantly 
longer than that of nonparenterally administered drugs 
(9.9 vs. 6.4 months, p = 0.022). We did not find any sig-
nificant differences in shortage durations for the other 
characteristics examined (Table 1). 
The median duration of a resolved shortage for drugs 
used in ELBW infants was 11.9 months (IQR 3.0–30.1) 
compared to 8.7 months for agents not used in ELBW in-
fants (IQR 3.8–18.2, ns). For high acuity agents, the me-
dian duration of a resolved shortage was 8.6 months (IQR 
3.0–25.8), compared to 9.3 months for not high acuity 
agents (IQR 4.4–18.2). However, if all therapeutic classes 
were compared (Table 2), the longest single shortage was 
for lorazepam injections (88.2 months). 
The results for high acuity agents and drugs used in 
ELBW infants are shown in Tables 3 and 4, respectively. 
Therapeutic Classes of Drugs on Shortage
The most frequent therapeutic class on shortage was 
antimicrobial agents (n = 91, 40.1%), followed by cardio-
vascular (n = 48, 21.1%), and anesthetic/analgesic (n = 27, 
11.9%, Table 2). Shortage duration differed significantly 
between therapeutic classes as determined by a Kruskal-
Wallis equality-of-populations rank test (χ2 [9 df] = 
17.259, p = 0.045). The longest shortage duration was 
found for drugs classified as fluids, electrolytes, and nutri-
tion (22.3 months, IQR 1.6–43), and the shortest duration 
was found among pulmonary drugs (3.6 months, IQR 
0.8–5.9). Across all therapeutic classes, the most frequent 
NICU drug on shortage was meropenem (9 times). 
Reasons for Shortages
Of known reasons, manufacturing problems were 
most commonly cited (n = 73, 32.2%) followed by supply 
and demand issues (n = 39, 17.2%). A Kruskal-Wallis 
equality-of-populations rank test showed that there was 
not a statistically significant difference in shortage dura-
tion by reason for shortage (i.e., unknown reasons ex-
cluded, χ2 [5 df] = 10.437, p = 0.064). 
Discussion
The majority of the top 100 NICU drugs were impact-
ed by drug shortages indicating a serious concern in neo-
natal care, especially for critically ill premature or ELBW 
infants. There are only a few therapeutic options based on 
lack of safety and efficacy data in this vulnerable popula-
tion, since only 35% of the most commonly prescribed 
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Table 1. Characteristics of NICU drug shortages and analysis of resolved shortages according to clinical and 
product characteristics
Shortages, n (%)
(n of resolved 
shortages = 199)
Median length of 
shortage, months 
(IQR)
Two-sample Wilcoxon rank-
sum (Mann-Whitney) test
(median length of shortage)
z-score p value
Shortage status as of December 31, 2016
Active1 (% of n = 227) 28 (12.3) 28.5 (6.6–63.9) 3.075 0.0021
Resolved (% of n = 227) 199 (87.7) 8.8 (3.6–21.3)
Parenteral administration 172 (86.4) 9.9 (3.8–26.5) 2.293 0.0218
Other route of administration 27 (13.6) 6.4 (2.4–11.9)
Drugs for ELBW infants (top 20) 46 (23.1) 11.9 (3–30.1) 0.943 0.3456
Not among the top 20 for ELBW 
infants 153 (76.9) 8.7 (3.8–18.2)
High acuity medications 94 (47.2) 8.6 (3.0–25.8) –0.108 0.914
Non-high-acuity medications 105 (52.8) 9.3 (4.4–18.2)
Generics 175 (87.9) 9.3 (3.8–20.2) 1.136 0.256
Nongeneric drugs 24 (12.1) 6.9 (1.7–24.6)
Single sourced products 66 (33.2) 8.7 (3.6–18.9) –0.384 0.7007
Multiple sourced products 133 (66.8) 9.2 (3.7–21.3)
Substitute available 171 (85.9) 9.4 (3.8–22.1) 1.025 0.3054
No substitute available 28 (14.1) 6.8 (2.9–17.4)
Substitute also affected 120 (60.3) 9.9 (3.8–23.9) 0.791 0.4288
Substitute not affected 79 (39.7) 7.8 (2.9–20.2)
1 Durations for active shortages calculated as of December 31, 2016.
Table 2. Therapeutic categories of shortages involving drugs used in neonatal intensive care
Therapeutic category Shortages, 
n (%) 
(total n = 227)
Median months 
on shortage 
(IQR)
Most common drug on shortage 
(total times on shortage)
Longest single shortage 
(total months)
Anesthesia/analgesia 27 (11.9) 17.7 (6.1–35.2) morphine carpujects (4) lorazepam injection (88.2)
Cardiovascular 48 (21.1) 9.2 (4.9–32.9) dopamine injection (5) alprostadil injection (84.5)
Endocrinology 18 (7.9) 10.6 (6–15.8) dexamethasone injection (6) and 
levothyroxine injection (6)
levothyroxine injection (41.1)
Fluids, electrolytes, nutrition 4 (1.8) 22.3 (1.6–43) vitamin A injection (3) vitamin A injection (44.6)
Gastroenterology 11 (4.8) 18 (11.9–22.1) metoclopramide injection (4×) metoclopramide injection (40.0)
Infectious diseases 91 (40.1) 9.1 (3.7–17.4) meropenem injection (9×) fluconazole injection (59.2)
Neurology 10 (4.4) 4 (1.7–15.1) phenobarbital injection (4×) and 
fosphenytoin injection (4×)
fosphenytoin injection (60.9)
Pulmonary 12 (5.3) 3.6 (0.8–5.9) albuterol inhalation solution (3×) 
and budesonide inhalation 
0.5 mg/2 mL (3×)
aminophylline injection (48.1)
Topical 1 (0.4) 9.3 (9.3–9.3) erythromycin ophthalmic 
ointment (1×)
erythromycin ophthalmic 
ointment (9.3)
Toxicology 5 (2.2) 4.6 (2.8–7.1) naloxone injection (5×) naloxone injection (22.9)
Kruskal-Wallis equality-of-populations rank test: χ2 with 9 df =17.259; probability = 0.0448.
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medications are FDA approved in these infants, and off-
label knowledge only exists for a limited number of agents 
[9]. Threats for patient safety are inevitable, since alterna-
tive agents to established treatments might be less effec-
tive or carry a higher risk of adverse effects. In the NICU, 
no life-threatening consequences of drug shortages have 
been reported so far. During the 2011–2012 norepineph-
rine shortage, an association between the drug shortage 
and mortality due to septic shock was observed in adult 
patients [11]. 
Parenterally administered drugs were on shortage for 
a longer time period due to the higher manufacturing 
quality standards of sterile injectable agents compared to 
agents used for other routes of administration. The pos-
sibility to use nonparenteral routes of administration in 
the NICU is limited, since alternative routes of adminis-
tration are never used in life-threatening conditions (e.g., 
sepsis). 
The most frequent drug shortages occurred within the 
therapeutic classes of antimicrobial agents, cardiovascu-
lar agents, and anesthetic/analgesic agents, of which most 
can be considered drugs used for high acuity conditions. 
The pediatric gentamicin preparation was largely impact-
ed by shortages. Using another than the usual formula-
Table 3. Shortages of high acuity drugs used in the neonatal intensive care unit
Therapeutic category High acuity
shortages, n (%) 
(resolved n = 94)
Median months 
on shortage (IQR)
Most common drug 
on shortage (total 
times on shortage)
Longest single shortage 
(total months)
Anesthesia/analgesia 8 (8.4) 23.6 (12.5–59.5) diazepam (2) 
indomethacin (2) 
lorazepam (2) 
midazolam (2)
lorazepam (88.2)
Cardiovascular 23 (24.2) 8.7 (2.6–38.2) dopamine (4) 
phenylephrine (4)
alprostadil (84.5)
Infectious diseases 44 (46.3) 9.9 (3.4–16.6) meropenem (9) fluconazole (59.2)
Neurology 9 (9.5) 4.0 (1.7–15.1) fosphenytoin(4) fosphenytoin (60.9)
Pulmonary 5 (5.3) 5.2 (0.9–5.7) albuterol (3) aminophylline (48.1)
Toxicology 5 (5.3) 4.6 (2.8–7.1) naloxone (5) naloxone (22.9)
Kruskal-Wallis equality-of-populations rank test: χ2 with 5 df = 8.084; probability = 0.1517.
Table 4. Shortages of drugs used in ELBW infants in the neonatal intensive care unit
Therapeutic category ELBW 
shortages, n (%) 
(resolved n = 46)
Median 
months on 
shortage (IQR)
Most common drug 
on shortage (total 
times on shortage)
Longest single
shortage
(total months)
Anesthesia/analgesia 7 (15.2) 21.5 (7.7–59) morphine carpujects (3) midazolam (60)
Cardiovascular 7 (15.2) 13.2 (2–54.2) dopamine (4) furosemide (77.8)
Endocrinology 8 (17.4) 9.7 (3.5–23) dexamethasone (5) hydrocortisone (31.6)
Fluids, electrolytes, 
nutrition 3 (6.5) 3.1 (0.1–44.6) vitamin A (3) vitamin A (44.6)
Gastroenterology 6 (13) 20.3 (12–29.1) metoclopramide (4) metoclopramide (40)
Infectious diseases 10 (21.7) 11.6 (7.6–26.7) ampicillin (2)
cefotaxime (2) 
gentamicin (2) 
vancomycin (2)
fluconazole (59.2)
Neurology 2 (4.3) 28.2 (1.7–54.6) caffeine citrate (2) caffeine citrate (54.6)
Pulmonary 3 (6.5) 0.9 (0.5–5.2) albuterol (3) albuterol (5.2)
Kruskal-Wallis equality-of-populations rank test: χ2 with 7 df = 7.829; probability = 0.3479.
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tion may lead to dosing errors. Compounding of pediatric 
formulations out of adult preparations may lead to inap-
propriate dosage, since additional dilution is needed, or 
microbial contamination [2]. 
Shortages of antibiotics are extremely critical in neo-
natal care due to limited alternative treatments, e.g. the 
use of ceftriaxone in term neonates is avoided due to the 
risk of kernicterus during neonatal hyperbilirubinemia. 
Substitutes have been prescribed during previous drug 
shortages in children, e.g. doripenem replaced merope-
nem in the therapy of pediatric patients with cystic fibro-
sis [12]. This strategy cannot be 100% applied to neonatal 
care, since possible alternatives may not have been stud-
ied in neonates. Neonates have an increased doripenem 
exposure, a longer elimination half-life, and a lower clear-
ance compared with infants > 4 weeks [13], but pharma-
cokinetic data may not be present for other substitutes of 
drugs on shortage. 
During the 2009–2010 shortage, erythromycin oph-
thalmic ointment, which had usually been used for neo-
natal ocular prophylaxis, was replaced by gentamicin sul-
fate ophthalmic ointment. As a complication, a higher 
rate of periocular ulcerative dermatitis was seen in treated 
newborns that likely resulted from the prophylactic use 
of this gentamicin ophthalmic ointment [5]. It was as-
sumed that either gentamicin itself or an excipient (e.g., 
benzalkonium chloride) was responsible for this adverse 
drug reaction. It was recommended to resume erythro-
mycin ointment use as soon as the shortage was resolved 
and to use caution when applying gentamicin ointment 
until then. 
Thus, the quality assessment of the substitute should 
also consider the excipient, since that may cause toxicity 
in neonates. For example, propylene glycol, which is used 
as an excipient of intravenous vitamin E, led to serum hy-
perosmolarity and even lactic acidosis in neonates [14].
Table 5. Mitigation strategies for drug shortages affecting medications used in the NICU
National level Provider network level Hospital level Ward level
Early information about 
anticipated drug shortages
Anticipate (regional) drug 
shortages
Use pediatric/neonatal 
formulations for these 
patients ONLY
Share drugs among patients and 
minimize drug waste: administer 
the same medications at the same 
time in order to save vials
Follow recommendations 
of the respective profes-
sional society, such as AAP, 
ASPEN, ASHP and COG
Avoid overpurchasing and 
hoarding
Conserve resources for the 
most vulnerable patients, e.g. 
pediatric/oncologic/
immunosuppressed patients
Prioritize the sickest patients (e.g., 
ELBW infants) and use 
substitutes/compounded 
formulations for other patients
Import drugs Expand current suppliers Use substitutes in less 
vulnerable (e.g., adult) 
patients
Use substitute drugs of the same 
or a different class within the same 
indication
Review available products Adapt therapy (e.g., 
administration route) in less 
vulnerable (e.g., adult) 
patients
Use alternative ways of 
administration for non-life-saving 
indications (e.g., oral/enteral)
Implement flexible supply 
strategies
Use compounded 
formulations in the hospital 
pharmacy (avoid constitution 
errors)
Avoid giving intravenous drugs via 
the oral/enteral route – use enteral 
formulations
Evaluate replacement 
algorithms
Compound drugs centrally in 
the hospital pharmacy
Assess the indication of treatment 
every day
Introduce clinical decision 
support tools for drug therapy
Use expired medications 
(only after regulatory 
approval)
AAP, American Academy of Pediatrics; ASPEN, American Society for Parenteral and Enteral Nutrition; ASHP, American Society of 
Health-System Pharmacists; COG, Children’s Oncology Group.
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We found long shortage durations for drugs used as 
part of parenteral nutrition regimens. Preterm infants 
have special nutrient and vitamin requirements [15]. In 
the NICU, complications have occurred due to a shortage 
of intravenous selenium which is an additive to paren-
teral nutrition [16]. The American Society for Parenteral 
and Enteral Nutrition (ASPEN) issued recommendations 
regarding the management of parenteral nutrition prod-
uct shortages during the peak of the 2010–2012 shortage 
[17]. The ASPEN recommended to use specific pediatric 
or neonatal products only for these patient groups [18]. 
If these are on shortage, however, parenteral nutrition 
should be saved for the patients in the NICU who need it 
most, such as very preterm or ELBW infants, or sick neo-
nates with enteral obstruction, necrotizing enterocolitis, 
or after surgery.
The 2010–2012 vitamin A shortage actually led to re-
evaluation of therapy when the occurrence of chronic 
lung disease or death in ELBW infants appeared to be un-
affected by the shortage [7]. 
Mitigation Strategies 
Since the implementation of the FDASIA in 2012, 
manufacturers are required to notify the FDA of antici-
pated product shortages or discontinuations. While the 
notifications about anticipated drug shortages and the 
prevented drug shortages increased significantly, there 
was a decline in newly occurring drug shortages in 2012. 
However, the FDA cannot require a manufacturer to pro-
duce any product, no matter how lifesaving, and has no 
authority to require manufacturers to have redundancies 
or contingency plans in case of shortages [19]. Importing 
medications from other countries is an option to help 
mitigate shortages; however, this temporary strategy may 
only be used when a sufficient supply is available without 
creating a shortage in another country [20].
Specific mitigation strategies are required for the care 
of newborns. A general approach for rational drug use 
during shortages is to treat the patients who need the 
same drug at the same time or within the shelf-life after 
preparation in order to minimize drug waste which has 
already been practiced in oncology. 
When other-than-usual preparations are used for re-
constituting neonatal formulations, preventive measures 
should be taken (e.g., by storing the alternative prepara-
tion at another place, using different labeling and double-
checking extemporaneous formulations) in order to 
avoid constitution errors. The NICU should be priori-
tized regarding delivery of drugs not containing toxic ex-
cipients [21].
The use of substitutes in the NICU regularly results in 
an increased off-label use (which was 65% as studied by 
Hsieh et al. [9]), which carries the risk of more adverse 
effects. Computer-based clinical decision support sys-
tems could impact the choice of the drug during a short-
age and reduce the use of drugs on shortage [22]. 
For all mitigation strategies implemented in neonatal 
units, professional pharmaceutical and/or pharmacologi-
cal advice should be sought [23]. The recommendations 
of the respective professional society should be followed, 
such as pediatric societies, the ASPEN, the Children’s 
Oncology Group, and the ASHP, and in part, mitigation 
strategies can be adopted from adult recommendations 
(Table 5) [2, 17, 24–26]. 
Limitations of This Study
A limitation of this study is that this analysis is based 
on data from a single provider network (operating 305 
NICUs) and from one single country, so perhaps not ful-
ly reflecting the situation in other countries. But, in terms 
of globalization and centralization of manufacturing, 
drug shortages in the USA may impact other countries as 
well, e.g., the 2018 shutdown of an ibuprofen manufac-
turing plant producing around a sixth of the global ibu-
profen supply may have consequences on the ibuprofen 
availability worldwide [27]. 
This data set included infants with a gestational age of 
33–38 weeks, therefore, the impact of drug shortages 
could be even severer in infants with a gestational age 
< 30 weeks. Although there were no preterm infants < 33 
weeks included in that study, we still think that, because 
of the sample size, the study is a reliable source of infor-
mation and that the studied ELBW infants are represen-
tative for this population.
Conclusion
Drug shortages affected a substantial number of the 
most common and high acuity agents used in the NICU, 
which can have quality and safety implications for patient 
care, especially in ELBW infants. Neonatologists must be 
aware of current shortages and implement mitigation 
strategies to optimize patient care.
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Antibacterial Drug Shortages From 2001 to 2013:
Implications for Clinical Practice
Farha Quadri,1 Maryann Mazer-Amirshahi,2 Erin R. Fox,3 Kristy L. Hawley,4 Jesse M. Pines,1,5 Mark S. Zocchi,4 and
Larissa May1
1Department of Emergency Medicine, George Washington University, and 2MedStar Washington Hospital Center, Washington D.C.; 3Drug Information
Service, University of Utah Health Care, Salt Lake City; 4Ofﬁce for Clinical Practice Innovation, and 5Department of Health Policy, George Washington
University, Washington D.C.
Background. Previous studies have described drug shortages; however, there has been no comprehensive
evaluation focusing on US antibacterial shortages.
Methods. Drug shortage data from the University of Utah Drug Information Service database were analyzed, with
a focus on antibacterial agents from 2001 to 2013. We used descriptive statistics to describe trends in drug shortages,
analyze drug classes commonly affected, and investigate whether drugs experienced multiple periods of shortages.
Results. One hundred forty-eight antibacterial drugs were on shortage over the 13-year study period, with 26 drugs
still active on shortage as of December 2013. The median number of new shortages per year was 10 (interquartile range
[IQR], 7). The number of drugs on shortage increased at a rate of 0.35 additional drugs every month (95% conﬁdence
interval, .22–.49) from July 2007 to December 2013 (P < .001). The median shortage duration was 188 days (IQR,
366.5). Twenty-two percent of drugs experienced multiple shortage periods.
Conclusions. There were a substantial number of drug shortages from 2001 to 2013, with a dramatic rise in short-
ages since 2007. Shortages of agents used to treat multidrug-resistant infections are of concern due to continued trans-
mission and limited treatment options.
Keywords. drug shortages; University of Utah Drug Information Service (UUDIS); National Drug Codes (NDC).
Drug shortages are an important issue in public health
and medical care delivery [1]. The US Food and Drug
Administration (FDA) deﬁnes a drug shortage as “a
situation in which the total supply of all clinically inter-
changeable versions of an FDA-regulated drug product
is inadequate to meet the projected demand at the user
level” [2]. There are several reasons for drug shortages,
including manufacturer mergers, facility consolidation,
manufacturing quality issues, and narrow proﬁt margin
for generic drugs [3].
Anti-infective agents account for 15% of all drug short-
ages, with injectable antibiotics frequently impacted [4].
A majority of infectious disease physicians surveyed
report having modiﬁed antimicrobial selection due to
shortages [5]. Shortages have signiﬁcant implications
in the context of other factors that limit availability of
effective antimicrobials, including a shrinking pipeline
of new antibiotics and increasing drug resistance [6–
8]. In this study, we evaluate antibacterial drug shortage
trends in the United States from 2001 to 2013 and dis-
cuss clinical implications. A recent government report
highlighted the public health crisis of drug shortages,
but to our knowledge, ours is the ﬁrst in-depth evalua-
tion of antibacterial drug shortages [9].
METHODS
We conducted a cross-sectional study of antibacterial
drug shortages using the University of Utah Drug Infor-
mation Service (UUDIS) database from January 2001 to
December 2013. UUDIS began collecting national drug
shortage data in January 2001, and it publishes critical
drug shortage information on a public website (www.
ashp.org/shortages) hosted by the American Society of
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Health-System Pharmacists (ASHP). The UUDIS deﬁnes a
shortage as a supply issue affecting how the pharmacy prepares
or dispenses a drug product or inﬂuences patient care when pre-
scribers must use an alternative agent [10]. For this study’s pur-
pose, we used this deﬁnition for a shortage, which is more
inclusive than the FDA deﬁnition. Detailed UUDIS methods
have been previously published [11]. UUDIS receives voluntary
drug shortage reports via the reporting feature on the ASHP
website. Clinical pharmacists at UUDIS verify the existence of
a shortage and determine all potential manufacturers of a
drug reported to be in short supply using National Drug
Codes (NDCs). Next, each manufacturer is contacted to deter-
mine which NDCs are in shortage at the national level. The
manufacturers are also asked for reasons for the shortage and
an estimated release date. UUDIS posts information at the
ASHP drug shortage website, noting which products are affect-
ed, methods for accessing available products, reasons for the
shortage, and estimated resupply dates. If applicable, patient
care implications, safety concerns, therapeutic alternatives,
and management strategies are also provided. UUDIS considers
a shortage to be resolved when all suppliers have all NDCs
(available strength and product size) available or have discon-
tinued their products. UUDIS collects the following drug short-
age data using Microsoft Excel: generic product name,
therapeutic category, date shortage began (date UUDIS was no-
tiﬁed), resolved date, duration, reason for shortage, and if the
drug is an injectable product. Drug shortages that occur due
to product discontinuation or withdrawal from the market are
also included in the UUDIS database and marked as having
shortage duration of zero days [10].
We analyzed drug shortage data from UUDIS from January
2001 to December 2013. Three investigators evaluated 1751
pharmaceutical products with reported shortages, focusing on
antibacterial drugs. In addition, our dataset included informa-
tion on whether the shortage was active or resolved, the reason
for shortage, whether the product was an injectable product,
whether the product was sole source (deﬁned as a single-
manufacturer product and determined by the investigator
using FDA approval dates), and whether alternative drugs
were available as a substitute.
The investigators further characterized each antibacterial
drug in the data set to general pharmacologic class and whether
the drug is broad spectrum or narrow spectrum in coverage
(with broad-spectrum deﬁned as treating both gram-positive
and gram-negative infections). Further classiﬁcation was con-
ducted to determine special pathogen coverage (eg, for methi-
cillin-resistant Staphylococcus aureus [MRSA] or Pseudomonas
aeruginosa). We excluded topical and ophthalmic antibacterial
agents. For example, tobramycin powder shortages were exclud-
ed because it is most commonly used in bone cement, although
the product is labeled for injection. This is due to the increased
time to reconstitute for intravenous use. Although it is possible
that some hospitals reconstitute the powder for intravenous use,
including this information would inaccurately account for the ac-
tual usage of systemic use. We also excluded antimycobacterial
agents, such as rifampin, as this study’s focus was to evaluate
shortages for antibiotics used to treat acute bacterial infections
and not tuberculosis. Shortage duration was calculated for resolved
shortages. Because this study did not include human subject data,
it was considered exempt by our institutional review board.
Data Analysis
Data were described using standard descriptive statistics. Uni-
variate analysis found that drug shortage time (measured in
days) was not normally distributed (right skewed). Therefore,
we used the nonparametric 2-sample Wilcoxon rank-sum
(Mann–Whitney) test to compare shortage times and describe
average shortage time using median and interquartile range
(IQR). Visual inspection of the drug shortages by month
showed a distinct upward (positive) trend from July 2007 to
2014. A segmented regression analysis of drugs shortages before
and after July 2007 was performed to assess this trend. Time was
coded as a continuous variable in 1-month intervals from 1
(January 2001) to 156 (December 2013). We excluded the
ﬁrst year of data collection (2001) from the regression equation
to adjust for a time lag for drugs to ﬁrst appear on the shortage
list. For the purposes of analysis, drugs that were on shortage for
>1 time period are counted as separate shortages. The total
number of antibacterial drugs on shortage was regressed on a
constant, a linear trend term (x), a dummy variable equaling
zero prior to July 2007 and 1 thereafter, and a post–July 2007
trend term (x-78) as described by Wagner et al [12]. A Durbin-
Watson test indicated presence of serial autocorrelation and was
corrected for by using the Cochrane-Orcutt transformation [13].
A P value of <.05 was considered signiﬁcant. Data were collected
in Microsoft Excel (Microsoft Corporation, Redmond, Washing-
ton), and analyses were conducted using Stata 13.1 (College
Station, Texas).
RESULTS
Over the course of the study period, 148 antibacterial drugs
went on shortage. Of those, 112 were resolved by the end of
the study period (31 December 2013), 10 were discontinued
by the manufacturer, and 26 remained active. Figure 1 presents
the trends in shortages over time.
The median number of new shortages per year was 10 (IQR,
7) and ranged from a low of 6 in 2004 to a high of 18 in 2011.
The median duration of a resolved shortage was 232 days (IQR,
373.5 days), or approximately 7.5 months.
We examined resolved shortage times for drugs with and
without injectable administration, drugs with and without
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available alternatives, and broad- vs narrow-spectrum drugs.
Drugs with injectable administration had a median shortage
time of 250 days (IQR, 457 days) vs 129 days (IQR, 288 days)
for drugs without injectable administration (P = .06).
Drugs without available alternatives had a median shortage of
149.5 days (IQR, 410 days) vs 262 days (IQR, 324 days) for drugs
with an alternative (P = .10). Drugs classiﬁed as broad-spectrum
had a median shortage of 232 days (IQR, 367 days) vs 199.5 days
(IQR, 366 days) for narrow-spectrum drugs (P = .74).
Over the study period, an average of 14.2 drugs were on
shortage per month (95% CI, 12.8–15.5). The number of
drugs on shortage in a given month increased over time
(Figure 1). On average, there were 9.7 drugs on shortage per
month prior to July 2007 vs 17.9 from July 2007 through De-
cember 2013 (P < .001). From July 2007 to December 2013,
the rate of increase was approximately 0.35 additional drugs
every month (95% CI, .22–.49) and was signiﬁcantly different
from the trend prior to July 2007 (P < .001).
Thirty-two drugs (22%) experienced multiple shortages over
the study period. The most commonly reported shortages were
meropenem (7); cefotetan and piperacillin-tazobactam (5 each);
and azithromycin, aztreonam, and nafcillin (4 each) (Table 1).
Cephalosporins were the most commonly reported drug class
shortage, with 27 reported shortages for a total of 446 months
over the study period. There were 11 aminoglycoside shortages
for 284 months, 22 penicillin shortages for 229 months, and 11
penicillin/β-lactam inhibitor shortages for 178 months over the
study period (Figure 2).
One hundred twenty of the 138 drugs (81%) were broad-
spectrum antibacterial agents. Trends are displayed in Figure 3.
Sixty-eight of the shortages (46%) involved drugs used to
treat high-risk pathogens, including 2 for Clostridium difﬁcile,
1 for carbapenem-resistant Enterobacteriaceae (CRE), 1 for
leprosy, 15 for MRSA, and 32 for Pseudomonas aeruginosa.
Seven of the drugs treat extended-spectrum β-lactamase–
producing organisms (ESBLs), and 4 treat human immu-
nodeﬁciency virus–related opportunistic infections. Two drug
formulations were speciﬁcally used to treat pediatric patients.
The most common reason for shortage included manufacturing
problems, with 35 reported shortages and 19 resulting from in-
sufﬁcient supply–demand ratio (Table 2)
DISCUSSION
There were several ﬁndings of concern in this study. First, there
were a substantial number of drug shortages from 2001 to 2013,
Table 1. Drugs With Multiple Shortages: Both Active and
Resolved, 2001–2013
Drug Name
No. of
Shortages Total Days
Cefotetan 5 2141
Aztreonam 4 1990
Piperacillin-tazobactam 5 1858
Kanamycin injection 3 1682
Cefotaxime injection 3 1542
Doxycycline injection 3 1515
Erythromycin lactobionate 2 1245
Gentamicin injection, pediatric strength 2 1173
Meropenem 7 1114
Ampicillin-sulbactam 3 1052
Minocycline injection 2 944
Piperacillin sodium 2 942
Cefepime injection 3 801
Nafcillin 4 763
Azithromycin injection 4 599
Gentamicin injection 2 574
Cephalexin suspension 2 535
Imipenem-cilastatin 2 502
Ciprofloxacin 500 mg tablets 3 442
Ceftizoxime 2 405
Clindamycin injection 2 394
Vancomycin 3 373
Cefpodoxime 2 344
Colistimethate 2 255
Paromomycin (Humatin) 3 192
Cefuroxime injection 2 185
Sulfamethoxazole-trimethoprim injection 3 165
Methenamine 2 133
Dalfopristin/quinupristin (Synercid) 2 125
Ticarcillin-clavulanate 3 123
Ceftazidime 2 69
Spectinomycin 2 0
Includes both active and resolved shortages. Values in boldface indicate that
the drug is currently experiencing a shortage.
Source: University of Utah Drug Information Service database.
Figure 1. Trends in drug shortages, 2001–2013.
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with concerning trends over time. These shortages are often of
very long duration, with a mean of nearly 9 months. Second,
these shortages often impact clinicians’ ability to treat infec-
tions, including multidrug-resistant pathogens for which there
is a limited selection of effective antibiotics. Finally, we found
that a substantial proportion of shortages (61 of 148) were for
unknown reasons, suggesting a need for improved tracking and
reporting.
A high proportion of recent drug shortages involved broad-
spectrum agents, injectable drugs, medications with no alternative
sources, or those used on pathogens with limited alternative treat-
ment options or in pediatric patients. Although we were unable to
determine the precise cause for the dramatic rise in antibacterial
shortages after 2007, the shortage increase coincides with the
downturn in the US economy, with the most common reasons
for shortages being business related. Since 2011, drug shortages
appear to have stabilized, but still remain high.
The upward trend in shortages of broad-spectrum agents is
driving the total increase in shortages. We found especially
Figure 2. Drug shortages by drug class, 2001–2013.
Figure 3. Trends in broad-spectrum vs narrow-spectrum shortages,
2001–2013.
Table 2. Common Reasons for Drug Shortages, 2001–2013
Shortage Reason No. of Drugs
General manufacturing/manufacturing delays or
problems
35
Supply and demand 19
Raw material shortage 13
Discontinued 10
Regulatory issues/regulatory problems 5
Regulatory (import ban) 3
Natural disaster 1
Business decision 1
Unknown 61
Total 148
Source: University of Utah Drug Information Service database.
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concerning the high shortage rates in antibacterial agents used
to treat highly drug-resistant pathogens, including MRSA, CRE,
and Pseudomonas. One hospital found that shortages occurred
in 7 antimicrobials over a 3-month period, with 87% being ge-
neric products [14]. Treatment options for CREs are likely to
become increasingly limited [15, 16].
Many shortages involve gold-standard therapies. For exam-
ple, aztreonam treats life-threatening infections caused by
gram-negative bacteria in patients allergic to penicillin and tri-
methoprim-sulfamethoxazole (TMP-SMX) for treatment of
Pneumocystis pneumonia (PCP) [2]. TMP-SMX shortages are
compounded because it is produced by a single manufacturer.
Seventy-three drugs (49%) were listed as having no alternative
production source. Use of therapeutic alternatives include lower
efﬁcacy rates and higher toxicity [1].The shortage of TMP-SMX
necessitating treatment with alternatives, such as clindamycin
and primaquine, has led to delayed care, as well as refractory
cases of PCP [13].
Implications for the clinical management of patients with crit-
ical infectious diseases in the setting of rising trends in drug resis-
tance have been studied previously. A survey study of >600
infectious disease physicians found that 78% reported having to
modify antibacterial choices due to shortages. In that study, clini-
cians reported the antimicrobials most commonly unavailable or
in short supply as TMP-SMX (65%), amikacin (58%), and aztreo-
nam (31%), which is supported by our ﬁndings. More than half
felt that the shortage had a negative impact on patient outcomes,
requiring the use of less effective, more toxic, or more costly alter-
natives. Most providers reported they learned of shortages after at-
tempting to prescribe the medication through their pharmacy [5].
Alternatives may not be as familiar to clinicians and thus may
lead to medication errors and adverse outcomes [1]. In a survey
of the Institute for Safe Medication Practices conducted in 2010,
clinicians reported adverse outcomes due to drug shortages in
20% of cases [17], as well as substantial resource utilization
when developing an action plan (82%) and a lack of suitable al-
ternatives (70%). Shortages may also lead to internal hoarding
of medications, posing ethical challenges. Potential patient
harm due to shortages includes medication overdoses, life-
threatening side effects, cross-contamination, and even death
[18]. For example, several patients with Pseudomonas infection
only and amikacin sensitivity experienced morbidity or mortal-
ity when the drug could not be provided [13–15].
There are several ways to potentially mitigate the clinical im-
pact of antibacterial drug shortages. One important strategy is
through improved communication with providers. In half of
cases, physicians and nurses learn about drug shortages from
pharmacy staff, often when the pharmacy is unable to dispense
the medication [13]. Institutions should consider prospectively
tracking potential shortages and making recommendations for
safe and appropriate use of therapeutic alternatives [19].
Strategies should also include keeping local inventory of critical
antibacterial agents, anticipating the need for alternatives, and
creating contingency plans. A multidisciplinary antimicrobial
stewardship plan should include a stewardship pharmacist to
help guide these efforts. One strategy would be guideline devel-
opment, ensuring narrow coverage based on culture results, en-
couraging intravenous to oral conversion, ensuring ethical
distribution to patients with the greatest need, educating clini-
cians, and developing protocols for when alternatives must be
used, so as to prevent errors [15]. An interdisciplinary drug
shortage task force can include physicians, pharmacists, nurses,
ethics members, and patient representatives [20]. Optimization
of utilization of the available supply and guidance regarding al-
ternative agents are imperative, with guidelines available [17].
Although more than a dozen new antimicrobial agents have
recently been developed against antibiotic-resistant pathogens,
few act on new targets; thus, it is imperative to address the
lack of agents, compounded by drug shortages, for these classes
[21]. Many times, manufacturers do not report shortages until
supplies are very low, and policy makers should advocate for
mandatory earlier reporting of shortages.
Limitations included the inability to account for all possible
shortages, lack of information on geographic disparities in short-
ages, and evidence of impact on clinical outcomes. Drug shortages
may impact individual healthcare facilities at different times and
with differing effects on clinical care. For example, not all facilities
stock all drugs or all formulations. Small or rural facilities may
have more difﬁculty accessing products that can only be pur-
chased directly from the manufacturer. Inventory and delivery
methods vary widely in the drug distribution chain. Furthermore,
it is somewhat difﬁcult to distinguish if the drug was completely
unavailable, discontinued, or available but in short supply, so we
cannot describe the severity of the shortage. We were also unable
to measure the time and effort hospital staff spends attempting to
mitigate shortages. Nonetheless, the database currently used rep-
resents the most comprehensive data source on trends and rea-
sons for antibacterial and other drug shortages.
In summary, there were 148 reported antibacterial shortages,
with 26 drugs still actively on shortage as of 31 December 2013,
with nearly half reported as having no alternative production
source. Given that 46% are used in the treatment of high-risk
pathogens, such as MRSA, CRE, and Pseudomonas, it is imper-
ative to develop a comprehensive strategy to mitigate the impli-
cations of shortages on clinical practice and patient outcomes,
including improved communication, alternative algorithms,
and antimicrobial stewardship policies.
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Purpose. Trends in shortages of vaccines and immune globulin products 
from 2001 through 2015 in the United States are described.
Methods. Drug shortage data from January 2001 through December 
2015 were obtained from the University of Utah Drug Information Service. 
Shortage data for vaccines and immune globulins were analyzed, focus-
ing on the type of product, reason for shortage, shortage duration, short-
ages requiring vaccine deferral, and whether the drug was a single-source 
product. Inclusion of the product into the pediatric vaccination schedule 
was also noted. 
Results. Of the 2,080 reported drug shortages, 59 (2.8%) were for vac-
cines and immune globulin products. Of those, 2 shortages (3%) remained 
active at the end of the study period. The median shortage duration was 
16.8 months. The most common products on shortage were viral vac-
cines (58%), especially hepatitis A, hepatitis B, rabies, and varicella vac-
cines (4 shortages each). A vaccine deferral was required for 21 shortages 
(36%), and single-source products were on shortage 30 times (51%). The 
most common reason for shortage was manufacturing problems (51%), 
followed by supply-and-demand issues (7%). Thirty shortages (51%) were 
for products on the pediatric schedule, with a median duration of 21.7 
months. 
Conclusion. Drug shortages of vaccines and immune globulin prod-
ucts accounted for only 2.8% of reported drug shortages within a 15-
year period, but about half of these shortages involved products on the 
pediatric vaccination schedule, which may have significant public health 
implications.
Keywords: bacterial vaccines, immunization, immunoglobulins, supply 
and distribution, vaccines, viral vaccines
Am J Health-Syst Pharm. 2017; 74:e504-11
Prescription drug shortages, defined by the Food and Drug Administra-
tion (FDA) as “a period of time when 
the demand or projected demand for 
the drug within the United States ex-
ceeds the supply of the drug,” have 
become increasingly prevalent over 
the past 2 decades.1,2 Manufacturing 
and quality-control problems, as well 
as economic factors, have resulted 
in frequent supply disruptions.2 Pre-
scription drug shortages have affected 
multiple specialties, including oncol-
ogy, emergency medicine, and infec-
tious diseases.3-5 Data have also re-
vealed that sterile injectable products 
are more commonly in short supply 
compared with products for oral or 
topical administration.2-5
Millions of vaccinations are ad-
ministered each year for infection 
prevention and control.6 Vaccine 
shortages can have significant pub-
lic health and clinical implications, 
as they may result in individuals not 
being fully vaccinated according to 
the recommended schedule, thereby 
compromising herd immunity and 
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creating the potential for epidemic 
outbreaks of communicable diseases. 
Vaccine shortages may affect not only 
the health of adult patients seeking 
secondary vaccinations but that of 
vulnerable infants and children who 
are in need of primary vaccinations, 
with a potential significant effect 
on communicable disease morbid-
ity and mortality due to reduced herd 
immunity. 
In the case of a vaccine shortage, 
the Centers for Disease Control and 
Prevention (CDC) may recommend 
to postpone or omit a dose of a rec-
ommended booster vaccination in 
order to allow unvaccinated children 
to receive a first dose of the vaccine 
in short supply.6 Data describing how 
drug shortages have affected vaccine 
and immune globulin availability are 
limited. Previous reports have focused 
on the availability of Haemophilus 
influenzae type b (Hib), pneumococ-
cal, and influenza vaccines.7-11 We as-
sessed the shortages of vaccines and 
immune globulins in the United States 
from 2001 through 2015.
Methods
The University of Utah Drug In-
formation Service (UUDIS) has been 
collecting national drug shortage data 
since January 2001 and publishes 
critical drug shortage information 
on a public website (www.ashp.org/
shortage) hosted by the American So-
ciety of Health-System Pharmacists 
(ASHP). UUDIS defines a shortage as 
“a supply issue that affects how the 
pharmacy prepares or dispenses a drug 
product or influences patient care when 
prescribers must use an alternative 
agent”.12 This definition differs slightly 
from, but is more inclusive than, FDA’s 
definition of a shortage. For example, a 
shortage of prefilled syringes of a spe-
cific product may cause significant lo-
gistic and safety issues, even if the same 
medication is available in vials. 
The Government Accountability 
Office (GAO) considers UUDIS data to 
be the most comprehensive and reli-
able source of drug shortage informa-
tion and has used UUDIS data for 4 re-
KEY POINTS
• From 2001 through 2015, half of
the vaccine shortages affected
the pediatric vaccine schedule.
• Nearly 90% of vaccines had
multiple shortages during the
study period.
• The mitigation of vaccine short-
ages is crucial for public health,
especially shortages of prod-
ucts on the pediatric vaccina-
tion schedule.
ports published on drug shortages.2,13 
Detailed methods describing UUDIS 
have been previously published.14 
Briefly, UUDIS receives voluntary 
reports of drug and vaccine short-
ages via the reporting feature on the 
ASHP website. Clinical pharmacists 
at UUDIS research each shortage re-
ported to verify that the shortage ac-
tually exists. This research includes 
determining all potential manufac-
turers of a reported drug or vaccine 
in shortage and all drug presentation 
National Drug Codes (NDCs). Next, 
each manufacturer is contacted to de-
termine which NDCs are in shortage 
at the national level. The manufac-
turers are also asked for a reason for 
the shortage as well as an estimated 
release date. If most manufacturers 
are having a national shortage, then 
UUDIS will post information on the 
ASHP drug shortage website noting 
which products are affected, which 
products are available, specific meth-
ods for accessing the product, reasons 
for the shortage, estimated resupply 
dates, and, if applicable, implications 
for patient care, safety concerns, al-
ternatives, and management strate-
gies. UUDIS considers a shortage to 
be resolved when all suppliers have all 
presentations available or have dis-
continued their products. UUDIS also 
follows FDA’s drug shortage website 
and will generally list shortages as re-
solved when FDA considers the short-
ages resolved.
UUDIS collects the following drug 
shortage data using Excel (Microsoft 
Corp., Redmond, WA): generic prod-
uct name, therapeutic category, date 
shortage began (date UUDIS was no-
tified), date shortage was resolved, 
duration of shortage, reason for the 
shortage, controlled substance sched-
ule (if applicable), and whether the 
drug is an injectable product. Drug 
shortages that occur due to a product 
discontinuation or withdrawal from 
the market have the same start and 
stop dates for a duration of 0 days. 
The data set was restricted to 
shortages that occurred between Jan-
uary 1, 2001, and December 31, 2015, 
and was analyzed in 2016. Members 
of the study team identified shortages 
that affected vaccines and immune 
globulins. All discrepancies were dis-
cussed until a consensus was reached. 
Shortage data were analyzed, focusing 
on the type of product, reason for the 
shortage, shortage duration, short-
ages requiring vaccine deferral, and 
whether the drug was a single-source 
product (produced by 1 manufactur-
er). Inclusion of the product into the 
pediatric vaccination schedule was 
also noted. The availability of a substi-
tute therapy and whether the alterna-
tive was also affected by a shortage at 
any time during the study period, as 
well as multiple shortages (those that 
were resolved but then another short-
age occurred) of the same vaccine 
were also noted. For some portions of 
the analysis, products were grouped 
together based on vaccine category, 
such as bacterial vaccines, viral vac-
cines, combination products, immune 
globulins, or toxoids. Shortage length 
was analyzed using Hodges-Lehmann 
median differences and the Kruskal–
Wallis test for comparisons of more 
than 2 groups. Negative binomial re-
gression was used to determine if the 
trend in new shortages observed each 
year was significant over the study pe-
riod. Discontinued products were not 
included in analyses of shortage dura-
tion (n = 3). Data were analyzed using 
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Stata, version 14.0 (Stat Corp., College 
Station, TX). These data do not meet 
the definition of human subjects’ re-
search and therefore were exempt 
from institutional review board review. 
Results
Number and duration of short-
ages. A total of 2,080 drug shortages 
were reported from January 2001 
through December 2015, 59 (2.8%) of 
which involved vaccines or immune 
globulins. The number of products on 
shortage decreased from 11 in 2001 
to 2 in 2015 (p = 0.08) (Figure 1). The 
median shortage duration was 16.8 
months (interquartile range [IQR], 
5.8–27.3 months). The median num-
ber of new shortages reported annu-
ally was 3 (IQR, 2–5). By the end of the 
study period, 2 products remained on 
active shortage (meningococcal vac-
cine for 230 days; yellow fever vaccine 
for 119 days). The median duration 
for the 57 resolved shortages was 18.3 
months (IQR, 6.1–27.4 months). Fifty-
three vaccines or immune globulins 
(90%) were the subject of multiple 
shortages during the study period. 
Rabies immune globulin had the lon-
gest shortage duration for any vaccine 
or immune globulin (2,717 days, from 
August 16, 2007, to January 23, 2015). 
Thirty shortages (51%) involved 
vaccines on the pediatric schedule, 
with a median shortage duration of 
21.7 months (IQR, 8.0–28.1 months). 
A vaccine deferral was required for 21 
shortages (36%), and single-source 
products were on shortage 30 times. 
Single-source products were involved 
in 51% of shortages, with a median 
shortage duration of 19.8 months 
(IQR, 11.1–26.7 months). Shortage 
durations did not differ significantly 
among the product types examined. 
Types of products involved in 
shortages. Of the 59 vaccine short-
ages during the study period, 34 (58%) 
involved viral vaccines, 18 (31%) in-
volved bacterial vaccines, and 7 (12%) 
involved toxoids. Combination prod-
ucts accounted for 9 (15%) of report-
ed shortages. Eight (14%) products 
affected by shortages were immune 
globulins (Table 1). Of all shortages, 
combination products had the long-
est median shortage duration (25.7 
months; IQR, 16.3–36.8 months); how-
ever, this duration was not significant-
ly different than that for other types of 
products (p = 0.202). The most com-
mon products with multiple shortages 
were viral vaccines, particularly hepa-
titis A, hepatitis B, rabies, and vari-
cella vaccines, with 4 shortages each 
(Table 2). 
Reasons for shortages. The 
most commonly reported reason for 
a shortage was manufacturing prob-
lems (51%), followed by supply-and-
demand issues (7%) (Table 3). A reason 
was not provided for 18 cases (31%) 
of vaccine shortages. Shortage dura-
tion differed significantly depending 
on the reason given for the shortage 
(p = 0.004, Kruskal–Wallis test). The 
longest durations were for products 
on shortage due to manufacturing 
problems (median, 22.8 months; IQR, 
16.8–31.1 months).
Discussion
Although the number of vac-
cine and immune globulin shortages 
(59 [2.9%]) was low compared with the 
total number of drug shortages (2,080) 
during the study period, shortages of 
these products can have far-reaching 
implications. Thirty (51%) of these 
shortages affected the pediatric vac-
cine schedule, and it is unknown how 
many children did not receive their full 
vaccination series due to these short-
ages. The National Immunization 
Survey reported that the vaccination 
coverage for diphtheria, tetanus, and 
acellular pertussis (DTaP) or measles, 
mumps, and rubella (MMR) was not 
affected by these shortages at a na-
tional level.15,16 It is unknown whether 
vaccination rates for vaccines not on 
shortage remained stable, as any de-
crease in these rates would imply that 
the shortages had a causal role. 
Nearly 90% of vaccines had mul-
tiple shortages during the study pe-
riod, including important childhood 
vaccines such as varicella and hepati-
tis B (Table 2). Recurrent shortages of 
the same products suggest systematic 
errors in the manufacturing process. 
Vaccines and immune globulin prod-
ucts have more complex manufactur-
ing requirements than do simple mol-
ecules and oral products. Problems 
with manufacturing these products 
Figure 1. Total number of vaccine and immune globulin products in short sup-
ply from 2001 through 2015. 
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accounted for 51% of the reported 
shortages (Table 3). Shortages of vac-
cines and immune globulin products 
usually take longer to resolve, and in 
many cases the actual manufacturing 
time of these products can take sev-
eral months. This means that short-
ages of these products will be lengthy. 
The mean duration of shortage was 
well over 1 year (median duration 
of resolved shortages, 18.3 months), 
with the longest shortage durations 
of over 2 years for combination prod-
ucts (median, 25.7 months), including 
shortages for vaccines on the pediatric 
schedule, and almost 2 years for tox-
oids (median, 23.3 months) (Table 1). 
The advantage of combination vac-
cines is that they reduce the number 
of injections a child needs to in order 
to be fully immunized against several 
diseases. If individual vaccines are 
used due to a shortage of combination 
vaccines, the number of injections 
required for a child would increase, 
which might lead to objections against 
vaccinations in general.
Single-source products. Prod-
ucts manufactured by a single com-
pany or facility are at higher risk of a 
drug shortage, because any disrup-
tion in the manufacturing process 
typically results in a shortage.17 GAO’s 
latest report on drug shortages also 
notes that products with few suppli-
Table 1. Types of Vaccine Products Affected by Drug Shortagesa
Product Typeb
No. (%) 
Shortages
Median Shortage 
Duration in Months (IQR)
Median (95% CI) 
Difference vs. Other 
Product Types, in Months
All products 59 (100) 16.8 (5.8–27.3) …
Bacterial vaccines 18 (31) 22.6 (11.1–27.4) 5.7 (–2.5 to 16.2)
Combination products 9 (15) 25.7 (16.3–36.8) 9.0 (–3.9 to 20.2)
Immune globulins 8 (14) 5.1 (3.7–13.9) –6.8 (–17.6 to 0.0)
Toxoids 7 (12) 23.3 (4.1–36.8) 2.2 (–18.2 to 21.5)
Viral vaccines 34 (58) 16.6 (6.1–27.8) –0.7 (–10.5 to 5.7)
Products on pediatric schedule 30 (51) 21.7 (8.0–28.1) 5.0 (–0.7 to 14.1)
Vaccine with deferral required during shortage 21 (36) 22.3 (11.1–27.4) 5.6 (–2.2 to 13.7)
Single-source products 30 (51) 19.8 (11.1–26.7) 3.5 (–3.5 to 11.9)
 aIQR = interquartile range, CI = confidence interval.
 bSome products may fit into more than 1 category.
ers are at greater risk of a drug short-
age.18 In this analysis, 51% of products 
on shortage were produced by a single 
manufacturer, and 5 products (8%) 
were affected by; at least 3 recurrent 
shortages (varicella, measles, mumps, 
rubella [MMR]; typhoid). Vaccines and 
immune globulin products are often 
single-source products or only sup-
plied by 3 or fewer manufacturers. 
For example, in 2006, there was only 
1 licensed manufacturer in the United 
States distributing MMR vaccine; vari-
cella vaccine; tetanus and diphtheria 
vaccine; inactivated polio virus vac-
cine; meningococcal conjugate vac-
cine; and pneumococcal conjugate 
vaccines.19
Implications of deferrals. Short-
ages of vaccines have the potential 
to cause profound public health im-
plications. The Advisory Committee 
on Immunization Practices (ACIP) 
recommends that clinicians evaluate 
vaccination status at each patient visit 
and avoid delaying vaccinations (e.g., 
deferral for mild illness).6 Shortages 
of vaccines can result in deferrals and 
delays of over a year for vaccinations 
because many school-aged children 
only see a provider annually and most 
vaccine shortages last longer than 1 
year. In this analysis, a vaccine defer-
ral was required for 36% of shortages. 
In addition, multiple shortages might 
have a greater impact on children 
who get their first vaccination series 
because recommended vaccinations 
might be deferred more than once.
Shortages of vaccines have also 
resulted in changes to school vacci-
nation requirements.20 A publication 
describing 2 shortages of pneumo-
coccal vaccine (heptavalent pneumo-
coccal conjugate vaccine, PCV7) in 
2001 and 2004 analyzed whether the 
vaccination behavior of pediatricians 
in Cincinnati was changed through 
the shortages. Only 66% of healthy 
children were documented as having 
received their first 2 doses of pneu-
mococcal vaccine on time, compared 
with 74% of healthy children during 
nonshortage periods.10 An analysis of 
the vaccination coverage rates of Hib 
during the 2008–09 vaccine shortage 
revealed 7.8–10.3% lower coverage 
rates compared with periods without 
a shortage.9 Results of another study 
found a higher Hib carrier rate in At-
lanta due to the vaccination  defer-
ral during the 2008–09 Hib vaccine 
shortage.8  
Unfortunately, our data show that 
many of the problems highlighted in 
GAO’s 2002 report on vaccine short-
ages still exist, such as manufacturing 
problems, demand exceeding supply, 
and a lack of redundancy in the man-
ufacturing process.20 In addition, vac-
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Table 2. Characteristics of Vaccines and Immune Globulins Affected by Shortages, 2001–15
Vaccine or Immune Globulin 
No. 
Shortages
Single 
Source?
Shortage 
Active on 
December 31, 
2015?
Included 
on 
Pediatric 
Schedule?
Hepatitis A 4 No No No
Hepatitis B 4 No No Yes
Rabies 4 No No No
Varicella 4 Yes No Yes
Haemophilus influenzae type b 3 No No Yes
Measles 3 Yes No Yes
Mumps 3 Yes No Yes
Rabies immune globulin 3 No No No
Rubella 3 Yes No Yes
Typhoid 3 Yes No No
Cytomegalovirus immune globulin 2 Yes No No
Diphtheria, tetanus, and acellular pertussis 2 No No Yes
Hepatitis B immune globulin 2 No No No
Influenza 2 No No Yes
Meningococcal (MCV4) 3 Yes Yes Yes
Measles, mumps, rubella, and varicella 2 Yes No Yes
Pneumococcal (PCV7) 2 Yes No Yes
Diphtheria and tetanus toxoids and acellular pertussis vaccine 
adsorbed 2 No No No
Diphtheria, tetanus, pertussis, and poliovirus antigens 1 No No Yes
Diphtheria, tetanus, pertussis, poliovirus, and H.influenzae type b 
antigens 1 Yes No Yes
Measles, mumps, and rubella 1 Yes No Yes
Pneumococcal (V23) 1 Yes No No
Yellow fever 2 Yes Yes No
Varicella immune globulin 1 No No No
Tetanus 1 Yes Yes No
Table 3. Reported Reasons for Vaccine and Immune Globulin Shortagesa
Reason for Shortage
No. (%) 
Shortages
Median (IQR) Duration 
of Shortage, in Months 
Discontinued product 3 (5) NA
Manufacturing problem 30 (51) 22.8 (16.8–31.1)
Supply-and-demand issues 4 (7) 16.4 (5.8–22.1)
Otherc 4 (7) 6.1 (4.5–15.5)
Unknown 18 (31) 7.8 (5.1–14.8)
aIQR = interquartile range, NA = not applicable.
bχ2 = 13.199 with 3 d.f. (p = 0.004), Kruskal-Wallis test.
cNatural disaster (n = 2), shortage of raw materials (n = 1), and product recall (n = 1).
cine shortages may have a disparate 
effect on vulnerable populations. For 
example, among children receiving 
vaccinations in public clinics, those 
living outside of urban areas, children 
in the South, and American Indian/
Alaska Native children were less likely 
to have received the fourth dose of the 
DTaP vaccine during the shortage.22,23 
Mitigation strategies. There are 
several potential strategies that may 
mitigate the impact of vaccine short-
ages, such as early notification about 
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foreseeable shortages, vaccine defer-
rals, vaccine stockpiles, and importa-
tion of commercial alternatives.24
Manufacturers should provide 
early notification about expected 
shortages to ensure that this infor-
mation is included in current rec-
ommendations.25 Providers should 
become more vigilant regarding an-
ticipated shortages and proactively 
incorporate recommended strategies 
regarding existing supplies and future 
distribution. Unlike  shortages of on-
cology or emergency drugs, vaccine 
shortages do not usually require insti-
tutional responses. Decisions on vac-
cine deferrals should only be made on 
an institutional basis in emergency 
situations  (e.g., by vaccinating only 
high-risk patients) because vaccines 
are not usually used during emergen-
cies. Instead, recommendations on 
deferrals should be issued on a state 
or national level. In the past, CDC, to-
gether with the American Academy of 
Pediatrics and the American Academy 
of Family Physicians, issued vaccine 
deferral recommendations, asking 
providers to withhold a third or fourth 
dose of PCV7 during the 2003–04 
shortage.21 
In another study, good adherence 
of pediatricians to vaccination rec-
ommendations was reported, with 
91% of assessed care providers stating 
that high-risk patients were fully vac-
cinated. At the same time, pediatri-
cians whose practice experienced no 
vaccine shortage were more likely to 
administer a fourth dose of PCV7 vac-
cine despite recommendations to the 
contrary.26 This highlights the com-
plexities of implementing vaccine de-
ferrals when the vaccine supply is not 
distributed equally.
In order to keep track of patients 
who miss a vaccine booster during a 
shortage, proper surveillance mea-
sures should be implemented. During 
the 2003–04 shortage of PCV7, systems 
to track children who missed doses 
due to redistribution of vaccines at 
the national level were reported in ap-
proximately two thirds of the practices 
that deferred a vaccination.21,26 
Influenza vaccine shortages were 
reported for patients at high risk dur-
ing the 2004–05 influenza season. 
During this time, pediatricians priori-
tized vaccination of younger children 
and those with chronic medical condi-
tions, such as chronic heart or kidney 
diseases and organ transplants or can-
cer.11 Another strategy used in emer-
gency medicine during a past shortage 
of tetanus vaccine was to provide teta-
nus boosters to patients with high-risk 
wounds only.27 
Although the tracking of current 
vaccine stocks and early notifica-
tion of when these stocks fall below 
certain levels do not prevent vaccine 
shortages, these methods could initi-
ate early mitigation measures even 
before a vaccine shortage hits by is-
suing preventive deferrals or modify-
ing immunization recommendations. 
The 2002 vaccine shortage resulted 
in multiple at-risk children not be-
ing vaccinated according to sched-
ule.20,22 In response, CDC used vaccine 
stockpiles for children to mitigate the 
risk of potential epidemics triggered 
by future shortages. One model sug-
gested that while stockpiles were suf-
ficient to meet future interruptions 
in manufacturing that last less than 6 
months, the prolonged median short-
ages (5.1 months for immune globu-
lins and 25.7 months for combination 
products) in this analysis (Table 1) 
suggest that such stockpiles may be 
inadequate to meet vaccination needs 
for children.22 A 6-month stockpile is 
therefore unlikely to be effective due 
to the typically lengthy duration of 
vaccine shortages.
While FDA has imported medica-
tions from other countries in the past 
to help alleviate drug shortages (e.g., 
propofol, nitroglycerin, doxorubicin), 
no vaccine products have been im-
ported to help alleviate vaccine short-
ages, and doing so could lead to extra 
costs due to the additional regulatory 
approval process. The importation of 
vaccines would be required if a U.S. 
vaccine product was discontinued 
without the availability of an adequate 
alternative. 
It would be useful to assess wheth-
er drug shortages in the United States 
also occur globally; however, the Unit-
ed States is one of the few countries 
with such a robust system for tracking 
drug shortages. Other countries do 
not have a systematic way of track-
ing drug shortages or their systems 
are in the course of development. 
Manufacturers of vaccines in multiple 
countries do not provide information 
about vaccines marketed outside the 
United States to clinicians in the Unit-
ed States.17 Despite this limitation, 
even if it is possible to know if a vac-
cine was marketed in another country, 
it is still impossible to know if there 
were shortages at that time in another 
country unless case reports were pub-
lished in the literature, as it was for a 
shortage of bacille Calmette-Guérin 
vaccine in Europe.28
Ethical frameworks. Regard-
less of the type of vaccine implicated 
in a shortage, it is important to have 
an organized and ethical framework 
for the distribution of limited vac-
cine supplies. General ethical recom-
mendations on the rationing of drugs 
respecting principles of justice and 
fairness include establishing an allo-
cation committee for drugs on short-
age to provide guidelines for patient 
prioritization.29 For vaccines repre-
sented in pediatric schedules, ACIP 
and CDC have often provided recom-
mendations for prioritizing patients. A 
strategy used for transferring ethical 
principles into oncology practice re-
garding drug shortages is the so-called 
“A4R” approach, which addresses rel-
evance, transparency, revision, and 
enforcement.30
A key difference between vaccine 
and immune globulin shortages and 
other drug shortages is that there is 
typically no immediate harm due to 
a shortage, but future harm may be 
long reaching if sufficient vaccines are 
deferred to reduce overall herd immu-
nity. There are also fewer available al-
ternatives for a vaccine shortage. 
Addressing reasons for short-
ages. The vaccine manufacturing 
process is complex and thus fragile. 
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A CDC publication described the vac-
cine shortages between 2000 and 2004 
and the reason for the shortages in 
detail.19 Factors disturbing the manu-
facturing process include produc-
tion problems, adherence to quality-
control measures, recommendations 
to remove the preservative thimerosal, 
and economic decisions. 
Production problems as a cause of 
shortages is not unique to vaccines. A 
summary of drug shortages (not lim-
ited to vaccines) found that injectable 
drugs accounted for 73% of all short-
ages in 2011 and that quality issues ac-
counted for 56% of shortages of sterile 
injectable drugs.31 Quality issues for 
injectables were defined as bacterial 
or mold contamination and the pres-
ence of foreign particles in vials. These 
findings suggest that manufactur-
ers should develop and expand their 
own quality-control measures in order 
to minimize these incidents.32 FDA, 
GAO, and the International Society 
for Pharmaceutical Engineering have 
identified quality issues and manufac-
turing problems as the key causes of 
drug shortages. It has been proposed 
that the reason for problems related to 
quality is a lack of transparency, which 
results in few manufacturers devoting 
resources to ensure the highest quality 
manufacturing.33
Ultimately, a multifaceted ap-
proach involving stakeholders from 
government and industry will be re-
quired to address the underlying rea-
sons for vaccine shortages. Suggested 
solutions include financial incentives 
for vaccine manufacturers, regula-
tory changes, and rotating vaccine 
stockpiles, particularly for pediatric 
vaccines.20
Implications for pandemic pre-
paredness. Influenza vaccine short-
ages have significant implications for 
preparedness for influenza epidemics 
and pandemics, particularly given the 
small number of influenza vaccine 
manufacturers. Even with 5 manufac-
turers of influenza vaccine, the total 
number of influenza vaccine doses 
provides a dose for less than half the 
population of the United States.34 In 
addition, the majority of influenza 
vaccine produced in the United States 
requires a lengthy egg-based manu-
facturing process.35 Cell-based and 
recombinant influenza vaccines are 
made by 2 separate companies but 
represent a low volume of the overall 
influenza vaccine market.34 Influenza 
vaccines were affected by 2 short-
ages during the observation period. 
While nonpharmaceutical interven-
tions such as social distancing and 
postexposure prophylaxis will play a 
major role during a pandemic, vacci-
nation remains an important strategy, 
particularly for at-risk populations.36 
Alternative strategies during short-
ages include targeting and prioritiz-
ing high-risk groups for vaccination 
as well as using modified formulations 
(i.e., split or whole virus formulations 
or adjuvants).37 
Additional preventive mea-
sures. CDC maintains a national 
stockpile that includes a 6-month ro-
tating supply of pediatric vaccines, 
which began as early as 1983 for some 
vaccines.19 Since then, stockpiles have 
been used to cover vaccine demand 
on at least 8 occasions until 2004.12 
Optimization efforts concerning 
stockpiling pediatric vaccines were 
implemented in 2002.19 
Several simulations exist to opti-
mize vaccine stockpiling.38,39 Planned 
stockpiling at a national level must be 
differentiated from individual physi-
cians’ practices to maintain vaccine 
stocks in their offices, which is better 
described as hoarding. Furthermore, 
SWOT analysis (strengths, weakness-
es, opportunities, threats) may help 
public health partners address short-
ages of vaccinations, such as influenza 
vaccine, to help develop strategies 
for rationing vaccines during public 
health emergencies.40
Study limitations. The major lim-
itation of this study was that we could 
not assess the actual effect of short-
ages on individual institutions or pa-
tient care (e.g., delayed or suboptimal 
therapy, resultant medication errors 
and adverse outcomes). We also could 
not describe the severity of shortages 
affecting a particular product (i.e., 
whether the product was in limited 
supply or completely unavailable) and 
how these were ultimately dealt with 
on a healthcare system level. However, 
CDC adjusted the vaccination sched-
ule for multiple products due to short-
ages of MMR vaccine, Hib vaccine, 
PCV7, and varicella vaccine. CDC also 
recommended deferring preexposure 
prophylaxis vaccinations during the 
rabies vaccine shortage. We did not 
take into account additional costs or 
toxicity when considering the use of 
available substitutes. In addition, the 
duration of shortages that were active 
at the end of the study period would 
be underestimated. Finally, we could 
not account for the time and resources 
used by institutions to mitigate drug 
shortages as well as the effectiveness 
of mitigation strategies. These are all 
potential areas for additional prospec-
tive studies. 
Conclusion
Drug shortages of vaccines and 
immune globulin products accounted 
for only 2.8% of reported drug short-
ages within a 15-year period, but 
about half of these shortages involved 
products on the pediatric vaccination 
schedule, which may have significant 
public health implications. 
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Preface 
Prescription drug shortages in the United States have reached critical levels and represent 
a major threat to public health. The consequences of these shortages come in the form of 
delayed or suboptimal care, medication errors, and increased healthcare costs. The 
investigations that comprise this thesis attempt to explore how drug shortages may impact 
different specialties, care settings, and age groups. This was accomplished primarily 
through retrospective studies of data from the University of Utah Drug Information 
Services, which is considered to be the most robust shortage data available.  
General Discussion 
The studies that comprise this thesis clearly demonstrate that prescription drug shortages 
are a major public health problem. We also describe some potential mitigation strategies, 
both in dealing with existing shortages and preventing future shortages from occurring. 
Mitigation strategies unique to each specialty and age group are presented in the 
individual chapters and a broader discussion is provided in Chapters 2 and 7. Ultimately, 
the optimal approach to managing shortages is complex and requires involvement from 
multiple stakeholders.  
Governmental Interventions 
On a governmental level, expanding the role of the FDA may help to mitigate shortages. 
With increased authority, the FDA could potentially require manufacturers to make 
products that are in critical need. This would limit the autonomy of pharmaceutical 
manufacturers and may impact profit margins, which could impact the prices of 
medications. Alternatively, incentives could be provided to encourage manufacturers to 
make products in need. These incentives could take the form of tax relief, rebates, or 
extended market exclusivity. Incentives can also be provided for manufacturers who keep 
their facilities in compliance with current good manufacturing practices. Although these 
interventions may make the supply chain more robust, there are some potential adverse 
consequences. Manufacturers may shift their production to make products that have 
incentives, precipitating shortages of medications that do not have incentives. In addition, 
extended exclusivity may increase drug prices and overall healthcare costs. For these 
reasons, incentives must be carefully balanced as to avoid unintended consequences. 
While the FDA does have a responsibility to ensure a stable drug supply, increased 
oversight would require more resources on the part of the agency, which would 
necessitate additional funding. A reasonable approach would be to expand the FDA 
authority in a some capacity short of requiring manufacturers to make specific products, 
and to provide some limited incentives to drug manufacturers in order to avoid driving up 
drug costs.  
In addition to providing incentives, there are other actions that can be taken to deal with 
shortages. The FDA can expedite approvals for additional manufacturers who want to 
bring a product to market as well as help to facilitate reviews of sites that are currently 
not in compliance with good manufacturing practices. The authority of the FDA could 
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potentially be expanded to allow for civil or monetary penalties for manufacturers who 
do not provide adequate notification regarding shortages or who regularly have facilities 
that are in poor repair. Monetary penalties could potentially be used to subsidize the 
additional resources that would be required by the FDA. Currently, under FDASIA, the 
FDA can require notification but cannot penalize manufacturers who do not comply with 
notification requirements. Another potential solution is to more proactively manage 
quality control at production facilities and improve transparency in the manufacturing 
process with increased FDA oversight. The FDA has also implemented an emerging 
technology program, which helps to incorporate new technologies that might help to 
streamline the manufacturing process, decrease costs, or prevent quality problems at 
facilities. Although these programs will need to be subsidized, they will help to build a 
robust supply chain that produces quality products at facilities that are in compliance with 
current manufacturing standards.  
Another potential option in mitigating shortages is to re-evaluate the pricing structure for 
generic drugs, which currently have limits on reimbursement, particularly as it relates to 
Medicare and Medicaid. We have demonstrated time and again, that shortages 
disproportionately impact generic injectable drugs. Removing some of the pricing 
constraints might help improve profit margins, attracting additional manufacturers and 
increasing redundancy in the supply chain. Once again, this must be a balanced approach 
as to avoid increasing healthcare costs; however, having fewer shortages may offset some 
of these costs, as shortages also increase healthcare costs. 
For critical medications, such as saline solutions, another option would be to have the 
Department of Homeland Security consider them as part of the essential infrastructure, 
which would require manufacturers to develop business continuity plans. However, this 
would be costly and time consuming. As such, this would only be a feasible option for 
only the most critical of medications and supplies.  
Temporary importation of drugs is a way to mitigate existing shortages; however, it does 
not address the underlying reasons why shortages occur. FDA has allowed for the 
importation of saline and other products during times of critical shortages. Importation 
has its limitations as well because importing an adequate amount of product to address a 
shortage in the U.S. may precipitate a shortage in the country of origin. The product to be 
imported should be up to current standards as set by the FDA. In addition, transportation 
of product, sometimes over long distances can increase healthcare costs. FDA has also 
allowed for extension of expiration dates and allowance of particulate matter if a filter 
needle is used in some instances. Overall, these are all feasible options to address current 
shortages if they can be done safely; however the ultimate goal is to prevent shortages 
from occurring in the first place.  
Recently, the FDA has announced the formation of a Drug Shortages Task Force. The 
purpose of this task force is to address the underlying causes of why shortages exist. It is 
a multi-disciplinarily team of experts representing stakeholders from the FDA, the 
Centers for Medicare and Medicaid Services, and the Department of Veterans Affairs. 
The ultimate role of this task force will continue to develop and evolve as it is currently 
in its infancy.  
Non­Governmental Mitigation Strategies 
Outside of the governmental initiatives, continued engagement of industry, state and local 
medical boards, healthcare organizations, and individual providers is also a critical 
component to solving the shortage problem. Pharmaceutical manufacturers should 
comply with current good manufacturing standards and federal and state regulations. 
Many professional societies and medical boards have also spoken out against drug 
shortages and should continue to play an active role in mitigation. At the institutional 
level, strategies to minimize waste, proactive substitution protocols, and development of 
an ethical framework for distribution of limited supplies will be required to minimize the 
impact of shortages at the bedside. In addition, emergency medical services will need to 
develop protocols that address shortages as well as incorporate shortages into their 
disaster planning efforts. Pharmacy staff must continue to continue to work to find 
alternative suppliers and to monitor stock. Information technology resources will also be 
required to update ordering platforms when products are substituted because of a 
shortage. All of the aforementioned interventions have to potential to mitigate or prevent 
shortages; however, their true impact has yet to be elucidated and represents an area of 
future prospective study.   
International Perspective 
There is mounting evidence the problem of drug shortages are not unique to the US; 
however, the data pertaining to these shortages is much less robust. In Europe, there are 
some reporting systems in individual countries, including England, Belgium, the 
Netherlands, France, Spain, and Germany. These reporting systems are heterogeneous in 
nature and each has its own standards for reporting. One study demonstrated that brand 
name oral medications were more commonly impacted, in contrast to what has been 
documented in the US. Although data are more limited, production problems and market 
factors are thought to be the major drivers of shortages in Europe as well. More recently, 
the European Medicines Agency (EMA) has gotten involved in managing shortages, 
although the bulk of shortages are dealt with at the national level. The EMA will 
generally only get involved if several states in the European Union (EU) are impacted or 
if there is a serious safety issue related to a shortage. A task force has also been created in 
the EU to assist in managing drug shortages, with a similar focus as the US. Legislative 
efforts have also taken place in Canada in response to drug shortages. Finally, the global 
impact of shortages may be felt in other markets that are less studied, where profit 
margins are smaller. One potential example could be HIV and tuberculosis drugs in 
developing countries. Ultimately, additional data will be required in order to better 
understand the global footprint of drug shortages.  
The situation regarding shortages of drugs in the Netherlands is highlighted in the textbox.
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Shortages of drugs in the Netherlands
Shortages of drugs is not restricted to the situation in the USA. Based on information by the 
Dutch Ministry of Health as well as the Royal Dutch Society of Pharmacists (KNMP),
alarming figures are published and a significant increase over the years of shortages of 
medication. In 2008 a total of 1390 reports were published on a potential shortages of a drug. 
In comparison to 2017, 536 reports were published of which 1000 different drugs were 
mentioned. This increase is not only due to a higher level of knowledge of this reporting 
agency but also due to real shortages. For instance in 2018, 769 drugs could not be delivered 
to the patients for at least a period of 2 weeks based on the figures of the pharmacists society 
KNMP Farmanco. The shortages were observed in a wide variety of drugs raging from 
anticonception; anti-hypertensive drugs; anti-epileptic medication and even levodopa with 
significant consequences for individual patients. At the back of this data, the origin of this 
problem is potentially due to problems with the production, as many of the active substances 
are produced in so called low-income countries such as China and India and in a very 
restricted number of factories. Any problems in the lines of production or other uncontrollable 
factors will have a major impact. This is also due to the low prices that insurance companies 
have negotiated with pharmacists and hospitals, leading to a low amount of storage in 
individual pharmacies. Insurance companies have identified one drug for an indication as the 
so called preference drug for that disease with serious consequences for the prescription  of 
alternative drugs that will not be reimbursed by health insurance companies. Although the 
restriction in healthcare costs is appreciated and calculated to be more than one billion euro’s 
the consequences for the individual patient are significant. In daily life 50% of all patients 
will not receive the prescribed drug directly from the pharmacist because it is not available. 
For this reason the ministry for Health (Minister B. Bruins) has now indicated that drugs 
storage is obligatory in the Netherlands for at least a period of 4 months. Which should result 
in a decrease of shortages with over 60%. This plan has not been approved so far by the 
European Union while the effect of Brexit in either way is hard to imagine. Another 
complicated point is the new European rules under the name of falsified medicine directive 
(FMD) that should prevent fraud of individual drugs because of every package of drugs one 
should be able to control the source and delivery with significant consequences for the way 
drugs are packed.
  
Limitations 
There are some notable limitations to the dataset that we used for the majority of the 
studies presented in this thesis. The UUDIS data examined reported shortages, but the 
impact of shortages may vary depending on the geographic area or individual institution 
or practice. We did not examine the severity of shortages, such as whether a product was 
completely out of stock or just in short supply, only whether a shortage was present. 
Finally, we did not examine the impact on patient care or increased cost or resource 
utilization.  
Future Directions 
There is a great deal of room for additional studies pertaining to drug shortages. Future 
prospective studies should examine the impact of specific legislative interventions. In 
particularly, we should evaluate the total number of shortages, number of new shortages, 
duration of ongoing shortages, types of medications impacted, severity of shortages, and 
reasons the shortage occurred. It is important to determine which legislative 
interventions are effective and, as mentioned previously, what unintended consequences 
occur as a result. At the same time, it may be difficult to study the impact of individual 
interventions, as they will rarely occur in isolation. We must continue to refine and 
optimize interventions moving forward, as the proposed solutions are not without cost 
and resource expenditure.  
In addition, it is critical that we evaluate the human costs of shortages. We should 
prospectively study the direct impact of shortages on patient care, in the form of delayed 
or suboptimal therapy. It would be useful for governmental agencies to provide research 
funding for institutions to actively study the impact of shortages rather to rely on passive 
reporting. In addition, we should have a mechanism in place for reporting adverse drug 
events or medication errors that occur as a result of shortages, similar to the MedWatch 
reporting system. In addition, we need pharmacoeconomic studies to determine the 
economic impact of shortages and to guide strategies to limit increased healthcare costs.  
Conclusions 
Prescription drug shortages are a major public health problem. This thesis contributes to 
the current body of knowledge pertaining to drug shortages in that it demonstrates the 
impact across multiple medical specialties and age groups. Shortages have the potential 
to impact countless lives by limiting access to care and causing harm. We have yet to 
determine the full human and economic burden of drug shortages. We must be vigilant in 
safeguarding access to medications for patients in need. While we have made some 
strides in mitigating the impact of shortages, additional interventions and studies are 
needed to determine the optimal strategies for mitigating and preventing shortages and to 
safeguard patient care.  
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Summary 
Introduction
Chapter 1 provides a description of the history of prescription drug shortages from the 
late 1990s to the present day landscape. This chapter also introduces the clinical and 
public health implications of drug shortages, as well as mitigation shortages that have 
been implemented to date. Finally, this chapter outlines the methods and goals of the 
research conducted within the context of this thesis.  
Adult Emergency Medicine/Acute Care 
Chapter 2 discusses the clinical and public health implications of shortages as they apply 
to the practice of emergency medicine. Situations that may occur as a result of shortages, 
such as delayed or suboptimal therapy and medication errors are reviewed. Specific 
considerations to the specialty of emergency medicine are discussed and examples of how 
patient care is impacted are provided. For instance, we reviewed a case where a patient 
was given a fatal dose of methohexital when propofol was in short supply. We also 
explore how the healthcare system is impacted on a larger scale, such as increased cost 
and resource utilization, and increased pharmacy staff required to manage inventory 
during times of shortage. We discuss mitigation strategies to date at the governmental 
and non-governmental levels. We address challenges facing emergency medicine 
providers and offer strategies for bedside clinicians. Finally, future directions for 
mitigation and prevention are discussed. It should be noted that many of the situations 
and strategies presented are applicable to other specialties as well. 
Chapter 3 is a retrospective study of the impact of shortages on drugs within the scope of 
adult emergency medicine from 2001-14. During the course of the study period, over a 
third of drugs impacted by shortages were within the scope of emergency medicine 
practice and there was an overall increase in shortages over time. Over 50% of the drugs 
on shortage were used for high-acuity or life-threatening conditions and 10% of these 
high-acuity drugs had no substitute available. Generic injectable drugs were most 
commonly affected by shortages and infectious disease drugs were the most common 
type of drug impacted, followed by analgesics and toxicology drugs. The median duration 
of resolved shortages was 9 months and the most common reason for shortage reported 
was manufacturing problems and delays. We discuss potential reasons for these findings 
and offer coping strategies for front line providers.  
Chapter 4 is a study of drug shortages affecting medications used in adult intensive care 
units (ICUs) from 2001-2016. During the study period, there were nearly 2000 drug 
shortages and over 50% impacted medications used in the ICU. Nearly a quarter of 
medications on shortage were used for high-acuity or life-threatening conditions. Over 
70% of shortages were for parenteral medications and nearly 40% were for single-source 
drugs. Generic drugs were also more commonly affected compared to their brand name 
counterparts. Therapeutic alternatives were available for the majority of the medications 
affected but nearly 25% of alternatives were also impacted during the study period. The 
median duration of resolved shortages was even longer than described for adult 
emergency medicine being13.6 months! The most commonly impacted medications, 
similar to prior studies were infectious disease drugs, which accounted for nearly 20% of 
ICU shortages. We discuss specific implications for the ICU, which is a particularly high-
acuity environment and close by offering mitigation strategies for intensivists. 
Chapter 5 is a study of shortages for drugs used to treat poisoned patients from 2001-
2013. We reviewed shortages of antidotes as well as medications used commonly in the 
management of poisoned patients. Toxicology shortages accounted for 8.1% of all 
shortages and shortages generally increased overtime, peaking in 2011. The median 
shortage duration was 5.5 months. Generic and injectable products were most commonly 
impacted and 41% of shortages involved single-source drugs. An alternative was 
available for 86% of drugs; however, 73% of alternatives were impacted at some point 
during the study period. The agent with the greatest number of shortages was naloxone. 
The most common class of toxicology drugs on shortage was sedative/hypnotics. 
Manufacturing problems was the most common reason for shortages. In the discussion, 
we draw attention to challenges faced by toxicologists and providers caring for poisoned 
patients, particularly with multiple naloxone shortages during the current opioid 
epidemic.  
Chapter 6 examines shortages of sterile medical solutions, including normal saline, 
dextrose, lactated ringers, and sterile water for injection over time. We found a 
substantial number of sterile solution shortages. The median shortage duration was 13.9 
months but the longest shortage lasted over 10 years. The most common product type 
involved was saline solutions. The most commonly cited reason for shortages was 
manufacturing problems. While there here was an overall increase in the number of 
sterile solutions over time, there was a significant increase at the end of 2017, which 
correlated with Hurricane Maria, which precipitated a critical saline shortage. We discuss 
the potential clinical impact of these shortages and coping strategies for providers and 
health systems.  
Chapter 7 is a perspective piece from the New England Journal of Medicine that further 
examines the critical saline shortages precipitated by Hurricane Maria. We review the 
history of saline shortages and explore factors that contributed to the previously existing 
shortages, such as lack of manufacturing redundancy and transparency. These shortages 
were acutely worsened by the natural disaster. We review implications for patient care 
and discuss coping strategies for health systems and providers as well. Finally, we offer 
policy strategies to prevent future shortages.  
Pediatric Drug Shortages 
Chapter 8 is a study of drug shortages that impact the practice of general ambulatory 
pediatrics from 2001 to 2015. There were over 300 ambulatory pediatric shortages over 
the study period, with a median duration of 7.6 months. Similar to prior studies, 
infectious disease drugs were the most commonly impacted class of medications. Nearly 
20% of shortages were for pediatric friendly formulations. An alternative agent was 
available for the majority of medications impacted; however, nearly 30% of alternatives 
were affected by shortages. In the discussion, we explore issues unique to pediatric 
shortages, such as a lack of safety and efficacy data for drugs in this population as well as 
a need for palatable formulations. We close by offering mitigation strategies for general 
pediatricians and suggesting policy solutions, in order to protect this particularly 
vulnerable population.   
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Summary 
Introduction
Chapter 1 provides a description of the history of prescription drug shortages from the 
late 1990s to the present day landscape. This chapter also introduces the clinical and 
public health implications of drug shortages, as well as mitigation shortages that have 
been implemented to date. Finally, this chapter outlines the methods and goals of the 
research conducted within the context of this thesis.  
Adult Emergency Medicine/Acute Care 
Chapter 2 discusses the clinical and public health implications of shortages as they apply 
to the practice of emergency medicine. Situations that may occur as a result of shortages, 
such as delayed or suboptimal therapy and medication errors are reviewed. Specific 
considerations to the specialty of emergency medicine are discussed and examples of how 
patient care is impacted are provided. For instance, we reviewed a case where a patient 
was given a fatal dose of methohexital when propofol was in short supply. We also 
explore how the healthcare system is impacted on a larger scale, such as increased cost 
and resource utilization, and increased pharmacy staff required to manage inventory 
during times of shortage. We discuss mitigation strategies to date at the governmental 
and non-governmental levels. We address challenges facing emergency medicine 
providers and offer strategies for bedside clinicians. Finally, future directions for 
mitigation and prevention are discussed. It should be noted that many of the situations 
and strategies presented are applicable to other specialties as well. 
Chapter 3 is a retrospective study of the impact of shortages on drugs within the scope of 
adult emergency medicine from 2001-14. During the course of the study period, over a 
third of drugs impacted by shortages were within the scope of emergency medicine 
practice and there was an overall increase in shortages over time. Over 50% of the drugs 
on shortage were used for high-acuity or life-threatening conditions and 10% of these 
high-acuity drugs had no substitute available. Generic injectable drugs were most 
commonly affected by shortages and infectious disease drugs were the most common 
type of drug impacted, followed by analgesics and toxicology drugs. The median duration 
of resolved shortages was 9 months and the most common reason for shortage reported 
was manufacturing problems and delays. We discuss potential reasons for these findings 
and offer coping strategies for front line providers.  
Chapter 4 is a study of drug shortages affecting medications used in adult intensive care 
units (ICUs) from 2001-2016. During the study period, there were nearly 2000 drug 
shortages and over 50% impacted medications used in the ICU. Nearly a quarter of 
medications on shortage were used for high-acuity or life-threatening conditions. Over 
70% of shortages were for parenteral medications and nearly 40% were for single-source 
drugs. Generic drugs were also more commonly affected compared to their brand name 
counterparts. Therapeutic alternatives were available for the majority of the medications 
affected but nearly 25% of alternatives were also impacted during the study period. The 
median duration of resolved shortages was even longer than described for adult 
emergency medicine being13.6 months! The most commonly impacted medications, 
similar to prior studies were infectious disease drugs, which accounted for nearly 20% of 
ICU shortages. We discuss specific implications for the ICU, which is a particularly high-
acuity environment and close by offering mitigation strategies for intensivists. 
Chapter 5 is a study of shortages for drugs used to treat poisoned patients from 2001-
2013. We reviewed shortages of antidotes as well as medications used commonly in the 
management of poisoned patients. Toxicology shortages accounted for 8.1% of all 
shortages and shortages generally increased overtime, peaking in 2011. The median 
shortage duration was 5.5 months. Generic and injectable products were most commonly 
impacted and 41% of shortages involved single-source drugs. An alternative was 
available for 86% of drugs; however, 73% of alternatives were impacted at some point 
during the study period. The agent with the greatest number of shortages was naloxone. 
The most common class of toxicology drugs on shortage was sedative/hypnotics. 
Manufacturing problems was the most common reason for shortages. In the discussion, 
we draw attention to challenges faced by toxicologists and providers caring for poisoned 
patients, particularly with multiple naloxone shortages during the current opioid 
epidemic.  
Chapter 6 examines shortages of sterile medical solutions, including normal saline, 
dextrose, lactated ringers, and sterile water for injection over time. We found a 
substantial number of sterile solution shortages. The median shortage duration was 13.9 
months but the longest shortage lasted over 10 years. The most common product type 
involved was saline solutions. The most commonly cited reason for shortages was 
manufacturing problems. While there here was an overall increase in the number of 
sterile solutions over time, there was a significant increase at the end of 2017, which 
correlated with Hurricane Maria, which precipitated a critical saline shortage. We discuss 
the potential clinical impact of these shortages and coping strategies for providers and 
health systems.  
Chapter 7 is a perspective piece from the New England Journal of Medicine that further 
examines the critical saline shortages precipitated by Hurricane Maria. We review the 
history of saline shortages and explore factors that contributed to the previously existing 
shortages, such as lack of manufacturing redundancy and transparency. These shortages 
were acutely worsened by the natural disaster. We review implications for patient care 
and discuss coping strategies for health systems and providers as well. Finally, we offer 
policy strategies to prevent future shortages.  
Pediatric Drug Shortages 
Chapter 8 is a study of drug shortages that impact the practice of general ambulatory 
pediatrics from 2001 to 2015. There were over 300 ambulatory pediatric shortages over 
the study period, with a median duration of 7.6 months. Similar to prior studies, 
infectious disease drugs were the most commonly impacted class of medications. Nearly 
20% of shortages were for pediatric friendly formulations. An alternative agent was 
available for the majority of medications impacted; however, nearly 30% of alternatives 
were affected by shortages. In the discussion, we explore issues unique to pediatric 
shortages, such as a lack of safety and efficacy data for drugs in this population as well as 
a need for palatable formulations. We close by offering mitigation strategies for general 
pediatricians and suggesting policy solutions, in order to protect this particularly 
vulnerable population.   
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Chapter 9 examines shortages involving pediatric emergency medicine and critical care 
(ICU) drugs. During the study period from 2001 to 2015, there were nearly 800 shortages 
impacting pediatric emergency and critical care. There was an overall increase in 
shortages over time, peaking in 2011. The median shortage duration was 7.6 months and 
similar to prior trends, infectious disease drugs and sterile injectable products were the 
most commonly impacted. Over a quarter of shortages impacted drugs used for high-
acuity or life-threatening conditions. While most drugs affected by shortages had an 
alternative, 43% of alternatives were impacted. Pediatric friendly formulations were 
impacted in 11% of shortages. In the discussion, we explore the safety issues unique to 
pediatric emergency and critical care, which is a particularly high-acuity environment and 
ways to mitigate the impact.  
Chapter 10 examines shortages that affected the top 100 drugs used in the neonatal 
intensive care unit (NICU). Nearly 75% of the 100 most commonly used NICU drugs 
were impacted by multiple shortages. The median shortage duration was 8.8 months. 
Generic injectable medications were the most commonly impacted. A significant number 
of medications used in extremely low birth weight infants also experienced shortages. We 
discuss the potential consequences of these shortages in this particularly fragile 
population in the setting of critical illness. This is further confounded by the fact that 
medications have the least safety and efficacy data in neonates and some excipients are 
contraindicated in this age group, leaving few alternatives. In addition, dosing must be 
very precise, and as such, adult formulations may not be a suitable alternative and 
dilution and compounding may lead to medication errors.  
Infectious Diseases 
Chapter 11 focuses on shortages of the most commonly impacted drug class-
antimicrobials. From 2001-2013, we found 148 antimicrobial shortages, with a median 
duration of 6 months. Over 20% of antimicrobials were impacted by multiple shortages.  
Shortages for broad-spectrum antibiotics were more common and nearly half of shortages 
involved medications used to treat high-risk pathogens such as methicillin-resistant 
Staphylococcus aureus. Cephalosporins and aminoglycosides were the most commonly 
impacted antimicrobial classes. We discuss mitigation strategies in the setting of 
increasing microbial resistance and a limited number of therapeutic options in the drug 
development pipeline.  
Chapter 12 examines shortages for vaccines and immune globulins (agents used for 
passive immunity). There were 58 shortages noted, with a median duration of 16.8 
months. Shortages for products that were for viral illnesses, such as hepatitis A, were 
more common. Thirty products on the pediatric schedule were on shortage and vaccine 
deferral was required for 21 shortages. Over half of the shortages were for single-source 
products. The most common reason for shortage was manufacturing problems. In the 
discussion, we focus on the public health implications in the setting of vaccine deferrals 
for primary immunizations, as this may impact herd immunity, as well as coping 
strategies for clinicians.  
Samenvatting
Inleiding
Hoofdstuk 1 beschrijft de geschiedenis van de tekorten aan geneesmiddelen op recept 
van het eind van de jaren 90 tot op heden. Dit hoofdstuk presenteert ook en de 
gevolgen van geneesmiddelentekorten voor de klinische praktijk en voor de 
volksgezondheid, alsook de compenserende maatregelen die tot nu toe zijn genomen. 
Tot slot worden in dit hoofdstuk in het kort de methoden en doelstellingen van de 
studies die zijn uitgevoerd in het kader van dit proefschrift beschreven.
Spoedeisende geneeskunde voor volwassenen
Hoofdstuk 2 gaat in op gevolgen van geneesmiddelentekorten voor de spoedeisende 
geneeskunde. Situaties die kunnen ontstaan als gevolg van tekorten, zoals vertraagde of 
suboptimale therapie en medicatiefouten worden belicht. Specifieke overwegingen met 
betrekking tot het specialisme van de spoedeisende geneeskunde worden besproken en 
met voorbeelden wordt duidelijk gemaakt wat de impact is op de patiëntenzorg. Zo 
hebben we bijvoorbeeld een geval bekeken waarin een patiënt een fatale dosis 
methohexital kreeg toegediend bij een tekort aan propofol. We onderzoeken ook hoe 
het gezondheidszorgsysteem op grotere schaal wordt beïnvloed, zoals meer kosten en 
meer gebruik van middelen, en de noodzaak van meer apotheekpersoneel voor het 
voorraadbeheer in tijden van schaarste. We bespreken de huidige compenserende 
maatregelen door de overheid en niet-gouvernementele organisaties. We gaan in op de 
uitdagingen waarmee aanbieders van noodgeneesmiddelen worden geconfronteerd en 
bieden strategieën voor clinici aan het bed. Ten slotte worden mogelijkheden voor 
mitigatie en preventie besproken. Opgemerkt moet worden dat veel van de 
gepresenteerde situaties en strategieën ook van toepassing zijn op andere specialismen.
Hoofdstuk 3 is een retrospectieve studie naar de impact van tekorten op 
geneesmiddelen in het kader van de volwassen spoedeisende geneeskunde in de 
periode 2001-2014. In de loop van de onderzoeksperiode viel meer dan een derde van 
de door tekorten getroffen geneesmiddelen binnen de spoedeisende geneeskunde en 
was er in de loop van de tijd een algemene toename van de tekorten. Meer dan 50% van 
de geneesmiddelen waarvan een tekort was betrof zeer acute of levensreddende 
omstandigheden en voor 10% van de geneesmiddelen voor zeer acute omstandigheden 
was geen vervangend middel beschikbaar. Generieke injecteerbare geneesmiddelen 
waren het meest getroffen door tekorten en middelen tegen infectieziekten waren het 
meest getroffen, gevolgd door pijnstillers en antidota. De tekorten waren na een 
mediane duur van 9 maanden ongedaan gemaakt en de meest gemelde redenen voor het 
tekort waren productieproblemen en vertragingen. We bespreken de mogelijke redenen 
voor deze bevindingen en bieden copingstrategieën voor de eerstelijnszorg.
Hoofdstuk 4 betreft een onderzoek naar tekorten aan geneesmiddelen in intensive care 
units (ICU's) voor volwassenen in de periode 2001-2016. Tijdens de 
onderzoeksperiode waren er bijna 2000 geneesmiddelentekorten en dit betrof meer dan 
50% van de geneesmiddelen die in de ICU’s werden gebruikt. Bijna een kwart van de 
geneesmiddelen waarvan een tekort was diende voor zeer acute of levensbedreigende 
aandoeningen. Meer dan 70% van de tekorten betrof parenterale geneesmiddelen en 
bijna 40% betrof geneesmiddelen waarvoor geen generiek alternatief was. 
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Chapter 9 examines shortages involving pediatric emergency medicine and critical care 
(ICU) drugs. During the study period from 2001 to 2015, there were nearly 800 shortages 
impacting pediatric emergency and critical care. There was an overall increase in 
shortages over time, peaking in 2011. The median shortage duration was 7.6 months and 
similar to prior trends, infectious disease drugs and sterile injectable products were the 
most commonly impacted. Over a quarter of shortages impacted drugs used for high-
acuity or life-threatening conditions. While most drugs affected by shortages had an 
alternative, 43% of alternatives were impacted. Pediatric friendly formulations were 
impacted in 11% of shortages. In the discussion, we explore the safety issues unique to 
pediatric emergency and critical care, which is a particularly high-acuity environment and 
ways to mitigate the impact.  
Chapter 10 examines shortages that affected the top 100 drugs used in the neonatal 
intensive care unit (NICU). Nearly 75% of the 100 most commonly used NICU drugs 
were impacted by multiple shortages. The median shortage duration was 8.8 months. 
Generic injectable medications were the most commonly impacted. A significant number 
of medications used in extremely low birth weight infants also experienced shortages. We 
discuss the potential consequences of these shortages in this particularly fragile 
population in the setting of critical illness. This is further confounded by the fact that 
medications have the least safety and efficacy data in neonates and some excipients are 
contraindicated in this age group, leaving few alternatives. In addition, dosing must be 
very precise, and as such, adult formulations may not be a suitable alternative and 
dilution and compounding may lead to medication errors.  
Infectious Diseases 
Chapter 11 focuses on shortages of the most commonly impacted drug class-
antimicrobials. From 2001-2013, we found 148 antimicrobial shortages, with a median 
duration of 6 months. Over 20% of antimicrobials were impacted by multiple shortages.  
Shortages for broad-spectrum antibiotics were more common and nearly half of shortages 
involved medications used to treat high-risk pathogens such as methicillin-resistant 
Staphylococcus aureus. Cephalosporins and aminoglycosides were the most commonly 
impacted antimicrobial classes. We discuss mitigation strategies in the setting of 
increasing microbial resistance and a limited number of therapeutic options in the drug 
development pipeline.  
Chapter 12 examines shortages for vaccines and immune globulins (agents used for 
passive immunity). There were 58 shortages noted, with a median duration of 16.8 
months. Shortages for products that were for viral illnesses, such as hepatitis A, were 
more common. Thirty products on the pediatric schedule were on shortage and vaccine 
deferral was required for 21 shortages. Over half of the shortages were for single-source 
products. The most common reason for shortage was manufacturing problems. In the 
discussion, we focus on the public health implications in the setting of vaccine deferrals 
for primary immunizations, as this may impact herd immunity, as well as coping 
strategies for clinicians.  
Samenvatting
Inleiding
Hoofdstuk 1 beschrijft de geschiedenis van de tekorten aan geneesmiddelen op recept 
van het eind van de jaren 90 tot op heden. Dit hoofdstuk presenteert ook en de 
gevolgen van geneesmiddelentekorten voor de klinische praktijk en voor de 
volksgezondheid, alsook de compenserende maatregelen die tot nu toe zijn genomen. 
Tot slot worden in dit hoofdstuk in het kort de methoden en doelstellingen van de 
studies die zijn uitgevoerd in het kader van dit proefschrift beschreven.
Spoedeisende geneeskunde voor volwassenen
Hoofdstuk 2 gaat in op gevolgen van geneesmiddelentekorten voor de spoedeisende 
geneeskunde. Situaties die kunnen ontstaan als gevolg van tekorten, zoals vertraagde of 
suboptimale therapie en medicatiefouten worden belicht. Specifieke overwegingen met 
betrekking tot het specialisme van de spoedeisende geneeskunde worden besproken en 
met voorbeelden wordt duidelijk gemaakt wat de impact is op de patiëntenzorg. Zo 
hebben we bijvoorbeeld een geval bekeken waarin een patiënt een fatale dosis 
methohexital kreeg toegediend bij een tekort aan propofol. We onderzoeken ook hoe 
het gezondheidszorgsysteem op grotere schaal wordt beïnvloed, zoals meer kosten en 
meer gebruik van middelen, en de noodzaak van meer apotheekpersoneel voor het 
voorraadbeheer in tijden van schaarste. We bespreken de huidige compenserende 
maatregelen door de overheid en niet-gouvernementele organisaties. We gaan in op de 
uitdagingen waarmee aanbieders van noodgeneesmiddelen worden geconfronteerd en 
bieden strategieën voor clinici aan het bed. Ten slotte worden mogelijkheden voor 
mitigatie en preventie besproken. Opgemerkt moet worden dat veel van de 
gepresenteerde situaties en strategieën ook van toepassing zijn op andere specialismen.
Hoofdstuk 3 is een retrospectieve studie naar de impact van tekorten op 
geneesmiddelen in het kader van de volwassen spoedeisende geneeskunde in de 
periode 2001-2014. In de loop van de onderzoeksperiode viel meer dan een derde van 
de door tekorten getroffen geneesmiddelen binnen de spoedeisende geneeskunde en 
was er in de loop van de tijd een algemene toename van de tekorten. Meer dan 50% van 
de geneesmiddelen waarvan een tekort was betrof zeer acute of levensreddende 
omstandigheden en voor 10% van de geneesmiddelen voor zeer acute omstandigheden 
was geen vervangend middel beschikbaar. Generieke injecteerbare geneesmiddelen 
waren het meest getroffen door tekorten en middelen tegen infectieziekten waren het 
meest getroffen, gevolgd door pijnstillers en antidota. De tekorten waren na een 
mediane duur van 9 maanden ongedaan gemaakt en de meest gemelde redenen voor het 
tekort waren productieproblemen en vertragingen. We bespreken de mogelijke redenen 
voor deze bevindingen en bieden copingstrategieën voor de eerstelijnszorg.
Hoofdstuk 4 betreft een onderzoek naar tekorten aan geneesmiddelen in intensive care 
units (ICU's) voor volwassenen in de periode 2001-2016. Tijdens de 
onderzoeksperiode waren er bijna 2000 geneesmiddelentekorten en dit betrof meer dan 
50% van de geneesmiddelen die in de ICU’s werden gebruikt. Bijna een kwart van de 
geneesmiddelen waarvan een tekort was diende voor zeer acute of levensbedreigende 
aandoeningen. Meer dan 70% van de tekorten betrof parenterale geneesmiddelen en 
bijna 40% betrof geneesmiddelen waarvoor geen generiek alternatief was. 
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Generieke geneesmiddelen werden ook vaker getroffen dan de corresponderende 
merkproducten. Voor het merendeel van de getroffen geneesmiddelen waren 
therapeutische alternatieven beschikbaar, maar bijna 25% van de alternatieven werd ook 
beïnvloed tijdens de onderzoeksperiode. De mediane tijdsperiode waarna de tekorten 
waren opgelost was zelfs langer dan beschreven voor de volwassenen spoedeisende 
geneeskunde van 13,6 maanden! De meest getroffen medicijnen, vergelijkbaar met 
eerdere studies, waren geneesmiddelen voor infectieziekten, die goed waren voor bijna 
20% van de tekorten op de ICU. Wij bespreken specifieke implicaties voor de ICU, die 
een bijzonder hoog spoedeisend karakter heeft, en presenteren ten slotte 
mitigatiestrategieën voor intensivisten.
Hoofdstuk 5 is een onderzoek naar tekorten aan geneesmiddelen voor de behandeling 
van vergiftigde patiënten in de periode 2001-2013. We onderzochten tekorten aan 
antidota en andere medicijnen die vaak worden gegeven aan vergiftigde patiënten. 
Tekorten aan antidota waren goed voor 8,1% van alle tekorten en de tekorten namen 
over het algemeen toe in de loop van de tijd en bereikten in 2011 een hoogtepunt. De 
mediane duur van de tekorten was 5,5 maanden. Generieke en injecteerbare producten 
waren het vaakst getroffen en 41% van de tekorten had betrekking op geneesmiddelen 
waarvoor geen generiek alternatief was. Een alternatief was beschikbaar voor 86% van 
de geneesmiddelen; aan 73% van de alternatieven was er echter op een bepaald moment 
tijdens de studieperiode een tekort. Het middel met het grootste aantal tekorten was 
naloxon. Sedativa/hypnotica vormden de meest voorkomende klasse van toxicologische 
geneesmiddelen waaraan een tekort was. Productieproblemen vormden de meest 
voorkomende oorzaak van tekorten. In de discussie vestigen we de aandacht op de 
uitdagingen waarmee toxicologen en zorgverleners van vergiftigde patiënten zich zien 
gesteld, vooral de meerdere perioden van tekorten aan naxalon tijdens de huidige 
opioïden-epidemie.
Hoofdstuk 6 onderzoekt de tekorten in de loop ter tijd aan steriele medische 
oplossingen, waaronder normale zoutoplossing, dextrose, Ringerlactaat en steriel water 
voor injectie. We vonden een aanzienlijk aantal tekorten aan deze middelen. De 
gemiddelde duur van het tekort was 13,9 maanden, maar het langste tekort duurde meer 
dan 10 jaar. De meest voorkomende productsoort betrof zoutoplossingen. De meest 
aangehaalde reden voor het tekort was productieproblemen. Terwijl er hier sprake was 
van een algemene stijging van het aantal tekorten aan steriele oplossingen in de loop der 
tijd was er eind 2017 sprake van een aanzienlijke toename, gecorreleerd met de orkaan 
Maria, die een kritiek tekort aan zout heeft veroorzaakt. We bespreken de mogelijke 
klinische gevolgen van deze tekorten en copingstrategieën voor zorgverleners en 
gezondheidzorgstelsels.
Hoofdstuk 7 is een ‘perspective piece’ uit het New England Journal of Medicine dat 
verder ingaat op de kritieke zout tekorten die door de orkaan Maria zijn ontstaan. We 
bekijken de geschiedenis van tekorten aan zoutoplossingen en verkennen factoren die 
hebben bijgedragen aan de eerder bestaande tekorten, zoals een gebrek aan redundantie 
en transparantie in de productie. Deze tekorten werden door de natuurramp acuut 
verergerd. We bekijken de gevolgen voor de patiëntenzorg en bespreken ook 
copingstrategieën voor zorgverleners gezondheidszorgstelsels en -aanbieders. Tot slot 
presenteren we beleidsstrategieën om toekomstige tekorten te voorkomen.
Tekorten aan geneesmiddelen voor kinderen
Hoofdstuk 8 betreft een onderzoek naar medicijntekorten die van invloed zijn op de 
praktijk van de algemene pediatrische ambulante gezondheidszorg van 2001 tot 2015. Er 
waren meer dan 300 van deze tekorten over de studieperiode, met een mediane duur van 
7,6 maanden. , Geneesmiddelen tegen infectieziekten waren de meest getroffen klasse 
van geneesmiddelen, evenals in voorgaande studies. Bijna 20% van de tekorten 
betroffen pediatrische formuleringen. Een alternatief middel was beschikbaar voor de 
meeste van de betrokken geneesmiddelen, maar er ontstond ook een tekort aan bijna 
30% van de alternatieven. In de discussie gaan we in op kwesties die uniek zijn voor 
pediatrische tekorten, zoals een gebrek aan gegevens over de veiligheid en 
werkzaamheid van geneesmiddelen in deze populatie, en behoefte aan smakelijke 
formuleringen. Ten slotte presenteren we mitigatiestrategieën voor algemene 
kinderartsen en stellen beleidsmaatregelen voor ter bescherming van deze kwetsbare 
groep patiënten.
Hoofdstuk 9 gaat in op tekorten aan geneesmiddelen die worden gebruikt in de 
pediatrische spoedeisende hulp en kritieke zorg. In de bestudeerde periode van 2001 tot 
2015 waren er bijna 800 tekorten aan deze middelen. In de loop van de tijd namen de 
tekorten in het algemeen toe, met een piek in 2011. De gemiddelde duur van de tekorten 
bedroeg 7,6 maanden en – vergelijkbaar met eerdere trends – geneesmiddelen tegen 
infectieziekten en steriele injecteerbare producten waren het meest getroffen. Meer dan 
een kwart van de tekorten betrof geneesmiddelen die gebruikt worden bij zeer acute of 
levensbedreigende omstandigheden. Terwijl er voor de meeste middelen waaraan een 
tekort ontstond een alternatief was, was ook 43% van de alternatieven onderhevig aan 
tekorten. Kindervriendelijke formuleringen vormden 11% van de tekorten. In de 
discussie gaan we in op de veiligheidsaspecten die uniek zijn voor de pediatrische 
spoedeisende hulp en kritieke zorg, en mogelijkheden om de gevolgen te verzachten.
Hoofdstuk 10 onderzoek tekorten aan de top-100 geneesmiddelen die worden gebruikt 
in de neonatale intensive care unit (NICU). Bijna 75% van de 100 meest gebruikte 
NICU-geneesmiddelen werden getroffen door meerdere tekorten. De gemiddelde duur 
van het tekort bedroeg 8,8 maanden. Generieke injecteerbare medicijnen werden het 
meest getroffen. Een aanzienlijk aantal medicijnen die worden gebruikt bij baby's met 
een extreem laag geboortegewicht hadden ook te kampen met tekorten. We bespreken 
de mogelijke gevolgen van deze tekorten in deze bijzonder fragiele populatie in de 
context van kritieke ziekten. Dit wordt nog verder vertroebeld door het feit dat er voor 
geneesmiddelen bij pasgeborenen de minste gegevens over veiligheid en werkzaamheid 
beschikbaar zijn en dat sommige hulpstoffen in deze leeftijdsgroep gecontra-indiceerd 
zijn, waardoor er weinig alternatieven overblijven. Bovendien moet de dosering zeer 
nauwkeurig zijn, en als zodanig kunnen formuleringen voor volwassenen geen geschikt 
alternatief vormen en kunnen verdunningen en samenstellingen tot medicatiefouten 
leiden.
Infectieziekten
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Generieke geneesmiddelen werden ook vaker getroffen dan de corresponderende 
merkproducten. Voor het merendeel van de getroffen geneesmiddelen waren 
therapeutische alternatieven beschikbaar, maar bijna 25% van de alternatieven werd ook 
beïnvloed tijdens de onderzoeksperiode. De mediane tijdsperiode waarna de tekorten 
waren opgelost was zelfs langer dan beschreven voor de volwassenen spoedeisende 
geneeskunde van 13,6 maanden! De meest getroffen medicijnen, vergelijkbaar met 
eerdere studies, waren geneesmiddelen voor infectieziekten, die goed waren voor bijna 
20% van de tekorten op de ICU. Wij bespreken specifieke implicaties voor de ICU, die 
een bijzonder hoog spoedeisend karakter heeft, en presenteren ten slotte 
mitigatiestrategieën voor intensivisten.
Hoofdstuk 5 is een onderzoek naar tekorten aan geneesmiddelen voor de behandeling 
van vergiftigde patiënten in de periode 2001-2013. We onderzochten tekorten aan 
antidota en andere medicijnen die vaak worden gegeven aan vergiftigde patiënten. 
Tekorten aan antidota waren goed voor 8,1% van alle tekorten en de tekorten namen 
over het algemeen toe in de loop van de tijd en bereikten in 2011 een hoogtepunt. De 
mediane duur van de tekorten was 5,5 maanden. Generieke en injecteerbare producten 
waren het vaakst getroffen en 41% van de tekorten had betrekking op geneesmiddelen 
waarvoor geen generiek alternatief was. Een alternatief was beschikbaar voor 86% van 
de geneesmiddelen; aan 73% van de alternatieven was er echter op een bepaald moment 
tijdens de studieperiode een tekort. Het middel met het grootste aantal tekorten was 
naloxon. Sedativa/hypnotica vormden de meest voorkomende klasse van toxicologische 
geneesmiddelen waaraan een tekort was. Productieproblemen vormden de meest 
voorkomende oorzaak van tekorten. In de discussie vestigen we de aandacht op de 
uitdagingen waarmee toxicologen en zorgverleners van vergiftigde patiënten zich zien 
gesteld, vooral de meerdere perioden van tekorten aan naxalon tijdens de huidige 
opioïden-epidemie.
Hoofdstuk 6 onderzoekt de tekorten in de loop ter tijd aan steriele medische 
oplossingen, waaronder normale zoutoplossing, dextrose, Ringerlactaat en steriel water 
voor injectie. We vonden een aanzienlijk aantal tekorten aan deze middelen. De 
gemiddelde duur van het tekort was 13,9 maanden, maar het langste tekort duurde meer 
dan 10 jaar. De meest voorkomende productsoort betrof zoutoplossingen. De meest 
aangehaalde reden voor het tekort was productieproblemen. Terwijl er hier sprake was 
van een algemene stijging van het aantal tekorten aan steriele oplossingen in de loop der 
tijd was er eind 2017 sprake van een aanzienlijke toename, gecorreleerd met de orkaan 
Maria, die een kritiek tekort aan zout heeft veroorzaakt. We bespreken de mogelijke 
klinische gevolgen van deze tekorten en copingstrategieën voor zorgverleners en 
gezondheidzorgstelsels.
Hoofdstuk 7 is een ‘perspective piece’ uit het New England Journal of Medicine dat 
verder ingaat op de kritieke zout tekorten die door de orkaan Maria zijn ontstaan. We 
bekijken de geschiedenis van tekorten aan zoutoplossingen en verkennen factoren die 
hebben bijgedragen aan de eerder bestaande tekorten, zoals een gebrek aan redundantie 
en transparantie in de productie. Deze tekorten werden door de natuurramp acuut 
verergerd. We bekijken de gevolgen voor de patiëntenzorg en bespreken ook 
copingstrategieën voor zorgverleners gezondheidszorgstelsels en -aanbieders. Tot slot 
presenteren we beleidsstrategieën om toekomstige tekorten te voorkomen.
Tekorten aan geneesmiddelen voor kinderen
Hoofdstuk 8 betreft een onderzoek naar medicijntekorten die van invloed zijn op de 
praktijk van de algemene pediatrische ambulante gezondheidszorg van 2001 tot 2015. Er 
waren meer dan 300 van deze tekorten over de studieperiode, met een mediane duur van 
7,6 maanden. , Geneesmiddelen tegen infectieziekten waren de meest getroffen klasse 
van geneesmiddelen, evenals in voorgaande studies. Bijna 20% van de tekorten 
betroffen pediatrische formuleringen. Een alternatief middel was beschikbaar voor de 
meeste van de betrokken geneesmiddelen, maar er ontstond ook een tekort aan bijna 
30% van de alternatieven. In de discussie gaan we in op kwesties die uniek zijn voor 
pediatrische tekorten, zoals een gebrek aan gegevens over de veiligheid en 
werkzaamheid van geneesmiddelen in deze populatie, en behoefte aan smakelijke 
formuleringen. Ten slotte presenteren we mitigatiestrategieën voor algemene 
kinderartsen en stellen beleidsmaatregelen voor ter bescherming van deze kwetsbare 
groep patiënten.
Hoofdstuk 9 gaat in op tekorten aan geneesmiddelen die worden gebruikt in de 
pediatrische spoedeisende hulp en kritieke zorg. In de bestudeerde periode van 2001 tot 
2015 waren er bijna 800 tekorten aan deze middelen. In de loop van de tijd namen de 
tekorten in het algemeen toe, met een piek in 2011. De gemiddelde duur van de tekorten 
bedroeg 7,6 maanden en – vergelijkbaar met eerdere trends – geneesmiddelen tegen 
infectieziekten en steriele injecteerbare producten waren het meest getroffen. Meer dan 
een kwart van de tekorten betrof geneesmiddelen die gebruikt worden bij zeer acute of 
levensbedreigende omstandigheden. Terwijl er voor de meeste middelen waaraan een 
tekort ontstond een alternatief was, was ook 43% van de alternatieven onderhevig aan 
tekorten. Kindervriendelijke formuleringen vormden 11% van de tekorten. In de 
discussie gaan we in op de veiligheidsaspecten die uniek zijn voor de pediatrische 
spoedeisende hulp en kritieke zorg, en mogelijkheden om de gevolgen te verzachten.
Hoofdstuk 10 onderzoek tekorten aan de top-100 geneesmiddelen die worden gebruikt 
in de neonatale intensive care unit (NICU). Bijna 75% van de 100 meest gebruikte 
NICU-geneesmiddelen werden getroffen door meerdere tekorten. De gemiddelde duur 
van het tekort bedroeg 8,8 maanden. Generieke injecteerbare medicijnen werden het 
meest getroffen. Een aanzienlijk aantal medicijnen die worden gebruikt bij baby's met 
een extreem laag geboortegewicht hadden ook te kampen met tekorten. We bespreken 
de mogelijke gevolgen van deze tekorten in deze bijzonder fragiele populatie in de 
context van kritieke ziekten. Dit wordt nog verder vertroebeld door het feit dat er voor 
geneesmiddelen bij pasgeborenen de minste gegevens over veiligheid en werkzaamheid 
beschikbaar zijn en dat sommige hulpstoffen in deze leeftijdsgroep gecontra-indiceerd 
zijn, waardoor er weinig alternatieven overblijven. Bovendien moet de dosering zeer 
nauwkeurig zijn, en als zodanig kunnen formuleringen voor volwassenen geen geschikt 
alternatief vormen en kunnen verdunningen en samenstellingen tot medicatiefouten 
leiden.
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Hoofdstuk 11 richt zich op de tekorten aan de meest getroffen medicijnklasse – 
antimicrobiële middelen. Over de periode 2001-2013 vonden we 148 tekorten aan deze 
middelen, met een mediane duur van 6 maanden. Meer dan 20% van de antimicrobiële 
stoffen had te kampen met meerdere tekorten. Tekorten aan breedspectrumantibiotica 
kwamen vaker voor en bij bijna de helft van de tekorten ging het om middelen voor de 
behandeling van pathogenen met een hoog risico, zoals meticilline-resistente 
Staphylococcus aureus. Cephalosporinen en aminoglycosiden waren de antimicrobiële 
klassen die het meest waren getroffen. We bespreken mitigatiestrategieën in de context 
van de verhoogde microbiële resistentie en een beperkt aantal therapeutische opties in de 
pijplijn.
Hoofdstuk 12 gaat in op tekorten aan vaccins en immuunglobulinen (middelen die 
worden gebruikt voor passieve immuniteit). Er werden 58 tekorten vastgesteld, met een 
mediane duur van 16.8 maanden. Dit betrof het meest middelen tegen virale ziekten, 
zoals hepatitis A. Er waren tekorten aan 30 producten op het pediatrische programma en 
vaccinatie-uitstel was nodig voor 21 tekorten. Meer dan de helft van de tekorten betrof 
middelen waarvoor geen generiek alternatief was. Productieproblemen vormden de 
meest voorkomende oorzaak van het tekort. In de discussie concentreren wij ons op de 
implicaties voor de volksgezondheid van het vaccinatieuitstel voor primaire 
immunisaties, omdat dit invloed kan hebben op de collectieve immuniteit, en richten ons 
ook op de copingstrategieën voor clinici.
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